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Acute Pancreatitis — a Retroperitoneal
Storm
N. Schmidt, MD, MSc, FRCSC
Member, Editorial Board, Canadian Journal o f Surgery. Director, Surgical Education, St. Paul's
Hospital, Vancouver

atural storms, and those creat
ed by man, are characterized
by unpredictability and varying de
grees of disaster and are not assess
able until the rage has passed. Such
is the process of acute pancreatitis
— subtle in its onset and uncon
trolled in its progression, leaving a
trail of complications minor to le
thal in degree.
In this issue (pages 137 to 145)
Amurawaiye and Brown present a
most important review of 30 years’
experience in managing acute pan
creatitis, sharing with us their ob
servations and reviewing the va
garies of this most devastating
acute abdominal and retroperitoneal
condition. The process of acute
pancreatitis has to be likened to a
retroperitoneal burn, proceeding in
various directions, progressing
often through the inflammatory
process to necrosis, liquefaction,
sepsis, fistulization, even lethal he
morrhage. These authors note that,
in spite of new radiologic investiga
tions, direct critical care monitor
ing, drugs and antibiotics, nutri
tional and surgical intervention,
these diagnostic and treatment pos
sibilities have not changed the
death rate. The causes of death
have changed, however, reflecting
our clinical capabilities, but also
telling us that we are still chasing a
destructive path rather than inter
rupting or controlling the events of
this disease. Renal failure and

N
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gram-negative sepsis are still the
common causes of death in severe
acute pancreatitis.
In the series of Amurawaiye and
Brown biliary tract disease account
ed for 50% of cases of acute pan
creatitis, as opposed to the
30-30-30 statistics that we usually
teach our students. Alcohol-related
pancreatitis accounted for 21%.
Sepsis occurred in 12.5% of the
patients with biliary related pan
creatitis but in none having the
alcohol-related form. Men were
found to be at greater risk for
pancreatitis than women, and 82%
of alcohol-related pancreatitis oc
curred in men. Alcohol-related pan
creatitis appears less likely to be
associated with sepsis, and there
fore less likely to progress to severe
disease. The incidence of severe
pancreatitis decreased in the last 5
years of the study compared with
the initial 10 years. The severe
cases were associated with a higher
death rate. This, no doubt, demon
strates our ability to support sicker
patients longer when, earlier in the
study, less severely affected patients
would have died. Hypotension oc
curred less frequently and gastroin
testinal hemorrhage seemed less
threatening, but nutritional deple
tion still exists. Prognostic factors
included the degree of amylase and
calcium derangement, the extent of
peripancreatic fluid and gram-nega
tive aerobic sepsis.

Acute pancreatitis can result in
system failures that lead to increas
ingly higher rates of morbidity and
mortality. The initial etiologic insult
sets off an enzymatic inflammatory
response in the pancreas and peri
pancreatic retroperitoneum that
creates an enormous third-space
fluid loss leading to volume failure
in the vascular system. This will
result in hypotension, oliguria and
arteriovenous pulmonary shunting,
which, if not corrected, will quickly
lead to death.
This retroperitoneal progression
results also in ileus or gastrointesti
nal failure with distension, ascites,
gastric retention, pain, restricted
ventilation and even vena caval
compression with failing cardiac
output. The value of gastrointesti
nal decompression is still arguable,
but if it will reduce these series of
consequences then I think naso
gastric suction should be instituted.
Careful monitoring of the patient’s
blood-gas levels and acid-base bal
ance will help to detect early and
often subtle respiratory failure. All
aspects of respiration — ventilation,
perfusion and diffusion — are af
fected. Pain, abdominal distension,
sedation and the obtunded prone
position interfere with ventilation.
Hypotension and pulmonary shunt
ing contribute to hypoxia through
altered pulmonary perfusion. The
effect of absorbed by-products of
pancreatic enzyme breakdown, va-

soactive amines, stasis, loss of sur
factant and untold degradation by
products lead to pulmonary alveolar
membrane edema, adult respiratory
distress syndrome and failing diffu
sion gradients of oxygen and car
bon dioxide.
Early diagnosis allows correction
of the problem and can be life-sav
ing. As if this is not enough
change, transport of toxic elements
through the portal system promote
hemopoetic failure of hepatic and
splenic function, enhancing bacter
emia, septicemia and hematogamous infection of necrotic tissues.
All these systems and related or
gans require careful monitoring as
pancreatitis progresses, otherwise
the process advances unrelentingly
and physiologic deterioration be
comes impossible to reverse.
In spite of all the physiologic
monitoring and observation carried
out, Amurawaiye and Brown state
that the death rate today for severe
pancreatitis is the same as when we
were unable to monitor system fail
ures. Areas still awaiting better un
derstanding in the care of acute
pancreatitis include the early identi
fication of necrosis,12 correct use of
nutrition3 and the prevention and
treatment of sepsis.4 5
Necrotic retroperitoneal pancreat
ic tissue is not necessarily infected,
is not uniform and will eventually
liquify to form cysts and abscesses.
Some milder forms of necrosis obvi
ously are absorbed by the inflamma
tory process and heal fully. More
severe necrosis becomes loculated
and requires drainage after localiza
tion. Surgical judgement at this

point is very important to patient
care. Acute pancreatitis is not en
tirely a surgical disease, but its
complications may require careful
and well-timed surgical interven
tion. Repeated ultrasonography,
computed tomography (CT) and,
more recently, CT angiography to
enhance the retroperitoneal tissue
are the best methods, along with
clinical responses on which to base
the decision of what, when, how
and where to drain. These decisions
are often crucial to the critically ill,
but the risk can be great either
way. Whether a surgical procedure
will help or hinder a patient may be
difficult to predict. The choice and
the extent of antibiotic care is not
clear either. Usually the broadest
spectrum antimicrobial drugs are
used, often leading to polypharma
cy. Drugs themselves become an
issue because serious morbidity
often results from the side effects of
the drugs, which may not penetrate
the infected necrotic tissue.6 Long
term survivors of severe pancreatitis
often can thank the technique of
total parenteral nutrition for their
survival. Controversies concerning
early nutrition in pancreatitis con
tinue, and the advantages of paren
teral versus enteric routes are yet to
be settled. Early nutrition may be
unnecessary and even detrimental,3
but, if the process becomes pro
tracted, the patient with acute pan
creatitis will not survive without
nutritional support.
Acute pancreatitis, progressing
through its various phases of sever
ity, will continue to challenge the
surgeon. Most patients, fortunately,

recover with routine but vigilant
care. Some will require extensive
physiologic monitoring with great
efforts being made to prevent vari
ous system failures. Agreement has
yet to be reached on some aspects
of care, including the control and
treatment of septic necrosis and
maintenance of nutrition. But as we
observe the results of what we do
and attempt to design new and
better treatment programs, we must
continue to treat our patients ag
gressively to our present level of
knowledge and skill, otherwise
when the storm has passed there
may only be debris remaining.
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Laparoscopic
Cholecystectomy
To the editors. I read with interest
the editorials by Schmidt and Keith
in the December issue of the Jour
nal (pages 433 to 436) and the
article by Dion and Morin (pages
483 to 486) and I wish to express
my view that widespread acceptance
of laparoscopic cholecystectomy at
this stage is inappropriate. The me
dium and long-term results of this
procedure are unknown. Already
bile-duct injuries are being report
ed. Serious bile-duct injuries during
open cholecystectomy are rare.
Even with laparoscopic cholecystec
tomy, they will be uncommon, but
this complication has such serious
consequences that even a low inci
dence is unacceptable.
Every general surgeon has an
interest in an orderly and controlled
development of this promising new
procedure. Inappropriate use or in
expert performance of an operation
will bring that procedure into disre
pute. Surgeons in small communi
ties need the “status quo” to be
maintained until the overall results
are known. The suggestion that
single-handed surgeons may lose
biliary surgery also implies that any
community not doing laparoscopic
cholecystectomy will also lose bili
ary surgery. If patient demand re
sults in a loss of biliary surgery
there will be overwhelming pressure
to climb on the band wagon.
At present in British Columbia
there is little control over the per
formance of surgery in small towns.
Privileges are given to surgeons by
family physicians who often have a
poor grasp of surgical realities. It
would be easy for a surgeon to raise
* - For prescribing inform ation see page 166

the money for the equipment local
ly, take a 3-day course in the United
States and be granted privileges for
the procedure.
Laparoscopic cholecystectomy is
a classic example of enthusiastic
and uncritical application of new
technology. An authoritative agen
cy is needed that will state that at
present this operation is not for
every patient, nor for every sur
geon. When the incidence of com
plications is better known, that will
be the time to begin training sur
geons on a large scale. Some sur
geons who are expert at open cho
lecystectomy may not have the
necessary eye and hand coordina
tion to perform this new procedure.
Who will be responsible for sug
gesting to these surgeons that they
should not perform this procedure?
Who will have the authority to
prevent them?
This matter should be addressed
urgently by the Royal College of
Physicians and Surgeons of Cana
da, the Canadian Association of
General Surgeons and the provin
cial colleges of physicians and sur
geons.
A.J. Lomax, MD, FRCSC
Consulting specialist surgeon
816 - 103rd Ave.
Dawson Creek, BC
V1G2G1

To the editors. It was with pleasure
that I read the December 1990
issue of the journal. In this issue,
laparoscopic cholecystectomy was
discussed quite well in editorials by
two members of the editorial board,
Drs. Nis Schmidt and Roger Keith
(pages 433 to 436). In addition,
Drs. Dion and Morin presented their
initial 60 patients who underwent

laparoscopic cholecystectomy with
good results (pages 483 to 486). I
believe the discussion of this topic
is very timely.
As all general surgeons know,
laparoscopic cholecystectomy has
enjoyed an immense popularity
worldwide. The primary reason for
this enthusiasm is patient benefit.
With this technique patients under
go one of the commonest surgical
procedures through minimal access,
with minimal pain and a dramatical
ly shortened recovery period. This
obviously has great implications for
society in general.
Despite my enthusiasm for this
procedure and the fact that I have
been an active promoter of the use
of laparoscopy in general surgery, I
must caution my colleagues in gen
eral. Laparoscopic surgery will take
an active role in our practices over
the next few years. Laparoscopic
cholecystectomy is only the first
procedure in this sphere to enjoy
popularity. It is the duty and re
sponsibility of general surgeons
across Canada to ensure safety for
our patients.
To achieve safe introduction of
this procedure it is mandatory that
surgeons undertake a graduated
training program for themselves.
They must familiarize themselves
with the procedure of diagnostic
laparoscopy, they must follow a
didactic course in laparoscopy as
well as experimentation on the por
cine model. Although most sur
geons undertake the procedure of
laparoscopic cholecystectomy after
this course, in my opinion the labo
ratory experience does not suffi
ciently prepare the surgeon to per
form the procedure on the human. I
advise that after the didactic lecCJS, VOL. 34. NO. 2, APRIL 1991
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tures, diagnostic laparoscopic expo
sure and experience with the por
cine model, surgeons must ensure
that when they initially apply the
procedure to humans, they have as
an assistant a surgeon already expe
rienced in laparoscopic cholecystec
tomy and laparoscopic procedures.
This kind of clinical supervision
should not be ignored when intro
ducing a procedure such as laparo
scopic cholecystectomy.
Laparoscopic cholecystectomy is
one of the most complex endoscop
ic procedures. For its safe comple
tion, it is mandatory that the sur
geon learn the technique under
proper supervision. I believe that if
we follow a proper training in this
procedure and others that will sure
ly follow, our patients will benefit
immensely. The surgeon will not be
embarrassed by complications, and
laparoscopy and laparoscopic sur
gery will enjoy their appropriate
place in the surgical armamentari
um.
This letter therefore is a plea to
my colleagues across Canada to put
aside the emotionalism that has
surrounded this new technique and
responsibly learn, perform and pro
mote this technique for the ultimate
benefit of their patients.
Alex G. Nagy, MD, FRCSC
Ste. 906
750 West Broadway
Vancouver, BC
V5Z 1J3

To the editors. In response to let
ters from Drs. Lomax and Nagy, I
believe that laparoscopic techniques
in general surgery have finally ar
rived and laparoscopic cholecystec
tomy is here to stay.
In an amazingly short time, some
18 months, what was a passing
interest among a few general sur
geons in abdominal laparoscopy,
has, like a “desert storm,” swept
across North America, Europe,
Great Britain and Japan, because
cholecystectomy can be performed
104
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with great facility by video-moni
tored laparoscopic techniques. Dr.
Lomax is not alone in his concern
that this is a “classic example of
enthusiastic and uncontrolled appli
cation of new technology.” Others
have blamed this rapid proliferation
on the unscrupulous drive of com
mercial interests. I disagree. First,
this new technologic advance is the
result of progress in the entire
medical instrumentation industry,
where fiberoptics, light sources and
electronics have provided surgeons
with superb instrumentation in en
doscopy and related fields. Second,
laparoscopic investigation and treat
ment techniques are nearly 30 years
old, but through the recent interest
of surgeons such as Reddick in
Nashville, Tenn. the design of
grasping, holding, dissecting and
clipping instruments has enabled
the safe performance of cholecys
tectomy. Industry has been quick,
as one would expect, being more
aware of opportunity than surgeons
usually are, to see the commercial
value in this new approach. While
we tend to view new surgical prog
ress with scepticism and alarm, in
dustry offered its support to surgi
cal innovators, resulting in a pletho
ra of training programs throughout
North America in this new surgical
technique. For those surgeons who
took advantage of this training ear
ly, their experience now extends
into the hundreds of cases. For
those slower to enter the arena,
training opportunities have been
limited and the shortage of instru
mentation has slowed the practice
of laparoscopic cholecystectomy
even more.
This probably has been for the
good. Drs. Lomax and Nagy rightly
express concern over patient safety
and the all-too-frequent complica
tions from this new procedure when
done by rapidly trained surgeons
still inexperienced in laparoscopic
cholecystectomy but otherwise ma

ture and skilled in general abdomi
nal surgery. Dr. Nagy, an experi
enced laparoscopist, skilled in lapa
roscopic cholecystectomy, wisely
emphasizes that a short course in
laparoscopic cholecystectomy is in
sufficient, and that now the pitfalls
of this procedure are known, those
starting out must avoid a learning
curve strewn with risks to the pa
tient. During the first few proce
dures they perform they should
seek the assistance of a surgeon
experienced in laparoscopic chole
cystectomy.
Large series of patients treated
by laparoscopic cholecystectomy
are now discussed in the literature,
at conferences and workshops. The
results of the surgery are well
known. Complications such as com
mon-bile-duct injury, bowel perfora
tion and hemorrhage are serious
and occur more frequently in the
early experience of the operating
team. Care in selection and perfor
mance does result in reduced mor
bidity. With experience, the myriad
of technical problems and potential
complications do fade. Cholecystec
tomy is still the basic treatment for
symptomatic cholelithiasis, so the
long-term results of laparoscopic
cholecystectomy need be no differ
ent than those of standard cholecys
tectomy. In the short term, the
immediate recovery and return to
full activity is impressively quick
and often spectacular. Patient com
pliance is great, and the public is
now fully aware of the advantages
of laparoscopic cholecystectomy
and is seeking this treatment prefer
entially over the standard proce
dure.
Laparoscopic cholecystectomy
training in Canada is now widely
available from several surgical train
ing institutions. The courses are
given by experienced faculty, and
enough surgeons are practising this
procedure so that help and preceptorships can be available to any
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surgical group in any community to
assist in the start-up and delivery of
this surgical technique.
From this surge of interest in
laparoscopic cholecystectomy, new
skills and application will emanate
for the wider use of laparoscopy in
general surgery. Patients will be
better served in diagnosis, in treat
ment and in recovery. Arguably,
also, there should be an overall
advantage to the health care system
for a treatment plan that keeps
people out of hospital and places
them back into their communities
more quickly after treatment.
I believe that all general surgeons
must be familiar with and, if possi
ble, offer laparoscopic cholecystec
tomy as one of their expert skills.
Nis Schmidt, MD, FRCSC
St. Paul’s Hospital
1081 Burrard St.
Vancouver, BC
V6Z 1Y6

To the editors. I appreciate the
opportunity to comment on corre
spondence from Drs. Lomax and
Nagy, concerning laparoscopic cho
lecystectomy.
I agree with the insight of Dr.
Lomax into patient demand for the
procedure, which currently drives
the surgeon to acquire variable
training in this new procedure, and
consequently increases the risk of
serious biliary complications, which
may result from inadequate experi
ence.
He also raises the question of
credentialling practitioners to pro
vide safe delivery of care through
this technology. The role of the
Royal College of Physicians and
Surgeons of Canada in this capacity
will involve the accreditation of
training programs in general sur
gery in which developing tech
niques in laparoscopic surgery will
become a part of the surgical edu
cation of residents. Thereafter, the
Royal College examinations will

verify completion of training to
standards of the specialty, by certifi
cation of the competent surgeon as
a specialist. However, the creden
tialling of general surgeons certified
before the introduction of laparo
scopic cholecystectomy, “ sur
geons” licensed by the provincial
colleges or those privileged by the
hospital boards, remains the re
sponsibility of individual hospital
boards through their credentials
committees.
Nagy has addressed the issues of
responsibility and specific training.
Responsibility for safe delivery of
surgical care is a part of the con
tract for procedural therapy con
sented to between the surgeon and
the informed patient. Prerequisite
to this responsibility is competence
obtained through accredited resi
dency training or appropriate con
tinuing medical education (CME)
programs. Such programs are usu
ally conducted by universities, na
tional specialty societies or regional
associations.
Credentialling of the quality of
appropriate CME is complex and
may involve the Royal College and
national specialty societies through
the evolution of the Maintenance of
Competence Program (MOCOMP)

under the direction of Dr. John
Parboosingh. At present, the gener
al surgeon is responsible for the
acquisition and maintenance of
competence which may involve new
therapies within the specialty, such
as laparoscopic cholecystectomy. In
order to provide direction for the
specialist, the Canadian Association
of General Surgeons, which is nei
ther a licensing nor a credentialling
body, has prepared1 and approved
guidelines for training in laparo
scopic cholecystectomy as outlined
in Table I. Implied within these
guidelines is a definition of the
general surgeon as one certified as
a specialist by the Royal College.
Upon completion of the training
outlined, the specialist may be eligi
ble for certification upon verifica
tion from the program director that
the registrant has completed the
program or is capable of independ
ent operating — depending on the
nature and duration of the cou-«e.
However, it remains the response .1ity of the hospital boards to approve
competence of the individual sur
geon for performance of laparo
scopic cholecystectomy.
It is gratifying to observe the
number of programs that have de
veloped at centres in Canada to

Table I. The Canadian Association of General Surgeons (CAGS) Guidelines for Training in
Laparoscopic Cholecystectomy
1.
2.
3.

4.
5.

The previously approved CAGS guidelines for laparoscopic cholecystectomy should be
followed.
Training in laparoscopic cholecystectomy may be received in a general surgery residency
program that includes routine laparoscopic cholecystectomy.
Training should be approved by a university and should include the following:
A. Cognitive knowledge including:
(1) laparoscopy,
(2) instrumentation,
(3) electrosurgical units,
(4) indications and contraindications for laparoscopic cholecystectomy,
(5) technique of laparoscopic cholecystectomy, and
(6) prevention, recognition and management of complications.
B. Practical laboratory experience.
C. Experience in the performance of laparoscopic cholecystectomy which may be obtained
as part of a formal university training program or from a general surgeon trained and
experienced in the procedure.
The surgeon is responsible for the adequacy of his or her training and continued
competence in laparoscopic cholecystectomy.
The granting of privileges to perform laparoscopic cholecystectomy remains the
responsibility of the board of directors of each individual hospital.
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enable general surgeons in this
country to acquire training in this
procedure. The window between
technologic advances and the spe
cialist’s education and training is
nearly closed. Programs for ongo
ing evaluation of the procedure and
its place in the general surgical
armamentarium will generate fur
ther information to ensure that re
sponsible care will be delivered by
the general surgeons practising in
our communities.

practice, the balloon of the catheter
was not inflated. After 4 weeks’
feeding through the jejunostomy,
the patient was considered fit for
oral feeding. However, 30 days
postoperatively, the patient report
ed an attack of intestinal colic.
During the attack the Foley cathe
ter migrated into the abdomen.
Clinical examination revealed no ev

idence of intestinal obstruction or
peritonitis.
Gastrointestinal contrast study
demonstrated the Foley catheter,
with the balloon inflated, inside the
intestine (Fig. 1). The patient was
advised to take a fluid diet and fecal
softeners orally. Six days later, the
patient passed the Foley catheter
along with feces.

Roger G. Keith, MD, FRCSC
Department of Surgery
University Hospital
University of Saskatchewan
Saskatoon, SK
S7N 0X0

V
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Enteral Migration of a Foley
Catheter After Jejunostomy
To the editors. In their article,
“ Feeding jejunostomy; a safe ad
junct to laparotomy” (Can J Surg
1990; 33: 181-184) Al-Sheri and
colleagues reported use of a Foley
catheter in 20 patients to construct
a feeding jejunostomy. In this con
text, we find it obligatory to report
an unusual complication of Foley
jejunostomy that we recently expe
rienced.

Case Report
A 37-year-old man had a feeding
jejunostomy constructed when an
anastomotic leak developed after
gastrectomy. A Foley catheter (no.
16 French) was used to construct
the jejunostomy by means of the
Stamm technique. As is our usual
106
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FIG. 1. Barium follow -through film dem onstrating enteral m igration of Foley
catheter (arrows). N ote inflated balloon.
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Comments
In our patient, the balloon of the
Foley catheter must inadvertently
have been inflated postoperatively.
The inflated balloon was propelled
by intestinal peristalsis, causing en
teral migration of the catheter. A
similar mishap in a less fortunate
patient might have resulted in acute
intestinal obstruction, requiring ac
tive interference. Gastrostomy tubes
of the Foley catheter type, incorpo
rating a balloon, have been reported
to cause gastric outlet obstruc
tion.12 The Foley cather has seldom
been recommended for jejunostomy.3 It offers no advantage over
plain catheters. In view of ballooninduced complication — enteral mi
gration of catheter and intestinal
obstruction — the Foley catheter
should not be used to construct a
feeding jejunostomy.
B.K. Jain, MS
R.B. Mehta, MS
Department of Surgery
Jipmer
Pondicherry 605 006
India
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Vaginal Laceration: a
Little-Known Hazard for
Women Water-Skiers
To the editors. Vaginal laceration
with severe hemorrhage is usually
associated with obstetric trauma,
rape or straddle injury. We recently

encountered such an injury associ
ated with water-skiing. Because wa
ter-skiing is increasing in popularity
among women, we wish to warn of
this real, but preventable danger.

Case Report
A 34-year-old woman went waterskiing for the first time wearing an
ordinary bathing suit. During her
several falls, she felt water enter her
vagina but ignored it as there was
no pain. When she got into the boat
to return to shore, she found blood
running down her legs. She was
taken to the local hospital where an
intravenous infusion was set up;
she was then transferred to our
hospital, 1 hour’s drive by ambu
lance.
This woman had been sterilized
after delivering her second child.
Her menses were regular, her last
menstrual period having begun 2
weeks earlier.
On admission, she was pale but
was not in shock. Her hemoglobin
level was 103 g/L . The abdomen
was soft and nontender. Speculum
examination was fruitless due to the
clots in the vagina and bleeding.
Digital examination showed a
closed os with a normal-sized uter
us and no adnexal masses. A lacera
tion was felt in the left fornix. The
patient was examined under anes
thesia without waiting for cross
matching of blood. She gave con
sent for a hysterectomy if it became
necessary for hemostasis. Under
general anesthesia, catheterization
drained clear urine. Clearing the
clots in the vagina revealed a cres
centic vaginal laceration at the for
nix, extending from the 12 o’clock
to 5 o’clock positions. There was
active bleeding apparently from
above the laceration. Suturing the
laceration stopped the vaginal
bleeding. It was not possible, clini
cally, to be certain that the lacera

tion had not extended into the
broad ligament. Therefore laparos
copy was carried out; there was no
evidence of intraperitoneal or broadligament hemorrhage.
The patient made an excellent
recovery and was discharged home
2 days later. Her postoperative he
moglobin level was 83 g /L . Oral
ferrous sulfate was prescribed. At
follow-up 3 weeks later the patient
was well. Her hemoglobin level was
107 g /L , and she was raring to go
water-skiing again, wearing a wet
suit this time

Discussion
A typical fall during water-skiing
is backwards with the thighs ab
ducted. Depending on the speed at
impact, water under pressure may
enter a potential space like the
vagina or rectum, causing a lacera
tion unless protective garments are
worn. In a parous woman in whom
the labia are not in close apposition
during water-skiing, even a minor
accident may result in a major lac
eration with catastrophic hemorrh
age.
Two similar cases reported in
Canada1 were managed by suturing
under local anesthesia. In other
cases reported from Australia23 the
women were examined under gener
al anesthesia, and the lacerations
sutured. Depending on the site,
vaginal lacerations can extend into
the broad ligament or involve the
bladder or rectum. It is therefore
imperative, when there is heavy
bleeding, that these patients are
examined adequately under anesthe
sia. Laparoscopy should be em
ployed when there is a possibility
that intra-abdominal hemorrhage
has occurred.
Water-skiers are often far from a
well-equipped hospital. An uncom
fortable wet-suit (a cut-off pair of
jeans is an acceptable alternative)
CJS, VOL. 34, NO. 2, APRIL 1991
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on a glorious sunny day may make
the difference between life and
death.
S. Kalaichandran, MD, MRCOG

Obstetrician & gynecologist
Prince County Hospital
259 Beattie Ave.
Summerside, PEI
C1N 2A9
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met at their extremities, and dissected
from without inwards through half the
substance of the sphincter ani; then by
the introduction of his finger, he drew
the diseased mass downwards, and re
moved it with a pair of scissars. Two
vessels only required securing. The cure
was completed in three months; the
patient keeps his faeces as well as ever,
and goes to stool without pain.
Bassem N. Nathan, FRCS, FRCS(Edin)

Surgeon
Mayday Hospital
Croydon
Surrey, UK
CRO 8XJ
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Excision of Rectal Cancer:
the First Reported Case
To the editors. Although Lisfranc
(1790-1847) is often credited as
being one of the first surgeons to
excise a rectal cancer,1 direct refer
ence to his work is lacking in the
English colorectal literature. I
would, therefore, like to present the
following description of the opera
tion he performed, as it appeared in
1827.2 It is interesting to see that
the concept of “disease limited to
the mucous membrane” is not, after
all, new.
M. Lisfranc related an operation
that he had performed at the Pitie.2
A cancer was situated at the lower part
of the rectum, extending nearly from
one tuber ischii to the other, and its
antero-posterior diameter being about
two inches in length. The finger could
be passed into the rectum above the
swellings, which were placed at about
two inches around this intestine. The
upper part of the swelling was easily
moved and drawn downwards. M. Lis
franc, supposing that the disease was
limited to the mucous membrane, at
tempted its removal; he made two semi
lunar incisions around the cancer which
108
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tum and Colon, 3rd ed, Bailliere Tindall,
London, 1974
2. Cancer of the lower part of the rectum
(E). Lancet 1827; 1: 10

B.F. Skinner in the
Operating Room
To the editors. Although there
have been many influential contrib
utors to modern education theory,
Burrhus Frederic Skinner is viewed
as perhaps the most important fig
ure in the past three decades.1 Even
though his writings have been con
troversial, and opposing education
theories exist, few would doubt that
much of what Skinner espouses has
considerable practical value when
appropriately applied.
One important aspect of B.F.
Skinner’s theories is his concept of
the use of positive and negative
reinforcement as a means to
strengthen a particular behaviour.
Skinner argues that educators
should concentrate on manipulating
the learning environment. He sug
gests that we should break learning
tasks into small parts, expect suc
cessive mastery of these compo
nents of the task, and, most impor
tantly, positively reinforce upon the

learner completion of each part. He
consistently emphasizes the use of
positive rather than negative rein
forcement as a teaching technique.2
It’s interesting to speculate about
what Skinner would say concerning
“modern” teaching techniques used
in the operating room to train sur
gical residents. Would he approve
of the mode of teaching in which
the use of aversive control is per
haps the dominantly applied psy
chological principle?
Aversive control is linked to the
phenomenon of negative reinforce
ment. The term is applied when a
particular behaviour is strengthened
in response to the removal of a
negative stimulus. The following
example serves to illustrate the con
cept. A staff surgeon is helping a
resident perform an operation. The
resident becomes indecisive and the
surgeon takes over the case as the
primary operator. In this scenario,
the surgeon applies the principle of
negative reinforcement to alter the
resident’s behaviour. The negative
stimulus is “losing the case.” The
desired behaviour is decisive operat
ing. The predicted result is that by
the use of this aversive stimulus,
the next time the resident will be
more decisive in operating. The
problem with this notion, however,
as Skinner points out, is that nega
tive reinforcement is unreliable and
unpredictable. The resident, having
been exposed to this negative stim
ulus, may repeatedly perform in this
undesired, hesitant manner. In addi
tion to withdrawal of privileges,
examples of the use of aversive
control include ridicule and sarcasm
as modifiers of performance and
criticism as a motivator. Few would
argue that this form of behavioural
control is widely employed in the
surgical setting under the guise of
its effectiveness in promoting prop
er surgical technique and the ability
to handle stress.
Skinner would point out that

CORRESPONDENCE

reliance on aversive control, howev
er, is a suboptimal heuristic. He
would state that positive reinforce
ment is certainly more efficient and
predictable, but aversive control can
reinforce unwanted behaviours.3 He
suggests that the use of negative
reinforcement (as well as punish
ment) is ineffectual in the long run,
although of potential success in the
short term. Like punishment, reli
ance on negative reinforcement is
habit-forming and can result in a
long list of unwanted by-products
such as stubbornness, hostility, un
responsiveness and avoidance beha
viour.
Residents, when consistently ex
posed to the use of aversive control,
can experience feelings of undue
anxiety, operate in an overly hesi
tant manner and feel a lack of
accomplishment. A sense of accom
plishment is something that Skin
ner views as integrally important in
an educational sense for continued
growth and maturation.
It is not difficult to imagine that
the change from negative to posi
tive modes of reinforcement can
easily be made. If a resident is
having difficulty with positioning a
needle on the driver, one could
encourage proper placement by

demonstrating appropriate tech
nique instead of criticizing or ridi
culing the mistake. The newly ac
quired correct method could then
be positively reinforced by an en
couraging comment or an appropri
ate gesture. When a resident is
incorrectly performing a manoeuvre
that has the potential for doing
harm to the patient, the surgeon
might, instead of simply taking
over, add a positive word that
would identify the situation as one
that is best handled by the attend
ing surgeon.
If a resident has just received a
scathing criticism, in the immediate
situation it is difficult, if not impos
sible, to learn from that mistake. It
is far more likely in this situation
that the resident’s thought will
dwell on the impact of the criticism
itself, the words expressed, the tone
conveyed and the relationship of
the resident to the attending sur
geon. On the other hand, the estab
lishment of a positive environment
for learning in the operating room,
by a conscious effort to avoid the
use of aversive control, is far more
likely to result in an increased
transfer of knowledge and skills.
Much of what we refer to as
surgical education is a matter of

altering behavioural responses in a
consistent, goal-directed manner.
Although some of the comments
stated here could be construed as
an attempt to promote “ molly-cod
dling” of surgical residents, there is
little reason to believe that sound
and tested educational principles
should not be applicable to the
surgical setting. To this end, Skin
ner would argue that creating an
improved atmosphere for learning
in the operating room by the con
sistent use of positive- rather than
negative-reinforcement techniques,
would serve well to improve the
dependability, efficiency and suc
cess of operative teaching.
Richard K. Reznick, MD
MP8-304
399 Bathurst St.
Toronto, ON
M5S 1B6
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In over 20,000 patients
worldwide who were treated with ‘Rocephin’,
the majority for severe or life-threatening infections,
the clinical efficacy of ‘Rocephin’
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Bronchial Carcinoids: Long-Term
Prognostic Factors
Denis Chapleau, MD, FRCSC;*Arthur Page, MD, FRCSCjf Alain Verdant, MD, FRCSC;t
Gilles Beauchamp, MD, FRCSC;t Gisele Nakhle, MSct
Between 1962 and 1987 bronchial carcinoids were diagnosed in 41 patients (21
men, 20 women) at l’Hopital du Sacre-Coeur and the Centre hospitalier
Maisonneuve-Rosemont. The patients ranged in age from 19 to 73 years (mean 47
years). Fourteen of the 19 asymptomatic carcinoids were discovered on routine chest
radiography. Twenty-two symptomatic patients presented with either pneumonia or
hemoptysis. Tumours involved the right and left lungs equally. Thirty tumours were
located centrally and 11 peripherally. Sensitivity of endoscopic biopsy specimens
was 66%. No complications occurred during biopsy. Cytologic examination of
sputum, lavage, brushing and transthoracic biopsy specimens was of no value in
establishing the diagnosis. Thirty-seven patients underwent surgical resection:
lobectomies (26, 3 with bronchoplasties), pneumonectomies (7), segmentectomies (2)
and wedge resections (2). One patient (3%) died, and there was one major
complication (3%) related to surgery. The mean follow-up was 8 years. The
probability of survival was 97% ± 3 at 5 years and 92% ± 6 at 10 years. None of the
19 patients treated for a peripheral tumour died, but two patients who had centrally
located tumours that exhibited transbronchial invasion and lymph-node metastasis
died. No prognostic information could be gained from tumour size or type. A
statistical association was found between transbronchial invasion and lymph-node
metastasis. Bronchial carcinoids are low-grade malignant tumours. Resection should
be conservative, but lymph-node involvement requires a more radical approach.

ronchial carcinoids originate
from Kulchitsky cells. These
endocrine cells are found in the
submucosal glands o f the central
bronchi and are part o f the mucosal
lining o f peripheral bronchi. For
merly classified as bronchial adeno
mas, these tumours are now consid
ered to be apudomas o f neuroectod
ermal origin with a low secretory
potential.1"3
Through the years, controversies
have centred on classification, diag
nosis, treatment and prognosis. The
purpose o f this study was to evalu
ate the long-term prognostic impor
tance o f some patient and tumour
variables.

B

Methods

De 1962 a 1987, 41 carcinoi'des bronchiques (21 hommes, 20 femmes) ont ete
diagnostiques a l’Hopital du Sacre-Coeur et au Centre hospitalier MaisonneuveRosemont. L ’age des patients variait de 19 a 73 ans (moyenne de 47 ans). Quatorze
des 19 carcinoi'des asymptomatiques furent decouverts a l’occasion d’une radiographie thoracique de routine. Vingt-deux patients symptomatiques montrerent soit
une pneumonie, soit de l’hemoptysie. Les tumeurs touchaient autant le poumon
gauche, que le poumon droit. Trente tumeurs etaient en position centrale et 11 en
Peripherie. La sensibilite de la biopsie endoscopique fut de 66%. Aucune complica
tion n’est survenue en cours de biopsie. L ’examen cytologique des expectorations,
lavages et brossages bronchiques et biopsies transthoraciques n’a pas contribue au
diagnostic. Trente-sept patients subirent une resection : il y eut 26 lobectomies
(dont 3 avec bronchoplastie associee), 7 pneumonectomies, 2 segmentectomies et 2
resections cuneiformes. II y eut un deces (3%) et une complication majeure (3%) de
chirurgie. La surveillance des suites therapeutiques fut de 8 ans. La probability de
survie fut de 97% ± 3% a 5 ans et de 92% ± 6% a 10 ans. Aucun des 9 patients
operes pour un carcinoide peripherique n’est decede, mais deux patients porteurs de
tumeurs centrales envahissant le parenchyme et les ganglions sont morts. Aucune
relation pronostique n’a pu etre etablie avec la taille ou le type histologique de la
tumeur. Une association statistiquement significative a ete notee entre l’envahissement transbronchique et l’atteinte ganglionnaire. Les carcinoi'des bronchiques sont
des tumeurs a faible potentiel malin. Leur resection doit etre conservatrice, mais
l’atteinte ganglionnaire commande une operation plus agressive.
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from Jan. 1, 1962 to Dec. 31, 1987
with the diagnosis of bronchial car
cinoids.
Diagnosis was confirmed in each
case by histologic examination of
biopsy specimens. The following
data were compiled and tabulated
for each patient: sex, age at the
time of diagnosis, mode of presenta
tion and radiographic and bronchoscopic findings.
Patients were classified according
to central or peripheral tumour lo-,
cation, the typical or atypical histo
logic variant and the transbronchial
invasiveness and lymph-node status
of the tumour.
All but one surgical patient (or
their relatives in the case of nonsur
vivors) were either interviewed or
examined. Data were entered on a
CYBER-70 (Control Data, Arden
Hills, Minn.) for validation and sta
tistical analysis. The SPSS4 was
used to perform actuarial analysis
based on the method described by
Berckson and Gage.5
The accuracy of bronchial biopsy
was evaluated by using the method
of Galen.6

Findings
Patient Data

Of the 41 patients, 21 were men
and 20 were women. They ranged
in age from 19 to 73 years (mean
47 years). Patients were referred
mostly because of single or repeti
tive pulmonary infections or abnor
mal findings on routine chest radi
ography (Table I).
Investigation

On chest radiography a hilar
mass or nodule was the most fre
quent finding (Table II). Bronchos
copy showed partial or complete
bronchial obstruction in 27 patients
(Table III). Of these, 16 underwent
endoscopic biopsy. Biopsy was not
112

done in 11 patients investigated
earlier in this series, because of the
risk of hemorrhage. With 10 true
positive, 1 false-positive and 5 false
negative results, the sensitivity of
cytologic examination of endobron
chial biopsy specimens was 66%,
and the predictive value of a posi
tive result was 91%.
No complication was caused by
endoscopic biopsy. Transthoracic
biopsy was done in six patients with
peripherally located tumour, and
the results were negative in all
cases. The results of all cytologic
studies (sputum, brushing and la
vage) were also negative.
No carcinoid syndrome was diag
nosed. However, 5-hydroxyindoleacetic acid (HIAA) levels were ele
vated in two patients presenting
hepatic metastases on postoperative
follow-up.
Surgical Treatment

Thirty-seven patients underwent
surgical resection. Twenty-three
(62%) had a lobectomy or bilobecto
my. Seven (19%) had a pneumonec
tomy and seven (19%) a paren
chyma-sparing procedure (three
sleeve resections, two segmentectomies and two wedge resections).
One patient (3%) died postoperatively of respiratory failure, and one
(3%) suffered a major hemorrhage
which was controlled by reopera
tion.
Pathological Findings

Mean tumour size of resected
specimens was 2.5 cm (range from
0.8 to 6 cm). Tumours were evenly
distributed between right and left
lungs and did not show any prefer
ential lobar location. Bronchial car
cinoids were located centrally (subsegmental or proximal larger bron
chi) in 76% of cases and peripheral
ly (distal and lesser than subsegmental bronchi) in 24%. Nearly half

of the centrally located tumours
demonstrated transbronchial inva
sion (Table IV). Lymph-node metas
tases were present in 10 patients
(27%); 9 had a central tumour with
transbronchial invasion in 8. Typi
cal carcinoid was present in 35
cases (95%); 2 cases (5%) were
atypical.

A *■

Survival and Follow-up

After a mean follow-up of 8
years, actuarial crude postoperative
survival was 97% ± 3% at 5 years
and 92% ± 6% at 10 years (Fig. 1).
Table 1. M o d e o f P re se n ta tio n o f B ro n c h ia l
C a rc in o id s in 41 P a tie n ts

Presentation

Number (% ) of
patients
1 7 (4 1 )
1 4 (3 4 )
5 (1 2 )
1 (2 )
4 (1 0 )

P u lm o n a ry in fe c tio n
X -ra y fin d in g
H e m o p ty s is
A u to p s y
O th e r

Table II. X -ra y F in d in g s
Number (% ) of
patients

Finding

1 8 (4 4 )

H ila r m a s s o r n o d u le
P n e u m o n ia or
in filtra tio n
P e rip h e ra l m a s s o r
n o d u le
N o rm a l

11 (2 9 )
1 0 (2 4 )
2 (5 )

Table III. B ro n c h o s c o p ic F in d in g s
Number (% ) of
patients

Finding
C o m p le te o b s tru c tio n
P a rtia l o b s tru c tio n
N o rm a l
O th e r
N ot done

1 4 (3 4 )
1 3 (3 2 )
1 0 (2 4 )
2 (5 )
2 (5 )

Table IV. P a th o lo g ic F in d in g s in 37
P a tie n ts

Number

Tumour
location

Number with
node
of patients metastases
(*/•)

2 8 (7 6 )
C e n tra l
L im ite d to
b ro n c h u s
15
T ra n s b ro n c h ia l
in v a sio n
13
9 (2 4 )
P e rip h e ra l

9
1
8
1
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Three atypical carcinoids were
diagnosed. Two were small and pe
ripheral. They were resected and
the patients are still alive. The third
was a huge, central, unresectable
tumour, and the patient died 3
months after diagnosis.
All nine patients who underwent
resection for peripherally located
carcinoids are alive. In the unope
rated case the tumour was an au
topsy finding.
Three patients who had centrally
located carcinoids did not undergo
operation because of local invasion
in two cases and a synchronous
inoperable lung cancer in the other.
All three patients died a few months
after diagnosis.
Twenty-eight patients who had a
centrally located carcinoid under
went operation. One patient died as
a result of surgery and two patients
died from liver metastases 7 and 15
years later.

Prognostic Factors

No prognostic information could
be gained by analysing patients’
sex, age at the time of diagnosis,
tumour size or histologic tumour
variants. Tumour location (central
or peripheral) was not statistically
significant, but the trend was to
ward a worse prognosis for central
ly located tumours.
Transbronchial invasion and
lymph-node metastasis considered
independently were of no prognos
tic relevance. However, the only
two late postoperative deaths oc
curred in the subgroup of eight
patients who had centrally located
carcinoids with both transbronchial
invasion and lymph-node metastasis
(Table V). Comparison of this sub
group with the other patients who
had centrally located carcinoids,
showed a nearly significant (p =
0.08) difference in the death rate.

-4

FIG. 1. Postoperative crude actuarial survival of patients who underwent resection.
Mean follow-up was 96 ± 11 months.

Table V. La te M o r ta lity o f R esected C e n tra lly L o c a te d C a rc in o id s
Lymph-node metastasis
Transbronchial invasion
A b s e n t, o = 1 5
P re se n t, n = 12

*p = 0 .0 8 .

Absent,
/> = 18

Present,
n= 9

0 /1 4

0 /1
2 /8 *

0 /4

Interestingly, a statistically signifi
cant association (p < 0.01) was
noted between transbronchial inva
sion and lymph-node metastasis.

Discussion
Bronchial carcinoids represent
1% of pulmonary neoplasms diag
nosed in our hospitals. Diagnosis is
never evident from history, clinical
examination or standard chest ra
diographs.7
Although these tumours may be
associated with carcinoid or Cushin
goid syndromes, such a relationship
was not encountered in this se
ries.1’2

Endoscopic features (fleshy,
smooth, well-vascularized, bosselated appearance) of the tumour are
clues to diagnosis. Even though the
sensitivity of specimens obtained by
endobronchial biopsy is low because
the mucosa is normally intact over
this submucosal growing tumour,
biopsy should be done without fear
of major complications. Submucos
al growth also explains why most
cytologic examinations are likely to
give negative results.
Nevertheless, every effort should
be made to reach a histologic diag
nosis before surgery or at least
intraoperatively. In this series, four
parenchym a-sparing resections,
rather than pneumonectomies,
could have been done if the diagno
sis had been made preoperatively.
Historically, most series have a
20% or lower rate of parenchyma
sparing procedures.8-12 However,
Jensik and colleagues13 treated 70%
of 33 patients with a parenchyma
sparing procedure and reported
good survival rates, thus proving
the reliability of lesser proce
dures.1415
The distinction between centrally
and peripherally located carcinoids
is relevant.1 The former originate
from submucosal glands and pres
ent a more uniform pattern on
CJS, VOL. 34, NO. 2, APRIL 1991
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microscopic examination. The latter
originate from bronchiolar epitheli
um and are more likely to be atypi
cal. However, it is not clear if these
differences have a prognostic signif
icance. McCaughan, Martini and
Bains,10 like us, showed a trend
toward a worse prognosis for cen
trally located lesions, but from their
results Okike, Bernatz and Woolner3 supported an opposite view.
Bronchial carcinoid is related to
oat-cell carcinoma by a common
neuroectodermal origin. Criteria to
differentiate one from another was
established by Fisher, Palekar and
Paulson,16 but their criteria failed to
recognize the atypical carcinoid.
The histologic features (mitosis, ne
crosis, architectural disorder or cel
lular pleomorphism) of this variant,
which carries an intermediate prog
nosis, have been clearly stated by
Arrigonni, Woolner and Bernatz.17
Moreover, electron microscopy and
DNA-content analysis are reliable
methods to differentiate carcinoids
from oat-cell tumours in difficult
atypical cases. Atypical carcinoids,
which have a median patient surviv
al rate of 22 to 33 months, carry a
worse prognosis than typical car
cinoids, but a much better progno
sis than oat-cell carcinoma of the
lung.117
Because of the small number of
patients in our study, we were un
able to produce a definitive state
ment on the prognostic importance
of lymph-node metastasis. Never
theless it is clear from the literature
that this finding indicates a more
ag
gressive surgical approach.11013-15
The same is true when an atypical
carcinoid is encountered.17
The statistically significant asso
ciation between transbronchial inva
sion and lymph-node metastasis
found in patients with centrally lo
cated carcinoids has never to our
knowledge been reported elsewhere.
This association is best explained
114
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by the slow growth pattern of these
tumours, which spread locally, then
regionally and finally metastasize to
distant sites.
Our data indicate a very good 5and 10-year survival. Long-term fol
low-up of patients is mandatory;
our two late deaths occurred 7 and
15 years after treatment. We have
also observed a patient who under
went a pneumonectomy in 1948
and presented 26 years later with
an inoperable recurrence in the me
diastinum.
Most patients treated for bronchi
al carcinoids are cured by surgery.
However, aggressive surgery is usu
ally not required because conserva
tive procedures are likely to give
comparable results.1415
We now prefer parenchyma-spar
ing procedures in the following si
tuations:
• for typical tumours without
lymph-node metastasis if lung tis
sue distal to the tumour has not
been adversely affected by repetitive
infectious trauma,
• for atypical tumours or tu
mours that have metastasized to
the lymph nodes, if lung conserva
tion is functionally important for
the patient.

References
1. Carter D, Eccleston JC: Carcinoid tu
mors. In: Tumors o f the Lower Respira
tory Tract. Atlas o f Tumor Pathology,
Armed Forces Institute of Pathology,
Washington, DC, 1980; 162-188
2. Duh QY, Hybarcer CP, G eist R: Car
cinoids associated with multiple endo
crine neoplasia syndromes. Am J Surg
1987; 154: 142-148
3. Okike N, Bernatz PE, Woolner LB:
Carcinoid tumors of the lung. Ann Tho-

rac Surg 1976; 22: 270-275
4. Nie NH, Hull CH, J enkins JG et al:

SPSS: Statistical Package for the Social
Sciences, 2nd ed, McGraw, New York,
1975
5. Berkson J, Gace R: Calculation of sur
vival rate for cancer. Proc Staff Meet
Mayo Clin 1950; 25: 270-286
6. Galen RS: Predictive value of laboratory
tests (C). Am J Cardiol 1975; 36: 536538
7. Altman RL, Miller E, Carr DT et al:
Radiographic appearance of bronchial
carcinoid. Thorax 1973; 28: 433-434

T, Blondal T, Nou E et al: The
choice of operation for bronchial car
cinoids. Ann Thorac Surg 1980; 32:
19-21

8. A berc

9. Turnbull AD, Huvos AG, Goodner JT
et al: The malignant potential of bron
chial adenoma. Ann Thorac Surg 1972;
14: 453-461

10. McCaughan BC, Martini N, Bains MS:
Bronchial carcinoids. Review of 124
cases. J Thorac Cardiovasc Surg 1985;
89:8-15
11. Ricci C, P atrassi N, Massa R et al:
Carcinoid syndrome in bronchial adeno
ma. Am J Surg 1973; 126: 671-676

Conclusions

12. Todd TR, Cooper JD, W eissberg D et
al: Bronchial carcinoid tumors. Twenty
years experience. J Thorac Cardiovasc
Surg 1980; 79: 532-536

Bronchial carcinoids are lowgrade malignant tumours that
occur infrequently and for which
endobronchial biopsy results have a
low sensitivity. Fear of hemorrhagic
complications with endobronchial
biopsy is unjustified.
Transbronchial invasion is predic
tive of nodal metastasis. Prognosis
may be related to features such as
transbronchial invasion and lymphnode involvement. Hence, surgical
treatment should generally be con
servative unless such features are
present and the patient’s pulmonary
reserve permits a more aggressive
resection.

13. Jensik RJ, Faber LP, B rown CM et al:
Bronchoplastic and conservative resec
tional procedures for bronchial adeno
ma. J Thorac Cardiovasc Surg 1974; 68:
556-565
14. Cooper DKC, Belcher JR: Conservative
surgery for bronchial adenomata. Tho
rax 1976; 31: 44-48
15. Hurt R, Bates M: Carcinoid tumours of
the bronchus: a 33-year experience.
Thorax 1984; 39: 617-623
16. Fisher ER, Palekar A, P aulson JD:
Comparative histopathologic, histochemical, electron microscopic and tis
sue culture studies of bronchial car
cinoids and oat cell carcinoma of the
lung. Am J Clin Pathol 1978; 69: 165172
17. A rriconi MG, W oolner LB, B ernatz
PE: Atypical carcinoid tumor of the
lung. J Thorac Cardiovasc Surg 1972;
64: 413-421
For prescribing information see page 156 —

ADVANTAGE: INSTAT
Collagen Absorbable Hemostat

Microfibrillar Collagen Hemostat

INSTAT* Collagen Absorbable Hemostat

INSTAT*
Collagen Absorbable Hemostat

A collagen hemostat that w ont stick
to gloves or instruments
• Easy to apply - wet or dry
• Easy to remove - or suture in place

r
a#

For rapid hem ostasis*,
choose non-stick

'Hemostasis with IN StAT* Collagen Absorbable
Hemostat is achieved within 2-5 minutes, depending on severity of bleeding.

SEE FOR
YOURSELF!

INSTAT*
Icollagen
■absorbable hemostat

MEDICAL PRODUCTS
’ Trademark of Johnson & Johnson
®1991 Johnson & Johnson MEDICAL
PRODUCTS Inc.

Complete and return this cou
pon to us. Our representative
will arrange a product
demonstration and supply
you with a FREE STERILE
SAMPLE.

PLEASE PRINT

Name:
Hospital:

Dept.:

Address:
City:

Prov.:

Postal Code:

Tel.:

Johnson & Johnson Medical Products Inc.
c/o INSTAT Absorbable Hemostat
P.O. Box 2044
Peterborough, Ontario K9J 7Y4

as

ErgamisoF + 5~FU.
The first adjuvant therapy proven to
reduce recurrence by 41%.
LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF
RESECTED COLON CARCINOMA
Abstract Twelve hundred ninety-six patients with resected
colon cancer that either was locally invasive (Stage B2) or
had regional nodal involvement (Stage C) were randomly
assigned to observation or to treatment for one year with
levamisole combined with fluorouracil. Patients with Stage
C disease could also be randomly assigned to treatment
with levamisole alone. The median follow-up time at this
writing is 3 years (range, 2 to 5%].
Among the patients with Stage C disease, therapy with
levamisole plus fluorouracil reduced the risk of cancer
recurrence by 41 percent (P < 0.0001). The overall death
rate was reduced by 33 percent (P == 0.006). Treatment
with levamisole alone had no detectable effect. The results
in the patients with Stage B2 disease were equivocal and

too preliminary to allow firm conclusions. Toxic effects of
levamisole alone were infrequent, usually consisting of
mild nausea with occasional dermatitis or leukopenia,
and those of levamisole plus fluorouracil were essentially
the same as those of fluorouracil alone-i.e., nausea,
vomiting, stomatitis, diarrhea, dermatitis, and leukopenia.
These reactions were usually not severe and did not greatly
impede patients’ compliance with their regimen.
We conclude that adjuvant therapy with levamisole and
fluorouracil should be standard treatment for Stage C
colon carcinoma. Since most patients in our study were
treated by community oncologists, this approach should
be readily adaptable to conventional medical practice.
(N Engl J Med 1990; 322:352-8.)'
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Efficacy and Distribution of Single-Dose
Preoperative Antibiotic Prophylaxis
in High-Risk Gastroduodenal Surgery
Ronald T. Lewis, MD, FRCSC, FACS; R. Graydon Goodall, MD, FRCSC, FACS;t
Breen Marien, MD, FRCSC;$ Myung Park, MD, FRCSC;$ Walter Lloyd-Smith, MD, FRCSC, FACS;*
Frederick M. Wiegand, MD, FRCSC, FACS*
Although a single preoperative dose of antibiotic is now the accepted means of
preventing postoperative surgical infection, the method has not been investigated
adequately. In patients at high risk of infection who underwent gastroduodenal
operations, the authors compared single-dose prophylaxis by intravenous cefotaxime
(26 patients) with short-course perioperative prophylaxis (27 patients). No wound
infection occurred, but in one patient in each group a subphrenic abscess developed
after leakage at the anastomosis. The half-life of cefotaxime (1.23 ± 0.12 hours) and
its apparent volume of distribution (16.7 ± 2.6 L/1.73 m2 resulted in perioperative
levels of the antibiotic in blood (34.76 ± 4.21 /xg/mL), gastric mucosa (32.04 ±
5.22 pg/mL) and subcutaneous fat (24.98 ± 5.89 pg/mL) more than twice the usual
minimal inhibitory concentration of the drug for organisms grown from the stomach
contents and wound fat.
These clinical and pharmacologic findings validate the efficacy of a single
preoperative intravenous dose of the antibiotic in preventing postoperative infection
in high-risk patients who undergo gastroduodenal surgery.
L’administration preoperatoire d’une dose unique d’antibiotique represente actuellement la norme pour prevenir les infections de plaie postoperatoires, mais cette
methode n’a pas ete etudiee adequatement. Chez des patients a haut risque
d’infection qui subirent des operations gastroduodenales, les auteurs ont compare
l’efficacite preventive d’une seule dose intraveineuse de cefotaxime (26 patients) a
celle d’une prophylaxie peroperatoire de courte duree (27 patients). Aucune
infection de plaie n’est survenue mais, dans chaque groupe, un abces sous-diaphragmatique est apparu apres fuite de l’anastomose. La demi-vie de la cefotaxime (1.23 ±
0.12 heure) et son volume apparent de distribution (16.7 ± 2.6 L/1.73 m2) a permis
d’obtenir des taux peroperatoires d’antibiotique dans le sang (34.76 ± 4.21 qg/m L),
dans la muqueuse gastrique (32.04 ± 5.22 pg/mL) et dans le tissu adipeux
sous-cutane (24.98 ± 5.89 pg/mL), deux fois plus eleves que les concentrations
minimales inhibitrices generalement requises pour les microorganismes retrouves
dans contenu stomacal et le tissu adipeux de la plaie.
Ces resultats cliniques et pharmacologiques justifient l’emploi d’une dose unique
de cet antibiotique par voie intraveineuse pour prevenir les infections
postoperatoires chez les patients a haut risque qui subissent une chirurgie
gastroduodenale.
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he efficacy of perioperative an
tibiotic prophylaxis in patients
who undergo gastroduodenal opera
tions is well established . 1^5 Howev
er, the optimal duration of the
antibiotic regimen has not been
defined. Stone and colleagues 6
showed that no additional benefit
results when the antibiotic is con
tinued beyond the day of surgery.
In a prospective study of high-risk
patients we found 7 that two doses
o f antibiotic provide effective pro
phylaxis. Hares and associates 4 ob
tained good results in patients who
received only a single preoperative
dose of cefuroxime, and this ap
proach has been recommended 8 and
applied by others .9 However, single
dose prophylaxis has not been
adopted widely. Furthermore, the
method has not been validated by
comparison with the standard
short-course regimen in a random
ized clinical trial, nor have any
attempts been made to correlate
efficacy with pharmacokinetic activ
ity of the antibiotic.
In this study, performed in pa
tients at high risk of postoperative
surgical
infection
after
ga s
troduodenal operations, we com
pared the efficacy of a single preop
erative dose with that of a short
course of the third-generation ceph
alosporin, cefotaxime. This antibiot
ic has not been found to be superior
to first-generation cephalosporins in
studies on prophylaxis . 1011 Cefotax
ime was selected because its extend
ed antibacterial spectrum is appro
priate to the greater likelihood of
wound contamination by aerobic
gram-negative bacteria in the high-
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risk patients studied.12-15 In this
way, the risk of confounding the
evaluation by postoperative infec
tion due to contaminating bacteria
resistant to the treatment antibiotic
was reduced. We also sought to
correlate the clinical effects of the
antibiotic with pharmacokinetic ac
tivity in blood and tissue.

Patients and Methods
Consecutive patients who under
went high-risk gastroduodenal sur
gery or emergency surgery for
bleeding gastroduodenal lesions
were studied. Patients at high risk
of postoperative infection have pre
viously been designated as those
with gastric cancer, gastric ulcer or
upper gastrointestinal bleeding, and
patients receiving histamine-2 re
ceptor blockers who undergo elec
tive operations for duodenal ulcer
intractable to medical therapy.513-16
The exclusion criteria were allergy
to cephalosporins or major allergy
to penicillin, refusal of informed
consent, additional operations on
the large bowel, a preoperative
serum creatinine level exceeding
273 mmol/L, grossly abnormal
liver function test results, pregnan
cy, antibiotic therapy in the preced
ing 24 hours and the presence of
established infection. The name,
age, gender, weight and height of
each patient were noted. Routine
hematologic and biochemical blood
tests were performed before surgery
and were repeated on postoperative
day 2. The preoperative serum albu
min and serum iron levels and the
iron-binding capacity (TIBC) were
measured by standard methods. At
operation, after the surgeon had
confirmed the position of the naso
gastric tube in the stomach, a sam
ple of gastric contents was aspirat
ed and the pH was measured using
pH paper. When the stomach was
opened, a swab of the mucosa was
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taken for routine culture; the sub
cutaneous fat of the wound was
also swabbed for culture before the
skin was closed. The swabs were
plated on 5% sheep’s blood agar
and MacConkey’s agar for growth
of aerobic and facultative anaerobic
bacteria and on trypticase soy agar
with sheep’s blood with gentamicin
and Brewer’s meat broth for growth
of anaerobic bacteria. The patients
were randomized using standard
statistical tables (Roussel Canada
Inc. Montreal) to receive the single
dose regimen (cefotaxime, 2 g by
rapid intravenous injection on call
to surgery) or the short-course regi
men (2 g cefotaxime on call to
surgery plus 2 g of cefotaxime
administered 4 hours later). Pa
tients having emergency operations
for gastrointestinal bleeding, who
have the highest risk of postopera
tive infection were stratified in a
separate randomization schedule. In
12 patients chosen at random, seri
al samples of blood were obtained
for assay of cefotaxime and cefotax
ime metabolites, before giving cefo
taxime, and at 30 minutes and 1, 2,
3 and 4 hours after. In these pa
tients a piece of gastric mucosa and
a sample of subcutaneous fat were
obtained for assay of tissue concen
trations of cefotaxime. At the end
of the operation blood was taken
from all patients for assay of the
postoperative blood concentrations
of cefotaxime and metabolites. The
assay of cefotaxime and cefotaxime
metabolites in blood and tissue was
performed using the high-pressure
liquid chromatography method
(HPLC), which shows good correla
tion with microbiologic assay by the
agar well-plate method.17
After surgery, the patients were
followed up by infection control
personnel who were not aware of
the patients’ treatment group. The
wound was inspected on postopera
tive days 5 and 7 and thereafter as
required, and a further report was

obtained from the surgeon 1 month
after operation.
A wound infection was diagnosed
when pus drained from the wound18
and a sample of the pus was ob
tained for culture. Postoperative
pneumonia was diagnosed by clini
cal examination and confirmed by
chest radiography and sputum cul
ture. Urine was obtained for culture
on postoperative day 5 for assess
ment of postoperative urinary tract
infection. Intra-abdominal infections
were diagnosed by the usual wellknown clinical and radiologic meth
ods. Patients were followed up for
adverse clinical occurrences, and for
hematologic and biochemical abnor
malities attributable to the antibiot
ic.
The preoperative blood lympho
cyte count, an index of the immune
status of the patient,19 was calculat
ed as the product of the total
leukocyte count and the percentage
of lymphocytes on the differential
blood smear. Ideal body weight for
height was determined from stan
dard tables20 and the percentage
actual of ideal body weight for
height was calculated for each pa
tient. A fever index was calculated
as the number of postoperative days
after the initial 48 hours on which
the body temperature exceeded
38°C. A risk index of postoperative
infection was calculated from the
age of the patient, the presence of
bacteria in the subcutaneous fat of
the wound before skin closure, the
wound class21 and the duration of
surgery. This index has previously
been validated as an indicator of
risk of wound infection in a pro
spective study by Davidson, Clark
and Smith.22 The serum transferrin
value was calculated from the
TIBC.23
Kinetic evaluation of the rapid
intravenous injection of cefotaxime
was made using a first-order, twocompartment open model. Serum
concentrations were plotted on
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semilogarithmic paper, and the ter
minal points, which appeared to be
randomly distributed about a
straight line, were used to calculate
the serum half-life, elimination rate
constant, area under the curve,
serum clearance and apparent vol
ume of distribution for the 0
phase.24’25
Statistical evaluation was per
formed when necessary, using Stu
dent’s f-test for comparison of in
dependent samples, and by x2 anal
ysis with Yates’ modification.

Results
Fifty-five patients were studied.
Two patients, one from each treat
ment group, died within 7 days of
surgery; 1 had advanced metastatic
gastric cancer, and the other had a
severe coagulopathy. Of the remain
ing patients 26 received the single
dose regimen and 27 received shortcourse cefotaxime prophylaxis.
Four patients in the single-dose
group received antibiotics postoperatively (none before postoperative
day 4), two for anastomotic leaks,
one for unexplained fever and one
for aspiration pneumonia. Two pa
tients in the short-course group
were given antibiotics postoperatively, one for an anastomotic leak
7 days after operation and the other
for unexplained fever on postopera

tive day 4. In three patients tissue
samples for cefotaxime assay were
lost or were not taken.
Table I shows that the treatment
groups are evenly matched with
respect to demographic and other
risk factors. However, significant
differences were found between pa
tients having elective operations
and the highest risk patients, who
underwent emergency surgery for
upper gastrointestinal bleeding (Ta
ble II). No wound infection was
observed in either treatment group.
Two patients who received only one
dose of cefotaxime suffered anasto
motic leaks; in one case a cervical
esophageal fistula and in the other
a left subphrenic abscess, which
required operative drainage. Culture
of this material yielded streptococci,
which had also grown from the
stomach swab, Hafnia sp. and Alcaligenes sp., the latter resistant to
cefotaxime. One patient who re
ceived short-course cefotaxime pro
phylaxis sustained a small leak

from the duodenal stump; a right
subhepatic abscess developed that
required operative drainage. The
drainage fluid yielded streptococci
and peptostreptococci. Culture of
the stomach content from this pa
tient yielded Candida sp.
Postoperative pulmonary and uri
nary tract infections were uncom
mon. Of the patients receiving sin
gle-dose cefotaxime, one had a uri
nary tract infection due to Es
cherichia coii and Pseudomonas sp.,
and three patients had postopera
tive pneumonia due to Staphylococ
cus aureus, Streptococcus pneumo
niae and Pseudomonas sp. respec
tively. Of patients receiving shortcourse cefotaxime, three suffered
urinary tract infections due to E.
coii and Pseudomonas sp., E. coli
and enterococci, and Staphylococ
cus epidermidis respectively. One
patient had pneumonia postoperatively due to Pseudomonas sp. The
mean fever index was 2.89 ± 2.02
days after single-dose prophylaxis

Table II. Emergency Versus Elective Surgery*
Factor

Elective

Age, yr
Preoperative lymphocyte count,
x 109/L
Risk index, %
Weight, actual/ideal, %
Serum albumin, g/L
Serum transferrin, g/L

Emergency

/rvalue

57.25 ± 16.3

67.45 ± 1 1 .8

0.048

1.626
28.7
107.5
37.5
22.2

2.252
41.8
125.8
28.2
18.4

0.007
0.012
0.015
0.003
0.26

± 0.548
± 13.6
± 2 3 .3
± 6.4
± 5.5

± 1.006
± 2 0 .2
± 16.4
± 4.3
± 4 .1

'Values are mean ± standard deviation.

Table 1. Comparison of Patient Groups
Factor
Age, yr*
Male/female
Preoperative lymphocyte
count, x 109/L *
Risk index, %*
Weight actual/ideal, %*
Serum albumin, g/L*
Serum transferrin, g/L*
Resection/no resection
Emergency/elective
Secondary diagnosis/none
Gastric pH, > 4 /< 4 /n o t done

Single dose,
rr = 26

Short course,
rr= 27

t ( x2)

/rvalue

60.2 ± 16.7
19/7

59.3 ± 15.1
21/6

0.196
0.006

0.846
0.534

1.755 ± 0 .6 9
31.8 ± 15.5
114.1 ± 27.7
36.8 ± 7.32
23.1 ± 6.1
21/5
7/19
8/18
1 7/5/4

1.788 ± 0 .7 5
31.6 ± 16.8
109.7 ± 17.4
35.9 ± 6.46
20.9 ± 4.6
23/4
6/21
10/17
19/6/2

0.167
0.05
0.686
0.43
1.18
0.004
0.006
0.037
0.213

0.868
0.96
0 496
0 669
0.245
0 503
0 534
0 662
0.544

’ Values are mean ± standard deviation.
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compared with 3.19 ± 2.02 days
for short-course cefotaxime prophy
laxis (p = 0.645).
A variety of gram-positive and
gram-negative bacteria as well as
Candida albicans were grown from
the stomach contents (Table III). Of
those receiving single-dose cefotax
ime an average of 1.8 organisms
per positive culture were obtained
from the stomach, and of those
receiving short-course cefotaxime
prophylaxis 2.1 organisms per posi
tive culture were obtained from the
stomach. Culture of the subcutane
ous fat in the two treatment groups
yielded organisms four and five
times respectively. The organisms
were invariably similar to those
grown from the stomach. An aver
age of 1.4 organisms per positive
culture were obtained in patients
receiving single-dose cefotaxime,
and 2 organisms per positive cul
ture in those receiving short-course
cefotaxime.
The results of HPLC assay of
blood and tissue for cefotaxime and
metabolites (Figs. 1 and 2, Table
IV) show that the mean postopera
tive plasma cefotaxime concentra
tion 181.4 ± 6.2 minutes after
administration was 34.76 ± 4.21
jtig/mL. This value is more than
twice the usual minimal inhibitory
concentration (MIC90) for the bacte
ria grown from the stomach. Simi
lar high tissue concentrations of
cefotaxime were identified in gastric
mucosa (mean 32.04 ± 5.22
/xg/mL) and in the subcutaneous
fat (mean 24.98 ± 5.89 ng/m L),
124.2 ± 15.6 minutes after antibi
otic administration.
No adverse hematologic or bio
chemical abnormalities due to the
administration of cefotaxime were
noted clinically, but four patients
had transient elevations of serum
bilirubin levels after receiving sever
al blood transfusions to replace
blood lost through gastroduodenal
bleeding.
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Discussion
This comparative study of singleversus short-course cefotaxime

sought not to justify the use of
cefotaxime for prophylaxis in highrisk gastric surgery but to validate
the efficacy of single-dose prophy-

T a b le III. B acte riologic Findings — S tom ach C ontents and S ubcutaneous Fat
Findings

Stom ach contents
No grow th
G ram -positive co cci*
C o lifo rm s t
Candida sp.
C lostrid iu m sp.
No. is o la te s /p o s itiv e specim en
Subcutaneous fa t
No grow th
G ram -positive co cci*
C lostrid iu m sp.
Candida sp.
No. of is o la te s /p o s itiv e specim en

S in g le dose

S h o rt course

12
16
4
5
1
1.8

12
16
7
6
4
2.1

16
5
1
1
1.4

17
6
2
0
2.0

'S tre p to c o c ci and stap hylococci.
t Escherichia coli, E nterobacter. K lebsiella and Pseudom onas sp.

FIG. 1. Mean serum levels ± standard error of cefotaxime (closed circles) and
cefotaxime metabolites (open circles) with rapid intravenous injection of 2 g of
cefotaxime.
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laxis. A single dose of cefotaxime
given just before surgery was strik
ingly effective in preventing postop
erative infection. Although the re
sults are equal in the two treatment
groups, they are far better than the
postoperative surgical infection rate
of 15% to 25% usually seen in the
absence of antibiotic prophylaxis,
and documented at this institution
in a previous double-blind random
ized controlled study.3 A control
group was not included in the pres

ent study because we believed it
was not ethical to do so. In the
older study, a difference of greater
than 25% was observed between the
trial group and the placebo group.
At least 52 subjects were therefore
required (a < 0.05) for an 80%
chance of detecting a similar differ
ence between short-course prophy
laxis and the experimental single
dose group.26 Our results confirm
that the treatment groups were
evenly matched. Further, the find

cefotaxime
jug/mL
100

80

60

•••

40

••••••

□□

_□_
20

□

ings summarized in Table II empha
size the importance of stratifying
the patients studied.
One patient from each group
(3.8%) had a subphrenic abscess
postoperatively. In each case techni
cal failure in the anastomosis or
suture line rather than antibiotic
failure accounted for it. The non
specific postoperative infections of
the urine and lungs were equally
frequent in the two treatment
groups. Local factors are probably
of greater importance than antibiot
ic prophylaxis in the genesis of
these complications.
The efficacy of cefotaxime in pre
venting postoperative surgical infec
tion correlated well with the phar
macokinetic distribution found.
With the half-life and volume of
distribution obtained, a single pre
operative dose of cefotaxime was
usually sufficient to provide high
blood levels throughout the surgi
cal procedure. In addition, cefotax
ime was well distributed in gastric
mucosa and in the subcutaneous fat
of the wound. Adequate concentra
tions of antibiotic in these tissues
are of critical importance in pre
venting postoperative surgical infec
tion.27
Cefotaxime inhibits the majority
of Enterobacteriaceae below a con
centration of 0.2 Mg/mL; it inhibits
gram-positive species such as S.
aureus and Streptococcus pyogenes
at concentrations under 3 y,g/m L.
In this study, the mean concentra
tions of cefotaxime in blood, gastric

□□

••••
•••••

T a b l e IV . K in e tic P a ra m e te rs o f C e fo ta x im e ,
2 g G iv e n b y R a p id In fu s io n *
H a lf-life , h

0

1 .2 3 ± 0 .1 2

E lim in a tio n ra te c o n s ta n t,

Blood

Fat

Mucosa

h -'

0 .6 4 ± 0 .0 7

A re a u n d e r c u rv e ,
jig /m U r '

2 5 2 .5 ± 2 6 .9

S e ru m c le a ra n c e ,

FIG. 2. Scattergram shows isolated measurements of postoperative serum concen
trations of cefotaxime in 50 patients, and of tissue concentrations of cefotaxime in
wound fat and gastric mucosa just before closure of abdomen. Horizontal lines
represent mean concentrations.

m L /m in - 1 .7 3 m ~ 2

1 7 6 .0 4 ± 3 3 . 1

A p p a re n t v o lu m e o f
d is tr ib u tio n , L / 1 . 7 3 m 2

1 6 .7 ± 2 . 6

‘ V a lu e s are m e a n ± s ta n d a rd e rro r.

CJS, VOL. 34. NO. 2, APRIL 1991

121

LEWIS ET AL

mucosa and subcutaneous fat were
well above the usual levels of MIC90
of the bacteria grown from the
stomachs of 29 patients and from
the subcutaneous fat of the wound
in 9 patients. These findings sub
stantiated the clinical success of
cefotaxime in preventing wound in
fections. Potent activity of cefotax
ime against gram-positive cocci af
forded good protection against the
staphylococci and streptococci
grown in most patients. In a previ
ous study,3 a second-generation
cephalosporin failed in one patient
who had a staphylococcal abscess.
In addition, the expanded spectrum
of cefotaxime covered well the di
verse spectrum of gram-negative
bacteria grown from the stomach
and subcutaneous fat in some highrisk patients.13' 15 Some of the gram
negative bacilli grown from the
stomach in our study were resistant
to first-generation cephalosporins
and might have complicated the
evaluation had one of these agents
been used.

Conclusions
In this prospective randomized
study, a single preoperative dose of
the antibiotic cefotaxime was as
effective as a two-dose regimen in
preventing postoperative surgical
infection in high-risk patients who
underwent gastroduodenal surgery.
No wound infection occurred in
either treatment group.
This salutary clinical effect corre
lated with the distribution of the
antibiotic in the blood, gastric mu
cosa and subcutaneous fat of the
abdominal wound. The concentra
tions of antibiotic found in these
tissues exceeded by far the usual
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values of MIC90 of contaminating
bacteria found in the stomach and
wound fat.
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Human Lymphocyte Responsiveness
Is Not Enhanced by Relief of Biliary
Obstruction: an In-Vitro Study
R.F. Pace, MD, FRCSC;* R. Gonzaga, MB, FRCS; E. Kaminski, MB, FRCP;
H.J.F. Hodgson, MB, PhD, FRCP; I.S. Benjamin, MB, BSc, PhD, FRCS
Impaired cell-mediated immunity has been described in obstructive jaundice and has
been attributed to depressant serum factors or to depressed intrinsic T-cell function.
The authors studied lymphocyte responsiveness to phytohemagglutinin stimulation,
the in-vitro correlate of T-cell function, in 11 patients with biliary obstruction.
Peripheral-blood mononuclear cells and serum were obtained before (mean serum
bilirubin level 302 pmo\/L) and after (mean serum bilirubin level 23 pmo\/V)
treatment of the biliary obstruction. Simultaneous cell culture of all samples
disclosed no evidence of a serum depressant factor in patients with obstructive
jaundice, and crossover incubation studies failed to suggest that there is a
depression of intrinsic T-cell responsiveness that can be reversed by biliary
drainage.
Une baisse de l’immunite cellulaire a ete decrite en rapport avec l’ictere par
obstruction, et elle a ete attribute a des facteurs seriques immunosuppresseurs ou a
une depression de la fonction intrinseque des cellules T. Les auteurs ont etudie la
reactivite des lymphocytes a une stimulation par la phytohemagglutinine, la
correlation in vitro de la fonction des cellules T, chez 11 patients souffrant d’ictere
par obstruction. Des cellules mononudeaires du sang peripherique et du serum ont
ete preleves avant (bilirubinemie moyenne de 302 /nmoI/L) et apres (bilirubinemie
moyenne de 23 #tmol/L) traitement de l’obstruction biliaire. La culture cellulaire
simultanee de tous les prelevements n’a revele aucun indice d’un facteur serique
immunosuppresseur chez les patients souffrant d’ictere par obstruction, et des
etudes d’incubation en chasse-croise n’ont pas permis d’indiquer qu’il existe une
depression de la reactivite intrinseque des cellules T pouvant etre inversee par un
drainage biliaire.

epsis is a major cause of mor
bidity and mortality in patients
with obstructive jaundice12 and may
be due to alterations in host-defence
mechanisms. Impaired cell-mediated
immunity has been implicated in

S

this increased susceptibility to infec
tion,3 possibly as a result of either a
serum depressant factor or impaired
intrinsic T-cell function. We studied
the in-vitro correlate of T-cell func
tion, lymphocyte responsiveness to
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phytohemagglutinin (PHA) mitogen
stimulation, in patients with ob
structive jaundice in an effort to
document the alterations in cellular
immunity that occur before and
after relief of the obstruction.

Patients and Methods
Patients proven to have obstruc
tive jaundice without clinical evi
dence of cholangitis were evaluated
before and after successful treat
ment of the cholestatic state. Peri
pheral-blood mononuclear cells and
aliquots of serum were collected at
each time point and stored until the
time of study. This was done to
permit simultaneous culture of the
jaundiced cells and the cells ob
tained following convalescence,
after resolution of jaundice. In this
fashion, the day-to-day variations in
cell culture conditions could be
avoided, and each patient could act
as his own control.
Lymphocytes were isolated on a
Hypaque-Ficoll density gradient,4
and, following three washes with
RPMI 1640 medium, the cell count
was adjusted to 7.5 X 106/m L . An
equal volume of 20% dimethylsulfoxide in fetal calf serum (FCS) was
added to the cell solution, and the
resultant mixture was slowly cooled
to —60 °C, then stored in liquid
nitrogen. Lymphocytes from a nor
mal donor were similarly isolated
CJS, VOL. 34, NO. 2, APRIL 1991
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and frozen for simultaneous study
with the patients’ cells.
The previously frozen cells were
thawed in a water bath at 37°C.
After three washes, the count of
viable cells was adjusted to 1 X
106/m L in RPMI 1640 with added
L-glutamine (0.3 m g/m L ), penicillin
(50 IU/mL) and streptomycin (50
Mg/mL). Triplicate cultures of 135
mL of the different lymphocyte solu
tions (jaundiced, convalescent and
normal donor cells) were set up in
96-well microtitre plates with 15 mL
of added serum (jaundiced, conva
lescent or FCS) to create a 10%
final serum concentration in each
well. To each group of three wells
was added either saline (unstimulat
ed) or PH A at dilutions of 1:10 or
1:100 (stimulated). After 72 hours
of incubation at 37°C in humidified
5% carbon dioxide, the cells were
labelled by adding 0.5 m Ci/well of
thymidine. After 4 hours the cells
were harvested on a Mash II harves
ter (Skatron AF, Lierbyen, Norway),
and the thymidine incorporation
was measured on a Beckman LS
1801 scintillation counter (Beck
man Instruments Inc., Irvine, Ca
lif.). The results were expressed as
the stimulation index (SI) where SI
=
stimulated cell c o u n t/u n stimulated cell count.
When appropriate, the paired
Student’s f-test was used to assess
statistical significance.

Results
Incubation studies were complet
ed for 11 patients, all of whom
presented with malignant biliary ob
struction (Table I). Treatment con
sisted of nonoperative internal bili
ary stenting in six patients and
operative biliary bypass in five. One
patient in the operated group had a
Whipple resection for a cholangiocarcinoma of the lower end of the
common bile duct. Serum samples
124
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and lymphocytes were obtained im
mediately before and 6 weeks after
treatment. All patients were deeply
jaundiced at the time of presenta
tion, the mean serum bilirubin level
being 313 /j,n10I/L (range from 181
to 475 |umol/L). After treatment
the serum bilirubin level dropped to
a mean of 23 mhioI/L (range from 9
to 41 jot10I/L).
The results of the incubation
studies at a PHA dilution of 1:10
are shown in Table II and Fig. 1.
No significant difference was found
between the mean SI obtained after
culture in jaundiced or convalescent
serum for any of the three cell types
studied (paired Student’s t-test). A
similar result was obtained after
stimulation with a PHA dilution of
1:100. These findings suggest that
there is no humoral factor present
in the icteric serum that might
significantly impair lymphocyte re
sponsiveness.
With respect to the responses of
the jaundiced and convalescent cells
in 10% FCS, no difference was
evident between the mean SI values.
This similarity held true for culture
in both of the autologous serum

samples, suggesting that there is no
difference in intrinsic T-cell func
tion whether or not cholestasis is
present. The normal donor cells
(previously frozen), showed similar
quantitative and qualitative re
sponses.

Discussion
Sepsis is a frequent postoperative
problem in patients with obstructive
jaundice.12 Although this increased
susceptibility to infection is proba
bly multifactorial in origin, with
malignancy, malnutrition and im
paired wound healing all playing a
part,35 alterations in the immune
response mechanism have also been
implicated.6
We examined lymphocyte respon
siveness before and after relief of
obstructive jaundice. Previous in
vestigators7 postulated a toxic ef
fect of either bilirubin or bile acids
on lymphocytes to account for the
depressed responses observed when
increasing concentrations of these
substances were added to culture
solutions. However, it is now clear

Table I. Clinical Data From the 11 Study Patients
Patient

Age, yr

1
2
3
4
5
6
7
8
9
10
11

64
56
65
50
82
54
51
70
74
64
52

Treatment

Diagnosis
Cancer of pancreas
Colorectal metastases
Cancer of pancreas
Cholangiocarcinoma
Cholangiocarcinoma
Cancer of pancreas
Colorectal metastases
Cholangiocarcinoma
Cancer of pancreas
Cholangiocarcinoma
Cholangiocarcinoma

Choledochoduodenostomy
Internal biliary stent
Internal biliary stent
Hepaticojejunostomy
Internal biliary stent
Choledochojejunostomy
Internal biliary stent
Internal biliary stent
Cholecystojejunostomy
Internal biliary stent
Whipple resection

Table II. Mean Stimulation Indices After Stimulation of Lymphocytes at a Phytohemagglutinin
Concentration of 1:10*
Serum
Cells

Jaundiced

Convalescent

Fetal calf

Jaundiced
Convalescent
Normal donor

307 ± 82
253 ± 49
383 ± 73

263 ± 53
268 ± 53
334 ± 76

122 ± 18
98 ± 22
84 ± 1 8

'Mean ± standard error.
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LYMPHOCYTE FUNCTION AFTER BILIARY DECOMPRESSION

that an impaired response occurs
only at concentrations far above
physiologic limits, and it is unlikely
that either bilirubin or bile acids are
clinically important immune depres
sant factors.89 Such a depressant
factor has been demonstrated in
infectious, autoimmune and inflam
matory hepatic diseases associated
with cholestasis,10-12 but evidence
for one has not convincingly been
shown in cases o f jaundice due
solely to biliary obstruction. New
berry and colleagues8 demonstrated
the presence of a transmissible
serum immune depressant factor in
two patients who had biliary ob
struction and complete clearance of
this factor within 1 week o f sur
gery. However, the two other pa
tients with biliary obstruction in

their study did not have similar
evidence o f such a factor, and it is
possible that the findings were af
fected by the presence of cholangi
tis or some other variable10 that
might have caused the impairment
in T-cell function and been correct
ed by the surgical procedure. In our
study there was no evidence o f a
humoral depressant factor in the
jaundiced serum, since the SI did
not significantly increase when the
cultures o f the anicteric, convales
cent serum were done. Similar qual
itative and quantitative results were
obtained when the incubations were
performed using freshly isolated
normal donor lymphocytes. These
findings are supported by the re
sults o f experimental studies per
formed in bile-duct-ligated rats,3
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FIG. 1. Scattergram of stimulation index values for study patients at phytohemag
glutinin (PHA) dilution of 1:10.

and o f two small clinical studies10'13
in which cholestatic serum did not
depress the stimulated lymphocyte
response.
The status o f intrinsic T-cell
function in obstructive jaundice is
critically important, especially if
there is evidence o f an enhanced
responsiveness after resolution of
the icterus. Such a finding would
validate continued attempts to im
prove postoperative morbidity and
mortality by preoperative drainage
o f the obstructed biliary tree, an
approach that has received consid
erable attention recently.14 Roughneen and associates3 noted a pro
found depression o f T-cell respon
siveness after 3 weeks o f biliary
obstruction in rats, but it seems
likely that other factors, possibly
nutritional, renal or infective, were
responsible. Certainly, in our clini
cal study, there was no evidence o f
a depressed response in the lympho
cytes harvested during the period of
jaundice.
As part o f larger studies, which
examined changes in cell-mediated
immunity due to hepatic diseases,
two clinical studies included a small
number of patients with biliary ob
struction10 and cholestasis o f un
stated cause.13 Although neither
study reassessed T-lymphocyte re
sponsiveness after correction o f
jaundice, the results were similar to
ours, namely that T-lymphocyte re
sponsiveness was preserved during
biliary obstruction.
Judging by the results o f other
experimental and clinical studies, it
is probable that obstructive jaun
dice does indeed alter some aspects
of immune function. Experimental
ly, biliary obstruction has been
shown to delay allograft rejec
tion,1516 depress hepatic reticuloen
dothelial cell function17 and impair
nonspecific cellular immunity.6 Not
all facets o f the immune system are
similarly affected, however, as some
aspects have been found to remain
CJS, VOL. 34, NO. 2, APRIL 1991
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(fluconazole/pfizer)

AN OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C14-alpha-dem ethylation. Mammalian cell dem ethylation is much less sensitive to
fluconazole inhibition. The subsequent loss of normal sterols correlates w ith the
accumulation of 14-alpha-methyl sterols in fungi and may be responsible for the fungistatic
activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment
of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective fo r the
treatm ent of serious systemic candidal infections, including urinary tract infection,
peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of
cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specimens fo r fungal culture and other relevant laboratory studies (serology,
histopathology) should be obtained prior to therapy to isolate and identify causative
organisms. Therapy may be instituted before the results of the cultures and other laboratory
studies are known; however, once these results become available, anti-infective therapy
should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have
shown hypersensitivity to fluconazole or to any of its excipients. There is no information
regarding cross hypersensitivity between fluconazole and other azole antifungal agents.
Caution should be used in prescribing DIFLUCAN to patients with hypersensitivity to other
azoles.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored
for the development of more severe hepatic injury. Although serious hepatic reactions have
been rare and the causal association w ith DIFLUCAN uncertain, if clinical signs and
symptoms consistent with liver disease develop that may be attributable to fluconazole,
DIFLUCAN should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential
benefit outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: It is not known whether fluconazole is excreted in human milk.
Because many drugs are excreted in human milk, caution should be exercised when
DIFLUCAN is administered to a nursing woman.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not
been established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to
be affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clinically meaningful extent; reduction of about 13% in AUC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
adm inistration had no clinically relevant effects on the absorption or elim ination of
fluconazole in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN
with an increase in cyclosporine plasma concentrations in renal transplant patients with or
w ith o u t im paired renal function. Therefore, when DIFLUCAN and cyclosporine are
coadministered, cyclosporine levels should be monitored and cyclosporine dose accordingly
adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was small (12% ), careful m onitoring of
prothrombin time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential fo r hypoglycemia due to decreased
elimination and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide,
glipizide and tolbutamide) has been demonstrated with concomitant administration of
DIFLUCAN. Blood glucose levels should be m onitored closely and the dose of the
hypoglycemic agent should be adjusted as necessary.
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant adm inistration of DIFLUCAN and rifam pin resulted in a 25%
decrease in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole
should be increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,

these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3%
of patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected
and non-HIV infected patients were similar. The proportions of patients discontinuing
therapy due to clinical adverse events were similar in the two groups (1.5%). The two most
serious adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative
skin disorders 2. Hepatic necrosis Because most of these patients had serious underlying
disease (predominantly AIDS or malignancy) and were receiving multiple concomitant
medications, including many known to be hepatotoxic or associated with exfoliative skin
disorders, the causal association of these reactions with fluconazole is uncertain. Two cases
of hepatic necrosis and one exfoliative skin disorder (Stevens-Johnson syndrome) were
associated with a fatal outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea
3.7% Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea
1.5% Other treatment-related clinical adverse events which occurred less commonly (0.2 to
<1%) are presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia
General: fatigue, malaise, asthenia, fever.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions
of patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route
(p.o. or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly
with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid,
or oral hypoglycemic agents. Clinically significant increases also were more frequent in
patients who: 1) had SGOT or SGPT elevations greater than three times the upper limit of
normal (>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis
at any time during the study and, 3) were identified as alcohol abusers. The overall rate of
serum transaminase elevations of more than 8 tim es the upper lim it of normal was
approximately 1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Number*
Percent
Number
Percent
Drugof
Percent
DrugLab
Of
Parameter
Patients
Abnormal
Related
Patients
Abnormal
Related
Baseline <3xULN
Baseline > 3xULN
3007
9.4
3.8
4.2
0.8
2874
4.8
1.0
3.1
0.0
Non-Hepatitis Patients
Hepatitis Patients
SGOT
160
10.6
1.9
2900
3.9
0.8
SGPT
11.4
2.1
2799
4.4
1.0
140
Non-Alcohol Abuse
Alcohol Abuse
4.2
0.9
SGOT
42
9.5
2.4
3018
4.7
1.0
SGPT
10.0
2.5
2899
40
Never Received
Received
I.V. Fluconazole
I.V. Fluconazole
4.2
0.9
SGOT
144
5.6
1.4
2916
4.7
1.0
SGPT
2800
139
5.0
0.7
< 65 Years Old
> 65 Years Old
SGOT
277
4.3
0.9
4.3
1.1
2783
4.8
1.0
SGPT
258
2681
3.9
1.2
'Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions
of patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0. 6 % ) .
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: Presently, there are no known sym ptom s of DIFLUCAN (fluconazole)
overdosage in man.
Treatment: In the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine following oral adm inistration in man. The oral bioavailability is
essentially complete (greater than 90%), and is independent of dose. Peak plasma
concentrations after oral administration are attained rapidly, usually within 2 hours of
dosing. Since oral absorption is rapid and almost complete, the daily dose of DIFLUCAN
(fluconazole) is the same for oral and intravenous administration. The terminal plasma
elimination half-life is approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the
infecting organism, the patient's condition and the response to therapy. Treatment should
be continued until clinical parameters and laboratory tests indicate that an active fungal
infection has been cured or has subsided. An inadequate period of treatment may lead to
recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent
oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.
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Recommended Adult Dosages
Loading Dose: Administration of a loading dose on the first day of treatment, consisting
of twice the usual daily dose, results in plasma concentrations close to steady state by
the second day. Patients with acute infections should be given a loading dose equal to
twice the daily dose, not to exceed a maximum single dose of 400 mg, on the first day of
treatment.
Oropharyngeal Candidiasis: 100 mg once daily. Treatment should be continued for at least
2 weeks to decrease the likelihood of relapse.
Esophageal Candidiasis: 100 mg to 200 mg once daily. Patients should be treated for a
minimum of 3 weeks and for at least 2 weeks following resolution of symptoms.
Systemic Candidiasis: 200 mg to 400 mg once daily. These patients should be treated for a
minimum of 4 weeks and for at least 2 weeks following resolution of symptoms.
Cryptococcai Meningitis: 200 mg to 400 mg once daily. Although the duration of therapy
for cryptococcai meningitis is unknown, it is recommended that the initial therapy should
last a minimum of 10 weeks.
Prevention of Recurrence of Cryptococcai Meningitis in AIDS: 200mgoncedaily.
DIFLUCAN (fluconazole) may be administered either orally or by intravenous infusion. The
intravenous infusion of DIFLUCAN should be adm inistered at a maximum rate of
approximately 200 mg/hour given as a continuous infusion. See Directions for Use .
Dosage in Patients With Impaired Renal Function
Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with
impaired renal function, an initial loading dose of 50 to 400 mg should be given. After the
loading dose, the daily dose (according to indication) should be based on the following
table:
Creatinine Clearance (mL/min)
Percent of Recommended Dose
>50
100%
21-50
50%
11-20
25%
Patients receiving
one recommended
regular hemodialysis
dose after each dialysis

Directions for Use: Inspect visually fo r particulate m atter or discoloration p rior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR
MULTIDOSE USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a m axim um rate o f 200 mg/hour. Flush DIFLUCAN intravenous solution
remaining in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets ("giving" sets).
DIFLUCAN I.V. infusion is compatible w ith (i.e. not susceptible to absorption) sets
constructed of a delivery tube (PVC) luer lock (modified phenylene oxide), flash ball (latex)
drip chamber (polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution fo r direct infusion. Each mL
contains 2 mg fluconazole and 9 mg sodium chloride. Supplied in clear glass bottles of 100
mL, affording doses of 200 mg fluconazole, sealed with a rubber bung.
STORAGE
DIFLUCAN TABLETS (fluconazole) 50,100, and 200 mg: Store below 30°C.
DIFLUCAN I.V. (fluconazole) 2 mg/mL: Store below 30°C. Do not freeze.
References: 1. DIFLUCAN new drug submission, Data on file, Pfizer Canada Inc.
2. Product monograph-DIFLUCAN*.
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When serum creatinine is the only measure of renal function available, the following formula
(based on sex, weight, and age of the patient) should be used to estimate the creatinine
clearance.
Males:
Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)
Females:
0.85 x above value

DIFLUCAN

Composition: DIFLUCAN Tablets (pink) contain 50, 100 or 200 mg fluconazole. Also
contains the following non-medicinal ingredients: microcrystalline cellulose, dibasic calcium
phosphate anhydrous, povidone, croscarmellose sodium, FD & C Red No. 40 aluminum lake
dye, and magnesium stearate.
DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.
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normal,3 while others may even be
supranormal.6 Future studies in this
area could be directed at examining
macrophage antigen processing and
delivery, or T-cell and B-cell interac
tions to increase our understanding
of the effects of obstructive jaun
dice on the immune system.
We studied the status of cellmediated immunity in 11 patients
before and after relief of biliary
obstruction by assessing the re
sponsiveness of lymphocytes to
PHA mitogen stimulation. We
found no evidence of a serum im
mune depressant factor associated
with the jaundice, nor did we find
any evidence for impaired intrinsic
T-cell function which could be re
stored by relief of the biliary ob
struction.
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Surgical Palliation of Spinal Oncologic
Disease: a Review and Analysis of Current
Approaches
Drew A. Bednar, MD, FRCSC; W. Timothy Brox, MD, FRCSC; G. Richard Viviani, MD, FRCSC
The clinical problem of primary and secondary vertebral tumours is encountered
with increasing frequency throughout North America as oncologic management
protocols evolve and the population continues to age. These lesions can present
problems of pain, instability and paralysis. Optimal surgical palliation is often of
benefit when more conservative methods have been unsuccessful.
Vertebral tumours can be approached either anteriorly or posteriorly. These
alternatives have led to the evolution in the clinical community of two “camps”
championing their respective approaches. The authors have reviewed the
accumulated literature up to December 1988 and have found that anterior
approaches offer improved clinical outcome without substantially increased
morbidity.

Le probleme clinique des tumeurs vertebrales primitives et secondaires se pose de
plus en plus frequemment en Amerique du Nord, avec 1’evolution des protocoles de
traitement d’oncologie et le vieillissement des populations. Ces lesions peuvent
presenter des problemes relies a la douleur, a l’instabilite et a la paralysie. Une
chirurgie palliative optimale est souvent bienvenue quand les methodes plus
conservatrices se sont montrees inefficaces.
Les tumeurs vertebrales peuvent faire l’objet d’un abord par voie anterieure ou
posterieure. Cette alternative a permis l’emergence au sein de la communaute
medicale de deux “camps” qui defendent leur abord respectif. Les auteurs ont passe
en revue la litterature publiee jusqu’a decembre 1988 et ont trouve que l’abord par
voie anterieure offrait de meilleurs resultats cliniques sans augmentation apprecia
ble de la morbidity.

C

urrent orthopedic12 and neuro
surgical34 literature provides
increasing support for anterior spi
nal surgery in the palliation of
appropriately selected patients with
spine tumours. Anterior spinal sur
gery is restricted mainly to referral
practices in major centres and is
considered to be excessively com-

plex, dangerous and morbid. How
ever, when nonsurgical treatment
alternatives have been exhausted,
the literature does suggest that an
terior surgery is safer and more
effective in the palliation of malig
nant disease of the spine than is so
called “conservative” posterior sur
gery.
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Posterior Surgery
Black5 reviewed the literature re
garding the surgical management of
spinal metastatic disease through
1979. He compared radiotherapy
with laminectomy as primary treat
ment modalities and revealed,
through collected series, that pri
mary radiotherapy was a more ef
fective alternative in neurologic pal
liation. He therefore recommended
primary radiotherapy as a first-line
treatment modality in spinal metastases with myelopathy. He found
that, after laminectomy, the average
death rate was 9%, there was a
progressive neurologic deficit in
12% of cases across collected series
and the rate of other surgical com
plications was 11%.
Black suggested that standard
posterior surgical approaches were
ineffective in patients having tu
mour in the anterior spinal ele
ments, with neurologic improve
ment occurring in 39% of patients
in whom dural compression was
from a dorsal aspect, but in only 9%
of patients in whom the compres
sive lesion was ventral. Even at that
early stage in the evolution of spi
nal tumour management it was rec
ognized that “in the presence of
vertebral bony collapse . . . removal
of posterior spinal elements (lami
nectomy) may further aggravate the
instability and angulation; ventral
cord compression . . . remains un
corrected.” Black, a neurosurgeon,
CJS, VOL. 34, NO. 2, APRIL 1991
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further recognized that “ in this
situation . . . an anterior fusion . . .
with vertebral body corpectomy and
removal of any tumour tissue com
pressing the spinal cord anteriorly”
would be necessary.
Most practitioners not heavily in
volved in spinal surgery have al
ways believed that anterior spinal
surgery is extremely risky and mor
bid and should not be indicated
except in the most dire circum
stances; many reports1’35' 9 and re
views of both the neurosurgical9
and orthopedic9 literature belie this.
The morbidity of posterior surgi
cal approaches in anterior (ventral)
spinal tumour management can be
high. Findlay10 reviewed 80 patients
who had unifocal thoracic metasta
sis with myelopathy treated with
laminectomy and found increased
neurologic deficit postoperatively in
almost 40% of cases, and in 50% of
these there was collapse of the
vertebral body before laminectomy.
Only 3% of patients in Findlay’s
series recovered sufficiently, neurologically, to be able to walk. Over
10% had postlaminectomy spinal
instability, requiring a stabilization
procedure.
The question of the ability of
laminectomy to effect decompres
sion of the theca in anterior tumour
compression has recently been com
prehensively addressed through ele
gant in-vivo experimentation by Al
len, Allan and Ferguson.11 They
showed that there is minimal retropulsion of the posterior dura
with marked compression of the
anterior theca, and that laminecto
my does little to alter the mobility
of the posterior dura in this situa
tion. It appears that the dura is held
in place largely by the dural nerve
root sheaths and anterior dural liga
ments rather than by the laminae.

Anterior Surgery
Several reports have documented
130

the safety and success of anterior
decompressive surgery in patients
with spinal metastasis. Fidler6 re
viewed 16 cases of thoracolumbar
metastases decompressed anteriorly
with single stage fusion and instru
mentation. Neurologic function im
proved substantially in 14 of 15
cases, and pain was completely re
lieved in 15 of 16 cases. One pa
tient died postoperatively of respira
tory insufficiency. After recognizing
that 85% of spinal metastases caus
ing myelopathy and instability arise
anteriorly in the vertebral column,
Harrington7 reviewed 77 patients
with metastases and instability
treated by single-stage anterior de
compression and stabilization. Sev
enty-two patients had good relief of
pain postoperatively and 52 of 62
who had significant preoperative
neurologic deficit had notable func
tional improvement. There were
four postoperative deaths and five
instances of late local instability
secondary to failure of stabilization,
all occurring early in the series and
associated with obvious technical
difficulties at operation. Kostuik
and colleagues1 reviewed 100 pa
tients with spinal tumours treated
by either anterior or posterior sur
gery, as indicated by the presence
of unifocal versus multifocal dis
ease; in this recent Canadian series,
71% of cases showed substantial
neurologic improvement after ante
rior decompression with singlestage fusion and instrumentation.
There was a 4% infection rate and
5% incidence of failure of instru
mentation with a mean postopera
tive survival of almost 1 year.
O’Neil, Gardner and Armstrong8
presented 14 cases of spinal tumour
in which the patient was treated
with anterior decompressive proce
dures. A majority of the patients
had substantial neurologic improve
ment. Perrin and McBroom,9 com
paring anterior with posterior de
compressive surgery for spinal tu

mour with myelopathy and instabili
ty in 200 patients, reported a 28%
rate of neurologic improvement to
the point of independent ambula
tion after posterior surgery; there
was an 8% death rate, and 80% of
patients achieved good relief of
pain. In anterior surgery 38% of
patients had improved neurologic
function to the point of ambulation;
there were no deaths and 90% of
patients had good relief of pain.
Sundaresan and colleagues3 re
viewed 43 patients with renal cell
carcinoma treated with anterior sur
gery and reported that 70% had a
markedly improved neurologic sta
tus postoperatively whereas radio
therapy was effective in only 45%.
4

Statistical Analysis
A randomized controlled trial of
anterior versus posterior surgical
approaches to management of spi
nal tumours would be required to
provide definitive data on the ad
vantages and disadvantages of ei
ther anterior or posterior technique.
Such a trial has not been reported
in the literature and is probably not
truly feasible because of the ethical
concerns that would be generated
by the surgeons involved.
The literature we reviewed con
sisted largely of a number of case
series, which, when analysed in
dividually, were of little signifi
cance. Pooled data from these se
ries can theoretically be compared
with the pooled results of posterior
procedures using the technique of
macroanalysis12 and standard x 2
computation. These series will cer
tainly contain multiple variables,
since differences of individual sur
geons, internal fixation and man
agement techniques affect their re
sults, but a pooling of such series
should limit variability outcome to a
function of the basic approach, that
is anterior versus posterior surgery.

%
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Such analysis is easily structured
through a theoretical cohort of 200
patients, 100 each undergoing ei
ther anterior or posterior surgery,
counts being converted from the
pooled percentage outcomes of the
reviewed series (Table I1-4-8). This
macroanalysis suggests that there
is a significantly greater probability
of neurologic improvement and pain
relief after anterior spinal surgery
with no greater postoperative mor
tality. It also suggests a significant
ly greater probability of increased
neurologic deficit after posterior
surgery.
Macroanalysis cannot provide de
finitive data but is only loosely
supportive of the clinical impres
sions gleaned from literature re
view. Moreover it cannot provide
the sort of definitive data that a
properly constructed prospective
and randomized controlled trial can.

surgical11 reviews concur that ante
rior single-stage decompression
with instrumentation and fusion is
the currently indicated palliative
procedure for localized tumour in
the anterior elements of the spine.
Such tumours cause local painful
kyphosis with compression of the
dura and myelopathy in the face of
radioresistant tumour or failed ra
diotherapy. Statistical analysis of
the available literature supports
these conclusions.
The indications for such pallia
tive procedures are well defined.
They include progressive impinge
ment on the spinal canal and com
pression of the spinal cord by radi
oresistant or recurrent tumour or
bone fragments from pathologic
fracture with kyphosis, progressive
kyphotic deformity with intractable
pain and disruption of all three
columns of the spine causing loss
of mechanical integrity.
The literature emphasizes the
safety and efficacy of anterior surgi
cal approaches to spinal tumour

Conclusions
Recent orthopedic12 and neuro
Table 1.

C om p a ra tiv e P o o le d R e s u lts o f A n te rio r V e rs u s P o s te rio r S u rg e ry *

Type of
surgery

Neurologic
impairment

Pain
relief

Death

Increased
neurologic
deficit

A n te rio r

1. K ostuik JP, Errico TJ, Gleason TF et
al: Spinal stabilization of vertebral co
lumn tumors. Spine 1988; 13: 2 5 0 -2 5 6
2. H arrington KD: Metastatic disease of
the spine. J Bone Joint Surg [Am] 1986;
6 8 :1 1 1 0 -1 1 1 5
3. S undaresan N, S cher H, Di Giacinto GV
et al: Treatment of spinal cord compres
sion in kidney cancer. J Clin Oncol
1986; 4: 1851-1856
4. S undaresan N, D i Giacinto GV, H ughes

JEO: Surgical treatment of spinal metastases. Clin Neurosurg 1986; 33: SOS-

522
5. Black P: Spinal metastasis: current sta
tus and recommended guidelines for
management. Neurosurgery 1979; 5:
726-746
6. F idler MW: Anterior decompression and
stabilisation of metastatic spinal frac
tures. J Bone Joint Surg [Br] 1986; 68:
8 3 -9 0
7. H arrington KD: Anterior decompres
sion and stabilization of the spine as a
treatment for vertebral collapse and spi
nal cord compression from metastatic
malignancy. Clin Orthop 1988; 233:
177-197

F id le r6

1 4 /1 5

1 5 /1 6

1 /1 6

0 /1 7

4 2 /6 2

7 2 /7 7

4 /7 7

1 /6 2

8. O’N eil J, Gardner V, A rmstrong G:

3 0 /4 1

—

-

3 /4 1

Treatment of tumors of the thoracic and
lumbar spinal column. Clin Orthop
1988; 227: 103-112

2 0 /2 1

1 9 /2 1

1 /2 1

1/21

c o lle a g u e s 1
O’ N eil, G ardner
and A rm s tro n g 8
S u n da re san ,
D iG ia cinto and
H u g h e s4
T o ta l

1 2 8 /1 6 0

1 2 8 /1 6 0

1 0 /1 6 0

0 /1 6 0

2 3 4 /2 9 9

2 3 4 /2 7 4

1 6 /2 7 4

5 /3 0 1

P o s te rio r
P o o le d , fro m
B la ck5

30%

70%

9%

12%

(o p tim u m )
A n a ly s is
x2

P

4 6 .4

6 .4 5

0 .6 4

7.6

< 0 .0 1

< 0 .0 5

> 0 .0 5

< 0 .0 1
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Accelerated Coronary Atherosclerosis
After Cardiac Transplantation: Major
Threat to Long-Term Survival
Michel Carrier, MD, FRCSC; Guy Pelletier, MD; Yves Leclerc, MD, FRCSC;
Yves Castonguay, MD, FRCSC; Raymond Cartier, MD; Ihor Dyrda, MD; Gilbert Gosselin, MD;
L. Conrad Pelletier, MD, FRCSC
Accelerated coronary atherosclerosis (ACA) has been documented at autopsy and
was noted at coronary angiography in seven patients, 11 to 48 months after cardiac
transplantation. To delineate the importance of this problem, the risk factors and
the therapeutic approaches in 7 patients who had ACA after heart transplantation
were compared with those in 28 patients free of ACA at annual coronary
angiography. Ischemic cardiomyopathy was the preoperative diagnosis in all but one
patient in the ACA group. The age of the transplant recipients, total myocardial
ischemic times and arterial blood pressures at follow-up were similar in both groups.
Donor age averaged 31 ± 3 years in the ACA group and 22 ± 1 years in patients
free of ACA. Preoperative cholesterol, triglyceride and high-density lipoprotein
levels were lower in ACA-free patients and the low-density lipoprotein level was
higher. At the last follow-up visit, serum lipid levels were similar in both groups.
The incidence of acute rejection and of infection was slightly, but not significantly,
higher in patients with ACA. The actuarial survival of ACA patients 4 years after
transplantation was 30% ± 20% compared with 100% for patients free of ACA (p <
0.01). Actuarial rates of freedom from ACA and from death due to ACA were 73% ±
11% and 81% ± 11% respectively. Stepwise discriminant analysis showed that older
donors and higher pretransplant triglyceride levels were independently related to
the development of ACA after cardiac transplantation. In conclusion ACA remains an
important cause of late death after heart transplantation. Although therapeutic
measures are limited, prevention should focus on strict control of serum lipid levels
after transplantation.

C

ardiac transplantation is now
well accepted as treatment for
end-stage cardiac disease. In Cana
da more than 400 cardiac trans
plantations have been performed
during the last 7 years, and the
number of programs is growing.
However, the long-term fate of
these patients is not yet well
known. Since 1983 significant coro
nary artery atherosclerosis has de
veloped in seven of our patients
who underwent heart transplanta
tion.
The objective of this study was to
evaluate the importance of this
problem and to define risk factors
and appropriate therapies.

Patients and Methods
Une atherosclerose coronarienne acceleree (ACA) a ete demontree a l’autopsie et fut
observee a la coronarographie chez sept patients, de 11 a 48 mois apres une
transplantation cardiaque. Dans le but de definir l’importance de ce probleme, les
facteuvs de risque et les modalites therapeutiques chez 7 patients qui avaient
souffert d’ACA apres une transplantation cardiaque ont ete compares a 28 patients
exempts d’ACA a leur coronarographie annuelle. Chez tous les patients du groupe
ACA sauf un, le diagnostic preoperatoire avait ete celui de cardiomyopathie
ischemique. L’age des greffes, le temps d’ischemie myocardique total et la tension
arterielle aux examens de controle etaient similaires pour les deux groupes. L’age
des donneurs etait de 31 ± 3 ans pour le groupe ACA et de 22 ± 1 ans pour le
groupe exempt d’ACA. Les taux preoperatoires de cholesterol, de triglycerides et de
lipoproteines a haute densite etaient plus faibles dans le groupe exempt d’ACA, et
les taux de lipoproteines a faible densite, plus eleves. Aux derniers examens de
controle, les taux seriquei.' de lipide etaient semblables dans les deux groupes.
L’incidence des crises de re;iet et des infections etait legerement plus elevee dans le
groupe ACA, mais de fa?on non significative. La survie actuarielle du groupe ACA,
4 ans apres la greffe, etait de 30% ± 20% comparativement a 100% pour le groupe
exempt d’ACA (p < 0.01). La probability actuarielle d’etre indemne d’ACA ou du
deces du a l’ACA etait de 73% ± 11% et de 81% ±11% respectivement. Une analyse
discriminance par etapes a montre que l’age plus avance des donneurs et les taux de
triglycerides plus eleves avant la greffe etaient independamment relies au developpement de l’ACA apres transplantation cardiaque. En conclusion, l’ACA constitue une
importante cause de deces eloigne apres une greffe cardiaque. Meme si les modalites
therapeutiques sont limitees, la prevention devrait etre centree sur un controle strict
des lipides seriques apres transplantation.

Since 1983, 67 heart transplanta
tions have been performed at the
Montreal Heart Institute. The 34
patients whose postoperative fol
low-up was 12 months or longer,
and another patient who died sud
denly 11 months after transplanta
tion, formed the study population.
All underwent coronary angiogra
phy annually.
Patients were divided into two
groups: group 1 comprised 28 pa
tients who were free of coronary
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artery disease at coronarography
and group 2 comprised 7 patients
who had accelerated coronary ath
erosclerosis (ACA) after transplanta
tion, as established at coronary an
giography (6) or autopsy (1).
All patients received a cyclos
porine-prednisone regimen. The di
agnosis of rejection was established

by endomyocardial biopsy, accord
ing to the criteria defined by Billingham.1 Acute rejection was treat
ed by pulsed steroid or by rabbit
antithymocyte globulin. The angio
graphic criteria for evidence of cor
onary artery disease after heart
transplantation were those of Gao
and colleagues.2

Risk factors for coronary artery
disease that were studied were as
follows: recipient and donor age;
cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein
(LDL) and triglyceride serum levels
before transplantation and at the
last follow-up visit; a diagnosis of
initial cardiac disease; graft isch
emic time; postoperative arterial
blood pressure; and episodes of re
jection and infection during follow
up. Statistical analysis of the data
was performed using Student’s ttest and the x2 test. A stepwise
discriminant analysis of variables
was performed.3 Actuarial, survival
of the two groups was compared by
the Mantel-Cox analysis, and the
results were expressed as mean ±
standard error of the mean (SEM).

Results
T— ,--- ,--------- ,---------,--------- ,---------,--------- ,---------,
0
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Years after transplantation
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FIG. 1. Actuarial freedom from accelerated coronary atherosclerosis (ACA) ( • ) and
from death due to ACA (O) after heart transplantation.

FIG. 2. Actuarial analysis of survival, p < 0.05 by Mantel-Cox analysis. • =
patients with ACA, O = patients free of ACA.
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Accelerated coronary atheroscle
rosis was discovered in seven pa
tients 11 to 48 months (mean 17 ±
5 months) after transplantation.
The overall postoperative follow-up
of these seven patients averaged 30
± 7 months. Diffuse atherosclerosis
of distal coronary arteries was
found in three patients; segmental
and proximal stenoses were found
in four.
The 28 patients in group 1, with
out ACA, were followed up for 12
to 72 months (mean 34 ± 3
months) after transplantation.
Actuarial freedom from ACA and
from death due to ACA, 4 years
after transnlantation was 73% ±
11% and 81% ± 11% respectively
(Fig. 1). Analysis of survival showed
a significant (p < 0.05) difference
between the two groups, patients
with ACA having a poor late surviv
al (30% ± 20% versus 100% at 6
years) (Fig. 2).
The age of the recipient, graft
ischemic time and blood pressure at
follow-up were similar in the two

CORONARY ATHEROSCLEROSIS AFTER HEART TRANSPLANTATION

groups (Table I). Ischemic cardiac
disease was the preoperative diag
nosis in six (86%) patients in group
2 compared with 17 (61%) patients
in group 1. This difference was not
significant.
The average donor age for group
2 patients was 31 ± 3 years com
pared with 22 ± 1 for group 1
patients (p = 0.01).
The preoperative serum choles
terol level averaged 6.18 ± 1.37
mmol/L for group 2 patients with
ACA compared with 4.60 ± 0.28
mmol/L for group 1 patients (p =
0.08). Average preoperative serum
triglyceride levels were 2.48 ± 0.42
mmol/L and 1.61 ± 0.12 mmol/L
respectively (p = 0.01). The average
postoperative serum cholesterol and
triglyceride levels were similar in
both groups. In group 1 patients,
serum cholesterol and triglyceride
levels increased respectively to 7.55

± 0.26 mmol/L and 3.16 ± 0.33
mmol/L from normal preoperative
values (p < 0.05). In group 2
patients, postoperative cholesterol
and triglyceride levels remained ele
vated.
The incidence of both rejection
and infection were higher among
group 2 patients (1.1 ± 0.4 and 1.9
± 0.6 episodes/patient) than
among group 1 patients (0.8 ± 0.2
and 1.6 ± 0.3 episodes/patient),
but the difference was not signifi
cant.
A stepwise discriminant analysis
of all factors in Table I, taking the
occurrence of ACA after transplan
tation as the end point, indicated
that donor age (p = 0.02) and
pretransplant triglyceride level (p =
0.03) were the only independent
predictors for the development of
ACA after cardiac transplantation.
Stepwise discriminant analysis, per

Table I. Characteristics of 35 Patients Who Underwent Heart Transplantation
Group*
1 Characteristic
Ischem ic cardiomyopathy,
\ no./total no. of patients
Afle, V
^Recipient
DiPnor
Graft'jschemic time, min
SerumNevels
Triglytseride, m m ol/L
Preopterative
P ostopkativet
Cholesterolrvnmol/L
Preoperati«$
Postoperative’1.
High-density lipoprotein,
mmol/L
Preoperative
Postoperative
Low-density lipoprotein,
mmol/L
Preoperative
Postoperative
Blood pressure, mm Hg
Systolic
Diastolic
Rejection, episodes/
patient
Infection, episodes/
patient

1
17/28
42 ± 2
22 ± 1
139 ± 9

2
6/7
42 ± 3
31 ± 3
121 ± 9

p value
0.20
0.94
0.01
0.34

1.61 ± 0.12
3.16 ± 0.32

2.48 ± 0.42
2.54 ± 0.64

0.01
0.4

4.60 ± 0.28
7.55 ± 0.26

6.18 ± 1.37
7.06 ± 0.72

0.08
0.4

0.70 ± 0.05
1.22 ± 0.05

0.93 ± 0.13
1.16 ± 0.16

0.07
0.8

3.21 ± 0.23
4.42 ± 1.73

2.30 ± 0.28
4.73 ± 0.83

0.08
0.7

135 ± 2
93 ± 2

142 ± 5
95 ± 3

0.12
0.66

0.8 ± 0.2

1.1 ± 0.4

0.4

1.6 ± 0.3

1.9 ± 0.6

0.6

'Group 1 = 28 patients free of accelerated coronary atherosclerosis (ACA), group 2 = 7 patients
with ACA.
H a s t follow-up visit.

formed after substitution of missing
values (pretransplant HDL and LDL
values in four patients, cholesterol
and triglyceride values before trans
plantation in two group 1 patients)
by median values of the respective
group of variables,4 showed a
Wilks’ X of 0.67. Using the discrim
inant function to the same samples,
we found that the overall percent
age of correctly classified individu
als was 77%.
Two patients with severe proxi
mal and localized coronary artery
stenosis underwent successful per
cutaneous angioplasty of a right
and circumflex coronary artery.

Discussion
Rejection and infection are the
two major complications early after
transplantation.5 Hypertension and
chronic renal failure due to cyclos
porine toxicity are the main causes
of late morbidity. Accelerated coro
nary atherosclerosis has been iden
tified as a major threat to late
survival of patients after heart
transplantation.6'7 In our series, of
the 35 long-term surviving patients
7 (20%) have had ACA and 4 (11%)
died of ACA within 4 years of
transplantation.
The cause of ACA remains un
known. Immunologic injury, serumlipid abnormalities, cyclosporine
and steroid toxic effects have all
been incriminated.8-16
Our study suggests that the de
velopment of ACA after transplanta
tion may be related to the patient’s
initial cardiac disease. Indeed all but
one patient with ACA after trans
plantation suffered from ischemic
cardiomyopathy initially. Older
donor age and higher pretransplant
triglyceride levels were also found
to be independent predictors of the
development of ACA after heart
transplantation.
Serum cholesterol and triglyceCJS, VOL. 34, NO. 2, APRIL 1991
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ride levels increased significantly
after transplantation in patients
who remained free of ACA at fol
low-up. Interestingly there was no
difference in postoperative serum
lipid values between the two
groups. Thus, the relation between
lipid metabolism and ACA after
transplantation is not clear and
needs further study, even though
the preoperative characteristics ap
pear to play a major role.1748 Never
theless we chose to normalize the
lipid values after transplantation by
taking an aggressive dietary and
pharmacologic approach, despite
the lack of clear evidence to sup
port the value of such an approach
in transplant patients.19-21
The current tendency to increase
the limit of donor age, because of
organ shortage and rising demand,
may well lead to a higher incidence
of ACA after transplantation. Coro
nary angiography should be done in
donors older than 40 years to rule
out the presence of coronary artery
disease, although early changes
may not readily be detected and yet,
stimulated by immunologic insult,
may lead to early atheromatous
disease.
Two patients underwent success
ful percutaneous dilatation of proxi
mal and segmental coronary artery
lesions, as shown by the disappear
ance of the lesion at angiography,
but long-term evaluation must still
be obtained. Severe, diffuse ACA at
1 and 2 years was found in another
patient with well-preserved ventric
ular function. Because of the poor
results with retransplantation re
ported by investigators from Stan
ford University,7’22 it was decided to
treat this patient for his symptoms
only and not to carry out retrans
plantation.
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From data reported by others and
from our experience, it appears that
immunologic injury to coronary ar
teries, an abnormal pre-existing me
tabolism of lipid and older donor
age play key roles in the develop
ment of ACA after transplantation.
Once ACA has developed, treatment
is limited to coronary angioplasty or
retransplantation. Because of the
high rates of occurrence and death
of ACA after transplantation, efforts
should be aimed at prevention by
maintaining lower levels of lipid
with dietary and pharmacologic
measures in all patients.
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Significant biliary excretion of antibiotics can have a very disruptive effect on
intestinal flora, which may promote the emergence of resistant strains of bacteria and
cause diarrhea.12 This can add substantially to the cost of treatment.3
CLAFORAN (cefotaxime sodium) has an excellent safety profile. With only 5% biliary
excretion, Claforan has little effect on intestinal flora, thus reducing the risk of
diarrhea and bacterial resistance.'3 And Claforan provides excellent coverage of
major nosocomial pathogens.
Over a complete course of therapy, if one looks at the average cost per patient,
Claforan makes good sense.5
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serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro-organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. taecalis), Straphylococcus
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
U rinary tra ct in fe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B a cte re m ia /S e p tice m ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal infe c tio n s: caused by Escherichia coli, and unspecified Klebsiella species.
G ynecological infe c tio n s: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis: anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus taecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results become available.
P rophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
a ntib iotics); therefore, it is im po rtant to consider its diagnosis in patients w ho develop diarrhea during
the adm inistration of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ype rsensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. H em ic and Lymphatic System ( < 1%); Mild, reversible leukopenia, granulocytopenia and thrombo
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with
Claforan. Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGPT,

Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see fable
with recommended mode of reconstitution according to route of administration).
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Daily Dose
Type of infection

(g )

Frequency and Route

Uncomplicated Gonorrhea

1

1 g IM (single dose)

Uncomplicated infections

2

1 g every 12 hours IM or IV

Moderately severe to severe infections

3-6

1-2 g every 8 hours IM or IV

Very severe infections (e.g. septicemia, CNS)

6-8

2g every 6-8 hours IV

Life-threatening infections

up to 12

2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates;
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections)
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
Males:

’I

Weight (kg) x (140 - age)
72 x serum creatinine

Females:

0.85 x above value

Administration
Intram uscular: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
bloodvessel.
.
Intravenous; The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vbntage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
Storage: Claforan in the dry state should be stored at room temperature protected from light and heat.
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A cu te Pancreatitis — 30 Years’
Experience at a Teaching Hospital
E.O. Amurawaiye, MB, BS; R.A. Brown, MD, FRCSC

Advances in medical technology and knowledge have influenced morbidity and
mortality in surgically treated diseases. The authors have compiled four consecutive
retrospective studies of demography, morbidity and mortality of patients with acute
pancreatitis to summarize the experience from 1956 to 1985 at the Montreal
General Hospital with 629 patients.
The death rate has remained unchanged. Hypotension, gastrointestinal bleeding
and respiratory failure have assumed lesser roles as major complicating factors.
Renal failure and gram-negative aerobic pancreatic sepsis are the common causes o f
death. The last two reviews revealed that surgical debridement and drainage
combined with appropriate biliary procedures salvaged two-thirds of the patients
with sepsis. Deteriorating nutritional status, heralded by a fall of serum albumin
level below 30 g /L , is associated with a poor prognosis. Interval cholecystectomy in
patients with mild biliary tract pancreatitis is associated with a low death rate
( 0. 01%).

Les progres de la technologie et des connaissances medicales ont influence la
morbidite et la mortalite associees aux maladies traitees chirurgicalement. Les
auteurs ont compile les resultats de quatre etudes retrospectives consecutives
portant sur les caracteristiques demographiques, la morbidite et la mortalite
observees chez les malades souffrant de pancreatite aigue, afin de resumer
l’experience accumulee chez 629 patients, de 1956 a 1985, a l’Hopital General de
Montreal.
Le taux de mortalite est demeure inchange. L’hypotension, les hemorragies
gastro-intestinales et l’insuffisance respiratoire assument maintenant un role moins
important comme facteurs de complications. L’insuffisance renale et la sepsie
pancreatique a aerobies gram negatif sont les causes frequentes de deces. Les deux
dernieres revues revelent que le debridement chirurgical et le drainage associes a
des interventions appropriees sur les voies biliaires permettent de preserver deux
tiers des patients atteints de sepsie. Une deterioration de l’etat nutritionnel,
annoncee par une chute de l’albumine serique sous les 30 g /L , est associee a un
mauvais pronostic. Une cholecystectomie a intervalles chez les patients souffrant
d’une pancreatite benigne des voies biliaires est associee a une faible mortalite
( 0 . 01% ).

ince the 19th century acute
pancreatitis and its complica
tions have challenged the medical
profession. Sean1 was the first sur
geon to recognize the need for
surgical intervention in a patient
with pancreatic necrosis and ab
scesses. The role o f the surgeon in
managing the disease remained con
troversial until 1949 when Trapnell
and Anderson2 published a retro
spective study proving that celioto
my when appropriate did not in
crease morbidity and decreased the
mortality o f patients suffering from
the complications o f acute pan
creatitis.
In the last 30 years management
o f acute pancreatitis has been modi
fied by new radiologic techniques,
direct aggressive critical-care moni
toring, the use o f new drugs, antibi
otics and surgical intervention
based on specific indications. To
assess the impact o f these interven
tions, we combined four consecu
tive, retrospective reviews3-5 o f pa
tients who had had acute pancreati
tis at the Montreal General Hospi
tal, a teaching institution o f McGill
University.

S
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Methods
The first three retrospective
studies covered the period from
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and from confirmatory laparotomy
findings when present. The criteria
of Ranson and Pasternak6 were
used in the last two reviews to
classify the severity of the disease.

1956 to 1980.3-5 In 1987 we car
ried out the fourth retrospective
study of patients admitted to Mon
treal General Hospital with acute
pancreatitis between 1981 and
1985. From these four studies we
examined the demography, morbidi
ty and mortality of acute pancreati
tis in 629 patients managed at the
hospital over the 30 years from
1956 to 1985. The senior author
(R.A.B.) was involved in all of these
studies.
Patient charts were reviewed to
determine age, sex, etiology of the
disease, operative procedures, com
plications and death rate. The diag
nosis of acute pancreatitis was
made from appropriate clinical fea
tures, from the presence of elevated
serum amylase levels or low or
normal serum amylase levels com
bined with low serum calcium levels

Results
Demography and Etiology

Biliary tract disease accounted
for 50% of the cases of acute pan
creatitis (Table I). The incidence of
alcohol-related pancreatitis in
creased from 11% (1956 to 1965)
to 20% (1981 to 1985), accounting
for 21% of cases.
Endoscopic retrograde pan
creatography (ERCP) caused acute
pancreatitis in seven patients; five
of the seven had severe pancreatitis
and one died.

Table 1. Etiology of Acute Pancreatitis in 629 Patients Managed at the Montreal General Hospital
Between 1956 and 1985
1956-1965
Etiology

No. (%)

Biliary
Alcohol-related
Idiopathic/other
Trauma/postop
ERCP*

83 (54)
17 (11)
53 (35)

1972-1980

1981-1985

No. (%)

No. (%)

No. (%)

95
51
24
5
1

50
20
22
2
6

100
50
42
8

—

—
153 (100)

Total

1966-1971

(50)
(25)
(21)
(4)
—

200 (100)

(54)
(29)
(13)
(3)
0)

(50)
(20)
(22)
(2)
(6)

100 (100)

176 (100)

The sex was recorded for all
patients in the last two reviews
(1972 to 1985) only. In those
studies, 59% of the patients were
men and 41% were women; biliary
tract pancreatitis occurred equally
in both men and women (Table II);
82% of alcohol-related pancreatitis
occurred in men (Table II); the
majority of patients with ERCPrelated pancreatitis were women
who were undergoing this investi
gative procedure for postcholecys
tectomy abdominal pain.
The mean age of the patients
increased from 52 years (1956 to
1965) to 57 years (1981 to 1985).
The incidence of the disease in
creased steadily with age, peaking
around the sixth decade (Fig. 1).
Complications

The proportion of cases designat
ed “severe” decreased from 39% in
Table II. Distribution of Patients by Sex
and Etiology for the Period 1972 to 1985
Etiology
Biliary
Alcohol-related
Idiopathic/other
Trauma/postop
ERCP
Total

'Endoscopic retrograde cholangiopancreatography.

Male

Female

74
58
26
4
2

71
13
20
3
5

164

112

Table III. Classification of Pancreatitis According to Severity and Death Rate, 1956 to 1985

Review period
1956-1965
1966-1971
1972-1980
1981-1985

Mild

Severe

No. (%)

No. (»/o)

93
117
140
85

60
83
35
16

(61)
(58)
(80)
(85)

(39)
(42)
(20)
(16)

Death rate in
severe pancreatitis,
%
—

14
23
40

Table IV. Complication Rate and Death Rates From Acute Pancreatitis, 1956 to 1985
Rate, %
Review period

Complication

Deaths in sepsis

Deaths overall

1956-1965
1966-1971
1972-1980
1981-1985

39.2
41.5
20.0
18.0

21.0
33.3
50.0
33.3

9.2
6.0
4.5
6.8

29.7

34.4

6.6

Mean
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FIG. 1. Mean age distibution of pa
tients with acute pancreatitis at Mon
treal General Hospital, 1956 to 1985.

ACUTE PANCREATITIS

the period 1956 to 1965 to 15% in
the period 1981 to 1985), but the
death rate in patients with severe
disease increased (Table III). The
frequency of complications de
creased from 39.2% in the period
1956 to 1971 to 18% in the period
1981 to 1985 (Table IV). The inci
dence of hypotension in the early
stages of acute pancreatitis and
pancreatic abscess or pseudocyst
formation remained constant. The
occurrence of respiratory failure de
creased from 9% in the period 1966
to 1972 to 4% in the period 1981 to
1985. Upper gastrointestinal he
morrhage, a life-threatening event
in patients from the 1966 to 1971
study, was eliminated in the 1981
to 1985 review (Figs. 2 and 3).

Severe nutritional depletion
noted in the 1966 to 1971 series4
was also present in the subsequent
studies. In the 1981 to 1985 series,
serum albumin measurements in the
first week of the disease process
were comparable regardless of the
cause of the disease: 8.3% of pa
tients with biliary pancreatitis and
10% of those with alcohol-related
pancreatitis had serum albumin lev
els lower than 30 g/L . Hypoalbuminemia, however, increased
markedly in biliary tract pancreatitis
after the first week (Table V), de
spite appropriate enteral or paren
teral nutritional support. Further
more, all the nonsurvivors in the
last review had serum albumin lev
els below 30 g/dL.

Total serum calcium levels were a
reliable prognosticator of serious
pancreatitis in three reviews.3*5 All
patients who died had serum calci
um levels of 2.0 g /L or lower. In
the second study,4 the majority of
patients who died had a normal or
low serum amylase level on admis
sion. However, in the last two
studies all patients who died had
high serum amylase levels.5
Sepsis occurred in 12.5% of pa
tients with biliary pancreatitis com
pared with 0% in patients with
alcohol-related pancreatitis. Gram
negative aerobes were present in all
pancreatic abscesses in the 1981 to
1985 review compared with 70% in
the 1972 to 1980 period (Table VI).
In the latter study, gram-negative
organisms found in patients who
had pancreatic sepsis were identical
to those cultured from the biliary

FIG. 3. Incidence of upper gastrointes
tinal hemorrhage in patients with
acute pancreatitis at Montreal General
Hospital, 1966 to 1985.
FIG. 2. Incidence of pancreatic pseudocyst or abscess, respiratory failure and
hypotension in patients with pancreatitis at Montreal General Hospital, 1966 to
1985.

Table VI. Organisms Cultured in Patients
With Pancreatic Pseudocyst or Abscess for
the Period 1972 to 1985
1972-1980 1981-1985

Table V. Etiology of Pancreatitis in Patients With Serum Albumin Level Less Than 30 g/L for the
Period 1981 to 1985
Serum albumin < 30 g/L
< 7 d after admission
Etiology
Biliary
Alcohol-related
Idiopathic/other
ERCP

Serum albumin < 30 g/L
> 7 d after admission

No.

%

No.

%

7
1
3

8.3
10.0
13.3

14
1
5
2

29
5
22
33

—

—

No. of
No. of
Type of organism organisms organisms
Gram-negative
aerobes
Gram-positive
aerobes
Gram-negative
anaerobes
Gram-positive
anaerobes

11

8

1

6

4

0

0

1
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tract in 14 of 15 cases. Identical
organisms were cultured in only
one of eight patients with sepsis in
the last review. Enterococcus pre
sented for the first time in five of
eight patients who had pancreatic
sepsis despite adequate prophylactic
coverage in two of the five. Clin
damycin, used prophylactically in
combination with other antibiotics,
was effective in 16 patients. Gram
negative aerobic pancreatic sepsis
developed in 25% of these patients
even though aminoglycosides were
given.
Renal failure, recognized in the
1972 to 1981 review, was not a
major cause of death. Six patients
in the 1981 to 1985 period had
renal failure that contributed to
death in five of seven patients.
Factors associated with renal fail
ure were, a history of hypotension
and sepsis (each three of six pa
tients), surgery (four of six patients)
and administration of aminoglyco
side in safe serum levels (two of six
patients) (Fig. 4). One patient, how
ever, had no identifiable risk crit
eria.

Sepsis

H y p er t e ns io n

Elective surgical procedures were
carried out on the biliary tract at
the same admission in 150 patients
with mild pancreatitis. In the 1966
to 1971 review, two patients with
mild disease had severe disease after
surgery on the biliary tract (chole
cystectomy plus prolonged difficult
common-bile-duct explorations) and
one died. The overall death rate did
not follow any significant trend (Ta
ble IV). The overall mortality was
6.6% compared with 6.8% in the
last series.

Discussion
This retrospective 30-year review
is the largest and longest consecu
tive series available in the literature.
The number of patients reviewed,
629, highlights the fact that it
takes a long time to acquire the
relevant clinical experience. Acute
pancreatitis is not a common dis
ease.
Our first paper published in 1966
classified the severity of the disease
as mild and severe. Any patient who

Hypotension

AminoGlycoside

None

Surgery

Factors
FIG. 4. Factors associated with development of renal failure in patients with acute
pancreatitis at Montreal General Hospital, 1981 to 1985.
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had the classic pain pattern of acute
pancreatitis, ileus, an elevated amy
lase level and no involvement of
adjacent organs was considered to
have mild pancreatitis. A patient
who had the classic pain pattern, a
history of hypotension and inflam
matory involvement of the adjacent
organs (lung, liver, duodenum and
colon) was considered to have se
vere pancreatitis. In the last two
reviews (1972 to 1985) the number
of patients with severe disease de
clined.34 This reflects the strict ap
plication of the criteria of Ranson
and Pasternak6 to classify the inten
sity of the disease. Another possibil
ity that must be considered is the
earlier admission of patients to hos
pital since Medicare became avail
able in 1970.
Hypotension remains a constant
threat to the patient with acute
severe pancreatitis in the early
hours of the disease. About 3% of
the patients studied had hypoten
sion. Factors responsible for this
complication include decreased pe
ripheral vascular resistance as a
result of a vasoactive substance,
increased capillary permeability
with consequent fluid sequestration
and a myocardial depressant sub
stance.7'8 The introduction of the
Swan-Ganz catheter, precise he
modynamic monitoring and aggres
sive fluid and inotropic support
have helped to reduce the death
rate from this complication. In the
1956 to 1965 series, hypotension
was the commonest cause of death,
but deaths still occurred in the last
two reviews from this complication.
Hemorrhage in severe, acute pan
creatitis can be either gastrointesti
nal or intra-abdominal in origin and
occurs in 1.4% to 41% of cases.9 It
may result from stress gastritis,
diffuse mucosal hemorrhage adja
cent to the inflamed pancreas, sple
nic vein thrombosis and erosions of
major vessels secondary to pancre
atic pseudocysts, necrosis or ab-
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scess.10 The gradually decreasing
occurrence of upper gastrointestinal
hemorrhage to zero in these cases
reflects better medical management
of critically ill patients. In spite of
concerns about the use of cimetidine in the treatment of acute pan
creatitis, it appears to have been of
definite benefit in preventing this
complication.1112
Nutritional depletion in severe
pancreatitis, noted previously,3 con
tinues to be a problem. Progressive
hypoalbuminemia occurs in a small
group of critically ill patients de
spite the use of parenteral and
enteral nutrition. As was noted in
1969, in this group of patients, a
negative nitrogen balance is re
versed by parenteral nutrition.4 The
grave prognosis of hypoal
buminemia has been documented in
the literature13'14 and is confirmed
by our 13.5% death rate in this
group. Possible explanations for the
drop in serum albumin levels in
clude decreased hepatic synthesis,
increased catabolism, urinary loss
and distribution within various body
compartments.13 Sequestration of
albumin into damaged pancreas and
tissues after surgery has been re
ported.1516 This might explain the
sudden jump in incidence of hypoal
buminemia in biliary pancreatitis
observed in our patients after the
first week (which corresponds to
the postoperative period).
The incidence of renal failure in
acute pancreatitis can be as high as
22% and carries a death rate as
high as 80%.17 In the last two
reviews, renal failure appeared as a
complication. During the 1981 to
1985 period the incidence was 6%,
with an associated death rate of
83%. The causes of renal failure in
patients who have acute pancreati
tis include decreased glomerular fil
tration rate and decreased renal
plasma flow. In addition there is
increased renal vascular resistance
in the absence of hypovolemia due

to the release of vasoactive sub
stances. Deposits of fibrin and fi
brinogen in the glomeruli and the
hypercoagulable state induced by
enzymes impair renal function. The
principal factor identified is hypo
volemia.17’21
Physicians’ efforts should be di
rected toward recognizing patients
at highest risk and preventing renal
failure. The high death rate and
unimpressive results of dialysis in
the management of this complica
tion mandate prevention. Precise
hemodynamic monitoring, aggres
sive resuscitation, using fluid and
blood to avoid hypotension, and the
elimination of sepsis are the keys to
prevention. In view of the high
renal vascular resistance seen in
these patients, low-dose dopamine,
which causes renal vasodilatation,
may have a protective role when
used early. Our recent clinical expe
rience supports the use of dopamine
early in the course of severe dis
ease, before the onset of renal fail
ure. When renal failure occurs, the
use of loop diuretics (furosemide)
may ensure less renal damage and a
favourable outcome in the ade
quately hydrated patient.22
Sepsis in the pancreas remains
the most difficult complication to
treat. In 1967, Thompson and asso
ciates3 voiced concern about gram
negative aerobic infection. In spite
of many new antibiotics, better di
agnostic techniques and improved
understanding of the disease proc
ess, sepsis is still a significant and
often fatal event in the evolution of
acute pancreatitis. The reason for
the high rate of sepsis in biliary and
ERCP-related pancreatitis is not
known. The manipulations of the
pancreatic duct, especially if the
biliary tract is colonized by bacteria,
appear to be responsible. The cul
ture of identical organisms in the
biliary tree and pancreas in 15 of 23
patients in our review indicates that
the biliary tree is a potential source,

especially in biliary pancreatitis.23
The literature suggests that up to
90% of patients with choledocholithiasis have positive bile cul
tures.2324 The passage of gallstones
through the ampulla is a suggested
pathophysiologic cause for biliary
pancreatitis.25'26 This process pre
sumably allows the bacteria to
reach the normal or diseased pan
creas. In ERCP-related pancreatitis,
the endoscope colonizes the pancre
atic duct system.
After the 1972 to 1980 review
period, laboratory studies were
done to test the penetration of
antibiotics into pancreatic tissue.
Only three antibiotics (clindamycin,
chloramphenicol and
metronidazole) had therapeutic tis
sue levels in the early hours of
experimental, acute, hemorrhagic
pancreatitis.27 Clindamycin is pres
ent in similar levels in operating
room pancreatic specimens resected
for cancer or transplantation.27
Based on this finding, clindamycin
became the antibiotic of choice
when prophylaxis was employed in
the 1981 to 1985 review. In all 16
patients receiving clindamycin prophylactically no patient had sepsis
involving organisms sensitive to the
drug. In the 1972 to 1980 review
this antibiotic eliminated bacteroids
present in 25% of patients with
pancreatic sepsis. Although these
findings are encouraging, four of
these patients had gram-negative
sepsis.
Each patient received amino
glycosides prophylactically and to
treat the pancreatic sepsis. Cultures
from the abscesses grew bacteria in
the laboratory that were sensitive to
this family of antibiotics. The fail
ure of aminoglycosides to treat or
prevent pancreatic sepsis has a
sound research basis. Previous
work in our laboratory revealed that
aminoglycosides did not attain ther
apeutic tissue levels in dogs with
severe pancreatitis.27
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In addition to the gram-negative
organisms usually cultured in pan
creatic abscesses, we also identified
enterococci in a high proportion of
our septic patients in our last re
view. The importance of this type of
bacteria in polymicrobial intra
abdominal abscesses is controver
sial.28 Most of the patients received
antibiotics prophylactically, and two
of the five patients infected with
enterococci received ampicillin. No
deaths occurred in the group of
patients who were infected with
enterococci.
The best method of preventing
infection in tissues likely to be
contaminated during surgery is to
administer prophylactic antibiotics
in high doses. The same principle
applies to the treatment of acute
pancreatitis. The reasons advanced
for the ineffectiveness of prophylac
tic antibiotics in the treatment of
acute pancreatitis are necrosis of
the pancreas or peripancreatic tis
sue and thrombosis of the pancreat
ic vessels,29 which do not allow
antibiotics to reach the pancreas.
However, our experience with clin
damycin and our laboratory find
ings of the levels of antibiotics in
pancreatic tissue27 suggest that
these anatomic aberrations might
be merely theoretical. Our success
in eliminating bacteroids by admin
istering clindamycin prophylactical
ly supports this hypothesis.
Surgical treatment is mandatory
when pancreatic sepsis does not
respond to appropriate antibiotic
coverage. In the world literature,
this complication carries a 100%
death rate unless the area is ade
quately drained and the peripan
creatic necrotic tissue is debrided.4
The surgical management of an
infected pseudocyst or pancreatic
abscess, with or without intrapancreatic sepsis, includes radical
debridement of peripancreatic tis
sue. It is imperative to establish
adequate surgical drainage. Drain
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age can be accomplished by insert
ing multiple Penrose drains or by
closed drainage methods using
sump drains. If abscesses reappear,
drainage employing computed to
mography or ultrasonography is in
dicated.
If, at the time of surgical drain
age, biliary tract disease is noted, a
cholecystostomy should be done
and the gallstones removed manual
ly. Decompression of the biliary
tract must be ensured at the time of
surgery. If the biliary tract is not
decompressed with cholecystecto
my, the more difficult procedure of
placing a T-tube in the common bile
duct must be done. This should
ensure complete biliary tract decom
pression. Following these principles
we have been able to salvage 67%
of the patients with these lethal
complications during the time span
of our last two reviews (1972 to
1985).
Elective surgery performed in the
first week after admission on the
biliary tract of patients suffering
from mild pancreatitis because of
gallstones carried a death rate of
1% to 3%.25 This policy received
acceptance in the surgical literature
as the standard of practice.2526'30
Reservations in older data30 are not
supported by our findings. In this
30-year review, 150 patients, in
whom acute mild pancreatitis was
evolving because of biliary tract
disease, underwent successful and
safe surgery for their biliary tract
disease. In only two patients did the
pancreatitis change from mild to
severe, and the resulting morbidity
and mortality was reported in our
second review. The overall mortality
was 0.01%.
Two patients do not make a
series, but the common problem
encountered in two of the patients
warrants discussion. Each patient
had an impacted, distal, commonbile-duct stone. One patient under
went a Jones sphincteroplasty that

resulted in death from severe pan
creatitis, sepsis and breakdown of
the anastomosis. In the second pa
tient damage to the distal common
duct with a fistula resulted in pro
longed illness from sepsis and se
vere pancreatitis. It has since be
come our policy to drain the com
mon bile duct with a T-tube only if
an impacted stone is found in the
distal common bile duct in a patient
with mild pancreatic disease and
choledocholithiasis. The calculus
may be removed later by enlarging
the passage by medical or endo
scopic means when the patient is in
a stable state postoperatively. Lamont and Passi31 reported a 96%
success rate for removal of stones
from the common bile duct by
means of endoscopy. Using this
technique we have removed impact
ed stones from four patients, a most
gratifying experience.
A recent study reported that en
doscopic papillotomy was of benefit
in the treatment of acute pancreati
tis.32 We have not used this thera
peutic tool to treat acute pancreati
tis. Kelly and Elliott, in a recent
editorial,33 viewed the use of this
procedure with scepticism. A ran
domized, double-blind study is
needed to verify the therapeutic
benefit of using endoscopic papil
lotomy in the treatment of this
disease.
Our mortality (6.6%) falls within
the 6% to 25% reported in the
literature.30 There has been no sig
nificant change in the death rate for
acute pancreatitis since our first
paper was published in 1967. This
was disconcerting at first, but we
believe it reflects the complexity of
features and the life-threatening
processes that evolve as pancreatitis
passes from its mild to severe form.
Aging also has a negative impact on
prognosis. The surgeon must be
vigilant and must aware of a mul
tifactorial process when treating pa
tients who have severe pancreatitis.
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Conclusions
Despite increased knowledge of
the disease process in patients who
have acute pancreatitis and despite
improvement in medical technology,
the death rate for this disease has
remained constant over the past 30
years at our institution. Renal fail
ure, gram-negative aerobic sepsis
and nutritional depletion are the
three major causes of death. Unre
sponsive hypovolemic shock and
gastrointestinal hemorrhage have
been eliminated as causes of death.
The use of prophylactic antibiotics
based on experimental tissue levels
is of benefit in the prevention of
pancreatic sepsis. Gram-negative
aerobic sepsis appears to be resis
tant to all antibiotics now available.
Pancreatic sepsis that fails to re
solve with appropriate antibiotics is
an absolute indication for surgical
drainage and debridement; the sal
vage rate is only 67% in our recent
experience. Interval cholecystecto
my is associated with a low death
rate (0.01%) in patients who have
mild pancreatitis. However, com
mon-bile-duct exploration in these
patients must be used judiciously to
avoid morbidity and mortality.
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Comparison of the Effects of SAG-M
and Whole-Blood Transfusions on
Postoperative Suppression
of Delayed Hypersensitivity
Hans Jurgen Nielsen, MD; Janne Henning Hammer, MD; Flemming Moesgaard, MD, PhD;
Henrik Kehlet, MD, PhD
The influence of perioperative whole-blood transfusion and transfusion with
erythrocyte suspension (SAG-M blood) on postoperative depression of cell-mediated
immunity (CMI) was investigated in 67 patients who underwent elective resection
for colorectal cancer. Cell-mediated immunity was assessed pre- and postoperatively
by skin testing with seven common delayed-type hypersensitivity (D TH ) antigens.
The postoperative skin-test response decreased more in the patients who received
whole blood (15 patients) than in those who received SAG-M blood (16 patients)
(60% versus 42%, p < 0.001) and in those who did not receive a blood transfusion
(36 patients) (60% versus 40%, p < 0.001). The enhanced postoperative
immunosuppression in patients who received whole-blood transfusions persisted
after matching according to age, sex, height, weight, hemoglobin and serum
albumin levels, duration of surgery and diagnosis. Thus, perioperative transfusion
with SAG-M blood does not enhance surgically induced immunosuppression as
effectively as does transfusion with whole blood.

L ’influence d’une transfusion perioperatoire de sang entier et celle de la transfusion
d’une suspension d’erythrocytes (sang SAG-M) sur la depression postoperatoire de
l’immunite cellulaire ont ete etudiees chez 67 patients qui ont subi une resection
elective d’un cancer du colon ou du rectum. L ’immunite cellulaire fut mesuree avant
et apres l’operation par cutireaction a sept antigenes courants provoquant de
l’hypersensibilite de type retarde. La cutireaction postoperatoire a diminue davantage chez les malades qui ont refu du sang entier (15 patients), que chez ceux qui ont
re?u du sang SAG-M (16 patients) (60% contre 42%; p < 0.001) ou que chez ceux
qui n’ont pas ete transfuses (36 patients) (60% contre 40%; p < 0.001).
L ’immunosuppression augmentee chez les patients qui avaient re?u des transfusions
de sang entier a persiste meme apres appariement selon l’age, le sexe, la taille, le
poids, les taux d’hemoglobine et d’albumine seriques, la duree de la chirurgie et le
diagnostic. La transfusion perioperatoire de sang SAG-M n’augmente done pas
l’immunosuppression provoquee par la chirurgie autant que ne le fait une
transfusion de sang entier.

T

he competence of the immune
system may be a significant
determinant of morbidity and mor
tality after surgery for colorectal
cancer.1 Thus, preoperative anergy

to a delayed-type hypersensitivity
(DTH) skin-testing regimen has
been used to identify patients at
increased risk of infectious, postop
erative complications and sepsis-
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related death.2'3 Surgically induced
immunosuppression4-6 increases the
risk of infectious complications.7'8
In addition, perioperative blood
transfusion may be an independent
risk factor9 and may be associated
with recurrence of malignant dis
ease in patients treated by surgical
excision.1011
Although the underlying mecha
nism has not been established, a
decreased helper/suppressor T-lymphocyte ratio, reduced natural killer
(NK) cell activity12 and decreased
generation of interleukin-2 (IL-2) by
splenocytes13 have been demonstrat
ed after transfusion with whole
blood. Recently, we discovered that
perioperative transfusion with
whole blood amplifies the postoper
ative impairment of the DTH skin
reaction.14
Since the use of autotransfusion
or of erythrocytes in artificial sus
pension has been suggested in sev
eral studies,15' 17 the purpose of this
study was to investigate the effect
of perioperative transfusion with
red cell suspensions on the postop
erative suppression of cell-mediated
immunity (CMI) and to compare it
with the effect produced by wholeblood transfusion and nontransfu
sion in colorectal cancer surgery.

Patients and Methods
Sixty-seven patients scheduled
for elective colorectal cancer sur
gery were studied. None had signs

TRANSFUSIONS AND DELAYED HYPERSENSITIVITY

of infective disease and none were
being treated with steroids, non
steroidal anti-inflammatory drugs,
histamine-2 receptor antagonists or
other known immunomodulating
drugs. Renal and hepatic function
were found to be normal on routine
laboratory analyses. Patients with
endocrine disease were excluded
from the study.
Perioperative (for 72 hours after
the skin incision) transfusion with
either whole blood or erythrocytes
suspended in the SAG-M additive
system18 were administered (no
combination of these two blood pro
ducts was given). Patients trans
fused in the preoperative period and
six patients who were transfused
for more than 72 hours after skin
incision were excluded.
Included in the study were 30
patients who had participated in a
previous study on whole-blood
transfusion-induced impairment in
CMI.14 Fifteen of them made up the
group of patients receiving wholeblood transfusion, and 15 became
part of the nontransfused group
(Table I). Of the 37 new patients
participating in the present study,
16 were transfused with SAG-M

blood and 21 were nontransfused
patients (Table I). Transfusion was
given when major bleeding (800 mL
or more, except in two cases in
which bleeding was more than 600
mL) occurred, to achieve a normal
postoperative hemoglobin concen
tration (Table I). Thus the study
population (67 patients) comprised
three groups: 36 patients who did
not have transfusion, 16 patients
who had SAG-M-blood transfusion
and 15 patients who had wholeblood transfusion.
SAG-M blood is composed of
erythrocytes suspended in saline,
adenine, glucose and, for preven
tion of in-vitro hemolysis, man
nitol.18 Before storage in the
SAG-M solution, whole blood was
suspended in a citrate-phosphatedextrose (CPD) solution, centri
fuged to remove platelet-rich plas
ma and recentrifuged to remove the
plasma and the buffy coat. Thus,
SAG-M blood is free from serum
and contains only leukocytes and
platelets in an amount approximate
ly equal to 5% of the content in
whole blood. When stored, SAG-M
blood should be used within 5
weeks. Whole blood used in the

study was plasma-reduced, but with
full content of leukocytes and plate
lets.
Cell-mediated immunity was as
sessed pre- and postoperatively
using a skin test system (Multitest,
Institute Merieux, Lyon, France)
consisting of a plastic disposable
multiple-puncture device capable of
simultaneous application of seven
common DTH antigens and a glyce
rin e / saline diluent (negative con
trol).1920 The antigens were two
toxoids (tetanus and diphtheria),
three bacterial antigens (Streptococ
cus, Proteus and tuberculin), and
two fungal antigens (Candida and
Trichophyton). The first skin test
was applied on the flexor side of the
left forearm 2 days before the oper
ation. On day 0 (48 hours later),
just before surgery, the test was
read. On day 1 (24 hours after the
operation) the second skin test was
applied on the flexor side of the
right forearm, and on day 3 (48
hours later) this test was read. The
cutaneous response to each anti
gen, read at 48 hours, was ex
pressed as a cumulative skin-test
response (sum of all indurated areas
calculated as circles on the basis of

Table I. Clinical Data (Median and Range) on 67 Patients Who Underwent Operation for Colorectal Cancer
No transfusion
Characteristic
Age, yr
Sex, M/F
Body weight, kg
Height, cm
Hemoglobin, mmol/L
Preop
Postop
Serum albumin, ^mol/L
Preop
Postop
Blood transfusion, mL
Duration of surgery, min
Skin testing
Test 1, mm2
Test 2, mm2
Test 2 - 1 (%)

Transfusion

Unmatched,
n = 36

Matched,
n= 15

SAG-M blood,
n = 16

Whole blood,
n = 15

65 (43-80)
25/11
74 (43-103)
171 (155-184)

64(51-77)
10/5
76 (57-103)
171 (159-181)

70 (44-82)
9/7
73 (42-90)
170(159-182)

69 (57-81)
8/7
68 (48-80)
164(151-184)

8.8 (7.5-11.1)
7.6 (6.6—9.5)

8.5(7.5-10.0)
7.3 (6.6-9.2)

8.2 (6.4-10.4)
8.2 (5.9—9.2)

7.9 (6.4-9.1)t
7.7 (6.4-9.21

568 (389-680)
457 (293-587)

555 (389-659)
421 (293-510)

168(100-290)

190(110-290)

544(319-717)
418 (286-556)
1050(300-3300)
198(115-300)

66(13-341)
45 (7-182)
40 (8-65)

50(13-111)
33 (7-71)
42 (8-65)

52 (13-144)
28 (9-99)
42 (28-48)

533
388
900
195

(373-617)
(292—439)t
(350-1800)
(85-320)'

57 (20-385)
23 (3-182)*t§
60 (43-85)tH ||

* p < 0.05; tp < 0.001, between whole-blood transfused and unmatched nontransfused patients.
§ p < 0.05; Ip < 0.001, between whole-blood transfused and matched nontransfused patients.
$ p < 0.05; ||p < 0.001, between whole-blood and SAG-M-blood transfused patients.
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the mean of two perpendicular
diameters).
Finally, blood was drawn for
analyses of blood hemoglobin and
serum albumin levels 48 hours be
fore, and 24 hours after, skin inci
sion.
The operations performed were
right hemicolectomy (7 patients),
sigmoid resection (27 patients), an
terior resection (19 patients), ab
dominoperineal resection (12 pa
tients) and subtotal colectomy (2
patients). The staging of the neo
plasms by Dukes’ classification was
similar in the three groups (no
transfusion, SAG-M transfusion and
whole-blood transfusion) (p >
0.05).
Nonparametric statistics were
used when appropriate (Wilcoxon
signed rank test or the MannWhitney test) in the SPSS system.
Informed consent was obtained
from all participants, and the study
protocol was approved by the Re
gional Ethical Committee of Copen
hagen Hospitals.

the duration of surgery was signifi
cantly (p < 0.05) longer in trans
fused patients, and preoperative he
moglobin and postoperative serum
albumin levels were significantly (p
< 0.001) lower.
The duration of surgery and preand postoperative hemoglobin and
serum albumin levels were similar
in the 15 patients receiving wholeblood transfusion and the 16 pa
tients receiving SAG-M-blood trans
fusion (Table I, Fig. 2). With similar
criteria, these two groups could be
exactly matched to 15 of the 36
nontransfused patients. However,
when the other 21 nontransfused
patients are excluded, the size of
the median postoperative skin-test
area still decreased 60% in patients
who received whole-blood transfu
sion, in contrast to 42% in those
who received SAG-M-blood transfu
sion or no transfusion (p < 0.001,
Table I, Fig. 3), emphasizing that

No transfusion
03
03
1—

CD

Results
The 15 patients who had wholeblood transfusion received a median
of 900 mL (range from 350 to 1800
mL). The 16 patients who had
SAG-M-blood transfusion received a
median of 1050 mL (range from
300 to 3300 mL). The median skintest response area decreased 60% in
patients given whole-blood transfu
sion compared with 42% in patients
who received SAG-M blood (p <
0. 001, Table I, Fig. 1) and 40% in
patients who did not require trans
fusion (p < 0.001, Table I, Fig. 1).
There was no difference between
the decrease in size of the postoper
ative skin-test area in patients who
received SAG-M blood and in nontransfused patients (p = 0.32, Table
1, Fig. 1). However, the clinical data
were not comparable (Table I), since
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n = 36

SAG-M-blood transfusion does not
further deteriorate the traumainduced immunosuppression (p =
0.92, Table I).
Postoperative infectious compli
cations in the 36 nontransfused
patients included respiratory insuffi
ciency in 3, wound infection in 2,
intra-abdominal abscess in 1 and
anastomotic leakage in 2 patients.
In the 15 patients who received
whole-blood transfusions, the post
operative complications included
respiratory insufficiency in 1,
wound infection in 2, intra-abdomi
nal abscess in 1 and anastomotic
leakage in 3 patients (followed by
septicemia in 2 of these). In the 16
patients who received SAG-M trans
fusions, the complications included
respiratory insufficiency in 2,
wound infection in 2 and anasto
motic leakage in 2 patients. As
would be expected from the small
number of participants, the num-

Transfusion
SAG-M blood

n =16

Transfusion
whole blood

n = 15
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CD
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FIG. 1. Postoperative change (%) in cumulative delayed-type hypersensitivity (DTH)
response to seven common DTH antigens in 67 patients who underwent major
elective resection for colorectal cancer with or without whole-blood or SAG-M-blood
transfusion. Patients receiving whole-blood transfusion had longer duration of
surgery and lower preoperative hemoglobin and postoperative serum albumin
levels (p < 0.05) compared with other two groups.

TRANSFUSIONS AND DELAYED HYPERSENSITIVITY

bers of postoperative infectious
complications were statistically in
significant between the groups.

Discussion
Perioperative blood transfusion is
associated with postoperative infec
tious complications921 and recur
rence of malignant disease in pa
tients treated by surgical exci
sion.1011’16 In a prospective study,
Tartter9 demonstrated that blood
transfusion was the most independ
ent risk factor for postoperative
infectious complications, and Maetani and colleagues22 found that
blood transfusion was the most sig
nificant variable in the development
of postoperative multiple organ fail

ure. Experimental studies have
shown that allogeneic, but not syn
geneic, blood transfusion decreases
resistance to infection2324 and de
creases survival following peritoni
tis.25
The evidence that major surgical
trauma impairs postoperative immunocompetence is substantial,24-7
and the suggested amplifying effect
of whole-blood transfusion on post
operative immunosuppression is
widely recognized.101114 Although
the underlying mechanism of
immunodepression induced by
whole-blood transfusion has not
been established, experimental
studies suggest that release of pros
taglandin E223 from allogene eryth
rocytes and exposure to major
histocompatibility (MHC) antigens26

from allogene leukocytes are impor
tant factors.
Our study confirms the sugges
tion that erythrocyte suspensions
are nonimmunosuppressive,15 be
cause the decrease in the size of
DTH skin reactions in SAG-Mtransfused patients and in matched
nontransfused patients was identical
(42% versus 42%, p = 0.92, Table I)
compared with a more pronounced
immunosuppression in whole-bloodtransfused patients (60%, p <

0 . 001 ).
At present, one can merely specu
late about the clinical implications
of these findings in patients who
undergo surgery for colorectal can
cer. Often these patients are hospi
talized with preoperative impair
ment of CMI,27-29 to be further
impaired by surgical excision and
whole-blood transfusion when need
ed, thereby potentially to increase
the risk of infectious complications
and spread of malignant disease.
Since perioperative SAG-M-blood
transfusion in our study did not
further reduce postoperative CMI, it
seems reasonable to use this blood
product when allogeneic blood
transfusion is needed. However, the
proof of a beneficial effect on post
operative infectious complications
and recurrence of malignant disease
requires a prospective randomized
trial.
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Cancer of the Breast: a Study of 1520
Consecutive Patients Operated
on Between 1960 and 1980
A. Peloquin, MD, FRCSC; M. Poljicak, MD, FRCSC; M. Falardeau, MD, FRCSC;
D. Gravel, MD, FRCSC; R. MoTsescu, MD; L. Peloquin, MD
A retrospective study was carried out of 1520 consecutive patients with breast
cancer operated on at the Hopital Notre-Dame in Montreal between 1960 and 1980.
Age and hormonal status of the patient, and duration, size, location, histologic type
and stage of the tumour were studied. The authors grouped the patients according
to four types of surgical treatment: radical (487 patients), modified radical (497
patients) and simple (220 patients) mastectomies and conservative procedures (316
patients). Adjuvant treatments included radiotherapy in 60%, hormone therapy in
4.7% and chemotherapy in 6.7% of patients.
Overall survival at 5,10 and 15 years was 71.3%, 58.7% and 51.1%; in patients
with stage I disease, survival rates were, respectively, 86%, 78% and 72%; rates for
patients with stage II disease were 74%, 62% and 53%.
The population characteristics and survival rates were similar to those reported
by others. The four types of treatment did not produce significantly different
survival rates in patients with stage I lesions. However, this was not the case in
patients with stage II and III lesions in whom simple mastectomy (McWhirter
procedure) was associated with significantly worse results. Finally, this study
confirmed the prognostic importance of stage, size of the tumour and degree of
axillary lymph-node involvement.

Les auteurs ont effectue une etude retrospective sur 1520 patientes consecutives
operees pour cancer du sein a l’hopital Notre-Dame entre 1960 et 1980. On a etudie
1’age et l’etat hormonal de chacune des patientes de meme que la duree, la
dimension, la localisation, le type histologique et le stade de la tumeur. Les auteurs
ont groupe les malades selon quatre types de traitements chirurgicaux: mastectomie
radicale (487 patientes), mastectomie radicale modifiee (497 patientes), mastectomie
simple (220 patientes) et technique conservatrice (316 patientes). Les traitements
adjuvants furent la radiotherapie chez 60%, l’hormonotherapie chez 4.7% et la
chimiotherapie chez 6.7% des patientes.
La survie globale a 5,10 et 15 ans fut de 71.3%, 58.7% et 51.1%; chez les
patientes de stade I, les taux de survie furent respectivement de 86%, 78% et 72%;
pour les cas de stade II, la survie fut de 74%, 62% et 53%.
Les caracteristiques de cette population de cancer du sein de meme que nos
resultats se comparent a ceux des autres publications. Les quatre types de
traitements n’ont pas produit de difference dans les taux de survie pour les patientes
ayant des lesions de stade I. Cependant, ceci n’a pas ete le cas chez les malades de
stade II et III ou la mastectomie simple (procede de McWhirter) a ete responsable
d’une survie nettement inferieure. Enfin, cette etude confirme l’importance pronostique du stade, de la dimension de la tumeur et du degre d’envahissement
ganglionnaire de l’aisselle.
From Department o f Surgery, Hopital Notre-Dame, Universite de Montreal, Montreal
Presented at the annual meeting o f the Quebec Association o f General Surgeons, Quebec, May
4-5, 1989
Accepted for publication Feb. 28, 1990
Reprint requests to: Dr. A. Peloquin, Departement de chirurgie, Hopital Notre-Dame, Universite
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n the early 1960s, all but a few
surgeons,1-4 favoured radical
mastectomy for the treatment of
breast cancer. But since then many
factors have contributed to the evo
lution of breast cancer treatment.
The Halsted theory gave way to a
more systemic approach.5 Prognosis
improved. The significance of
lymph-node invasion changed and
was thought to be more a cause
than a consequence of the disease.6
Smaller cancers of the breast are
now found more often because
mammography and screening pro
grams have improved. Chemothera
py has made great progress. Finally
increasing importance has been
given to the cosmetic and psy
chologic aspects of breast cancer
treatment.
We reviewed the various modali
ties of breast cancer treatment used
during these years and compared
our results with those reported in
the literature. We also focused on
the patterns of our breast cancer
population, considering the fact
that a certain degree of inbreeding
has taken place over the last 300
years in Quebec, in a rather closed
population.

I

Methods
Between 1960 and 1980, 1520
patients with a diagnosis of breast
carcinoma were treated and fol
lowed up at the Hopital Notre-Dame
in Montreal. We excluded from this
study patients whose cancer was
first treated elsewhere, those with
secondary carcinomas of the breast,
men with breast cancer and inflamCJS, VOL. 34, NO. 2, A P R I L 1991
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matory or bilateral cancers of the
breast. Only 14 patients (0.9%) were
lost during follow-up. Others have
been followed up between 5 and 25
years.
All information from the records
was computerized. Analysis of sur
vival analysis was done with the
Lee-Dezu nonparametric test. The
X2 test was used to validate the
significance of the results.

Findings
Population

Patients in this study were all
white women, and most (99.6%)
were French Canadian. They ranged
in age from 20 to 88 years (mean
and median 55 years). Menopausal
status was based on the date of the
last menstruation; 560 (36.8%) pa
tients were premenopausal and 957
(63.0%) postmenopausal. For three
patients (0.2%) information on
menopausal status was missing.
Diagnosis

The patient discovered her tu
mour in 89.5% of cases, the doctor
in 7.7%. Forty-three cancers (2.8%)
were detected by mammography,
rarely used for screening at the time
of this study. In five patients the
tumour was diagnosed after a sus
pect lymph node in the axilla was
discovered. Diagnostic information
was missing in four cases.
Interval Before Treatment

In 516 (33.9%) patients tumour
had been present for less than 2
months, in 374 (24.6%) between 2
and 4 months and in 150 (9.9%)
between 4 and 6 months. In 456
(30%) cases the tumour had been
present for more than 6 months
before therapy. Data were missing
in 24 cases (1.6%).
152
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The Tumour

Clinical study of the 1520 pa
tients showed that the tumour in
278 (18.3%) patients was smaller
than 2 cm, in 813 (53.5%) patients
it was between 2 and 5 cm and in
307 (20.2%) patients it was larger
than 5 cm. Severe skin signs (ulcer
ation, edema and skin invasion)
were noted in 72 patients (4.7%).
Only 48 (3.2%) had a nonpalpable
tumour. Data on tumour size were
incomplete in 2 (0.1%) patients.

tomy without axillary dissection
was performed in 220 (14.5%) pa
tients, but these patients always
underwent radiotherapy.
Breast conservation followed by
radiotherapy was performed in 316
(22.8%) patients: 140 partial mas
tectomies (9.2%) with or without
axillary dissection and 176 lumpec
tomies (11.6%). Our study included
only patients with operable breast
cancer. The 34 patients with stage
IV disease had lumpectomy or,
more often, simple mastectomy as a
palliative measure.

Tumour Location

Carcinoma was distributed equal
ly between both breasts. Location in
the breast is shown in Table I. In
1% of patients the information on
tumour location was incomplete.
Histologic Findings

The histologic types of the tu
mours are given in Table II. Can
cers classified as “other” are rare
forms, such as hydrosadenoid, malpighian, carcinoid and papillary tu
mours. In only one case was the
tumour, although proven to be can
cer on biopsy, not clearly classified.

Adjuvant Treatment
Surgery was the only form of
therapy in 406 (26.7%) patients.
Radiotherapy as adjuvant treatment
was used in 910 (59.9%) patients at
a rate of 50 to 60 Gy. In 96.4% of
these, irradiation was to the breast,
when present, and to the skin and
regional lymph nodes. In cases of
radical surgery, radiotherapy was
generally added to the surgical
treatment when more than three
axillary lymph nodes were found to
be affected. Radiotherapy was also

1. Location of Tumour in 1520
Patients With Breast Cancer

T a b le

Clinical Stage

P ercent of cases

Location

Clinical staging was based on the
TNM classification.7 Among our
1520 cases, 308 (20.3%) cancers
were classified as stage I, 806 (53%)
as stage II, 370 (24.3%) as stage III
and 34 (2.2%) as stage IV. In only
two cases was the cancer not classi
fied, because information on the
size of the tumour was missing.

Surgical Treatment
In our study we performed 487
(32%) Halsted radical mastectomies
and 497 (32.7%) modified radical
mastectomies. Simple total mastec

Upper outer quadrant
Upper inner quadrant
Lower outer quadrant
Lower inner quadrant
Subareolar

T a b le II.

55.1
16.0
11.2
8.0
8.7

Histologic Types of Breast Cancer
in 1520 Patients

T y p e of cancer

Infiltrating ductal
Infiltrating lobular
Medullary
Mucinous
Paget's disease
Intraductal in situ
Lobular in situ
Other
Incomplete data

N um b er
(% ) of patients

1154 (75.9)
167 (11.0)
68 (4.5)
48 (3.2)
26 (1.7)
7 (0.5)
5 (0.3)
44 (2.9)
1

BREAST CANCER

used as an adjunct in all patients
who underwent simple mastectomy
or conservative breast procedures.
Hormone therapy was seldom
used: only 103 (4.7%) patients had
some form of hormone therapy (es
trogen, androgen, castration, an
tiestrogen). Adjuvant chemotherapy
was exceptional before 1980: only
101 (6.7%) patients had this form of
adjuvant treatment.

another cancer and 146 (9.6%) had
died of other causes (including car
diac disease, pulmonary problems,
cerebrovascular accident), most of
them many years after the diagnosis
of cancer of the breast and always
without evidence of cancer recur
rence. Fourteen were lost to follow
up.

Survival
Axillary Lymph-Node
Involvement

The survival study was based on
1482 patients. Thirty-eight patients
were excluded: in 2 the cancer
stage was unknown, in 22 the exact
date of the operation or of the last
visit was missing, so these 24 pa
tients must also be considered, with
the other 14, as lost to follow-up.
Overall survival for patients with
stage I, II or III cancer7 at 5 years
was 71 .3%, at 10 years was 58.7%
and at 15 years was 51.1%.
Survival was studied with respect
to clinical stage, type of surgery,
size of the tumour and degree of
axillary node involvement.

Axillary dissection was done in
1048 patients. Lymph-node involve
ment was found in 46.8% of pa
tients who underwent radical mas
tectomy, in 52.1% of those who had
modified radical mastectomy and in
40.2% of those who had partial
mastectomy with axillary dissection.

Follow-up
Present Status
Of the 1520 patients, 664
(43.7%) were still alive at the end of
1985, 656 (43.2%) had died of
breast cancer, 40 (2.6%) had died of

Survival and Clinical Stage
Long-term survival is closely re
lated to the clinical stage. Table III

Table III. Stage and Survival Rates (% ) in 1482 Patients
Survival, yr

Stage

Number
of patients

5

10

15

1
II
III
IV

301
790
359
32

86.0
74.2
5 2 .6
19.5

77.7
61.8
35.1
9.7

71.6
52.6
29.5
9.7

Table IV. Survival Rates (%) in 301 Patients W ith Stage

Halsted m astectomy
Modified radical
mastectomy
Total m astectomy
Partial m astectomy

Survival According to Clinical Stage
and Type o f Operation
Table IV shows the survival of
301 stage I patients according to
four types of operations. Differ
ences in survival were not signifi
cant even when pairs of different
treatments were compared (p
ranged from 0.065 to 0.998). The
overall comparison was also not
significant (p = 0.207).
For 790 stage II patients there
was a significant difference (p —
0.014) between the four groups
together (Table V), but when com
parisons were made by pairs, the
significant difference was always to
the detriment of total mastectomy
(p = 0.0010 to 0.0213). In this
group the survival rate was worse.
On the other hand, comparison of
the two types of radical mastectomy
and the partial mastectomies re
vealed no significant differences
(p = 0.3979 to 0.9384).
The study of 359 stage III pa
tients gave the same results (Table
VI). All pairwise comparisons be
tween the Halsted operation, modi
fied radical mastectomy and partial
mastectomy were not significant
(p = 0.2944 to 0.6076). Again the
only significant differences were ob
tained when the worst results of
total mastectomy (McWhirter proce
dure) were compared with each of
the three other types of surgery
(p = 0.0066 to 0.0315).

Breast Cancer According to Type of

Surgery

Type ot surgery

shows the results at 5, 10 and 15
years. Differences in survival are
statistically highly significant (p =
0 . 0000 ).

Survival and Tumour Size
Survival, yr

Number
of patients

5

10

15

108

8 6 .8

8 2 .9

76.6

85
31
77

88.1
7 6 .6
8 6 .3

80.3
60.7
73.9

80.3
60.7
59.6

Table VII demonstrates the sur
vival of patients according to the
size of the tumour. There was a
very significant difference between
each group (p = 0.0000), confirm
ing the strong prognostic value of
CJS, VOL. 34, NO. 2, APRIL 1991
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this factor. Nonpalpable tumours
were associated with a survival
equal to that for T2 tumours.
Survival and Lymph-Node
Involvement

The survival of patients who had
an axillary dissection is shown in
Table VIII. Survival rates differed
significantly between the five
groups (p = 0.0000). There was
probably no or minimal lymph-node
invasion in the 32 cases in which
the pathologist did not find any
involved lymph nodes in the speci
men. This group of patients had the
second-best survival rate.

times better, than that reported in
the literature.12-17 In stage I lesions,
there was no significant difference
in survival whatever type of surgical
treatment was used. On the other
hand, in stages II and III, a statisti
cally significant difference was obvi
ous, but only with respect to simple
mastectomy plus radiotherapy
(McWhirter technique),21 for which
survival was worse. This form of
treatment was used mostly in the
1960s. These poor results were
reported from our hospital by Ar-

Table V. Survival Rates (%) in 790 Patients With Stage II Breast Cancer According to Type of
Surgery
Survival, yr
Type of surgery

Discussion
Owing to the known inbreeding
for many generations in Quebec, we
expected that our breast cancer
population would be somewhat dif
ferent from others. Study of age
and hormonal status of the pa
tients, and of the size, location,
stage and histologic type of the
tumour confirmed the similarity be
tween our population and others in
the Western world.8-11 The only
difference we found was in the
interval from diagnosis to therapy.
Indeed 30% of our patients were
first treated more than 6 months
after the discovery of the tumour.
However, this did not seem to influ
ence survival, because our overall
survival rates are comparable to
those reported in the literature.12-17
Many18-20 have demonstrated the
minimal influence of delay upon
survival. In our survival study we
mostly analysed the value of differ
ent types of surgery (all patients
underwent operation), associated
with radiotherapy in 60% of cases.
Indeed other adjuvant therapy was
seldom used in this study.
Overall survival and survival ac
cording to stage is as good, some
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chambault and Henckes17 in 1964
and were even worse in the present
series. We cannot explain the poor
results of this treatment in our
hands. Others21-24 have reported
better results with the McWhirter
technique.
Nevertheless, our survival rates
with conservative procedures are
statistically as good as those of
radical mastectomies for each stage.
This is confirmed by recent publica
tions.25-28 However, in the patients
who underwent conservative proce-

Halsted mastectomy
Modified total
mastectomy
Total mastectomy
Partial mastectomy

of patients

5

10

15

281

72.8

63.8

54.0

265
110
134

78.9
59.2
80.4

63.0
50.9
63.2

58.6
46.9
47.4

Table VI. Survival Rates (%) in 359 Patients With Stage III Breast Cancer According to Type of
Surgery
_____

Type of surgery
Halsted mastectomy
Modified total
mastectomy
Total mastectomy
Partial mastectomy

Number
of patients

Survival, yr
5

10

15

85

53.3

40.6

32.6

131
66
77

57.8
38.4
52.9

39.8
24.6
31.4

39.8
16.7
29.2

Table VII. Survival Rates (%) According to Tumour Classification and Size

Tumour class/size, cm
T 1 /< 2
T2/2 - 5
T 3 /> 5
T4
Nonpalpable

Survival, yr

Number
of patients

5

10

15

271
795
300
69
47

85.6
74.0
53.6
35.3
71.3

76.8
61.6
36.5
22.6
61.3

70.7
52.5
31.3
19.6
56.2

Table VIII. Survival Rates (%) Associated With Lymph-Node Invasion

Lymph-node invasion
None
1 to 3 positive nodes
4 to 10 positive nodes
> 11 positive nodes
No lymph nodes
identified

Survival, yr

Number
of patients

5

10

15

490
308
152
36

87.4
70.8
47.0
37.6

79.2
54.4
29.9
19.3

73.1
43.3
26.6
19.3

32

80.6

70.4

60.9

BREAST CANCER

dures, the tumours were smaller,
and in half of these operations
axillary dissections were performed.
This was not the case with patients
who underwent the McWhirter pro
cedure. Also, because most conser
vative procedures were done in the
1970s, the follow-up is shorter than
for the McWhirter group.
Although it is retrospective, our
study confirms the significant prognostical value of both tumour size
and the degree of nodal invol
vement.12_14'19'29'31
Although we used radiotherapy
extensively in our series, our good
results cannot be attributed to this
adjuvant therapy, since it is well
known that radiotherapy has no
effect upon survival.1232'34 Never
theless, it does decrease the rate of
local recurrence in the skin and
axilla, and in the breast that is not
removed.23-35-37

Conclusions
This study illustrates that our
population is similar to other breast
cancer populations. Our results
compare favourably with those of
most reports. Although our study is
retrospective, the prognostic value
of staging, of tumour size and of
the degree of lymph-node involve
ment is clearly illustrated. Until we
learn more about the fundamentals
of cancer and about the biologic
behaviour of a tumour in a given
patient, we consider that any fur
ther improvement in the treatment
of breast cancer, will probably be
obtained only by cooperative, ran
domized, prospective studies. Our
hospital is now involved in such
ongoing trials.
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INDICATIONS:

CONTRAINDICATIONS:
INSTAT Absorbable Hemostat should not be used in
the closure of skin incisions as it may interfere with
the healing of skin edges. This interference is due
to simple mechanical interposition of dry collagen
and not due to any intrinsic interference with wound
healing. It has been reported with another
absorbable collagen hemostat that, in filling
porosities of cancellous bone, collagen may reduce
the bonding strength of methylmethacrylate.
Therefore, INSTAT Absorbable Hemostat should not
be applied on bone surfaces to which prosthetic
materials are to be attached with
methylmethacrylate adhesives.

WARNINGS:
INSTAT Absorbable Hemostat is inactivated by
autoclaving. It should not be resterilized. As with
any foreign substance, use in contaminated wounds
may enhance infection.
INSTAT Absorbable Hemostat should not be used in
instances of pumping arterial hemorrhage.
INSTAT Absorbable Hemostat should not be used
where blood or other fluids have pooled or in cases
where the point of hemorrhage is submerged.
INSTAT Absorbable Hemostat will not act as a
tampon or plug in a bleeding site, nor will it close off
an area of blood collecting behind a tampon.
Only the amount of INSTAT Absorbable Hemostat
necessary to provide hemostasis should be used.
The long-term effects of leaving INSTAT Absorbable
Hemostat in situ are unknown. Opened, unused
INSTAT Absorbable Hemostat should be discarded
because it cannot be resterilized.

PRECAUTIONS:
As with other hemostatic agents, it is not
recommended that INSTAT Absorbable Hemostat
be left in an infected or contaminated space, nor is it
recommended for use in persons known to be
sensitive to materials of bovine origin. When placed
into cavities or closed spaces, care should be
exercised to avoid overpacking INSTAT Absorbable
Hemostat as it may absorb fluid and expand and
press against neighbouring structures.

ADVERSE REACTIONS:
INSTAT Absorbable Hemostat is a collagen product.
Although several types of postoperative
complications were observed in INSTAT Absorbable
Hemostat-treated patients, none were attributed to
INSTAT Absorbable Hemostat except one case of
fibrotic reaction where INSTAT Absorbable
Hemostat involvement could not be ruled out.
Adverse reactions reported for other collagen
hemostats include hematoma, potentiation of
infection, wound dehiscence, inflammation and
edema. Other reported adverse reactions that may
be related to the use of collagen hemostats include
adhesion formation, allergic reaction, foreign body
reaction and subgaleal seroma (in a single case).
The use of microfibrillar collagen in dental extraction
sockets has been reported to increase the incidence
of alveolalgia. The possibility that all of the above
reactions may occur with INSTAT Absorbable
Hemostat cannot be excluded.

ADMINISTRATION:
INSTAT Absorbable Hemostat is applied directly to
the bleeding surface with pressure. INSTAT
Absorbable Hemostat can be cut to size. The
amount needed and the period of time necessary to
apply pressure will vary with the type and amount of
bleeding to be controlled. Hemostasis time depends
upon the type of surgery and degree of pretreatment
bleeding. It usually occurs between 2 to 5 minutes
with INSTAT Absorbable Hemostat.
INSTAT Absorbable Hemostat maintains its integrity
in the presence of blood and is not dispersed when
wet. It is easily removed from the site following
hemostasis. It is most effective when used dry.
INSTAT Absorbable Hemostat may be left in situ
whenever necessary. However, the surgeon, at his
discretion, should remove any excess of INSTAT
Absorbable Hemostat prior to wound closure.
Animal implant studies have demonstrated that
absorption and tissue reaction to INSTAT
Absorbable Hemostat are similar to those observed
with another absorbable collagen hemostatic agent.
In these studies, on visual examination, most of
INSTAT Absorbable Hemostat was found to be
absorbed within 8 to 10 weeks after implantation.

CLINICAL STUDIES:
The safety, effectiveness and handling
characteristics of INSTAT Absorbable Hemostat
were evaluated in a variety of surgical procedures.
The median time to hemostasis for INSTAT
Absorbable Hemostat was 3 minutes. Passive
Hemagglutination Assay (PHA) and Enzyme-Linked
Immunoabsorbent Assay (ELISA) methods have
been used to evaluate the immunologic potential for
INSTAT Absorbable Hemostat to produce
antibodies in patients. These assays revealed mild
elevation of antibody titers in both INSTAT
Absorbable Hemostat-treated patients and patients
treated with a collagen control hemostat, confirming
that INSTAT Absorbable Hemostat, like other
collagen hemostats, is a weak antigen.

HOW SUPPLIED:
INSTAT Absorbable Hemostat is supplied in a
sponge-like form in peelable plastic envelopes in the
following sizes:
2.5 cm x 5.0 cm (1 in. x 2 in.)
7.5 cm x 10.0 cm (3 in. x 4 in.)
The sterility of the product is guaranteed unless the
individual envelope is damaged or opened.
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children and pregnant women. Therefore, INSTAT
Absorbable Hemostat should only be used when
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INSTAT Absorbable Hemostat is not intended to be
used to treat systemic coagulation disorders.
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Pyoderma Gangrenosum After Reduction
Mammoplasty
P.A. Clugston, MD; R.P. Thompson, MD, FRCSC; O.L.A. Schlappner, MD, FRCPC
The authors report a case of pyoderma gangrenosum in a 37-year-old woman that
occurred at surgical sites after reduction mammoplasty. The diagnosis was delayed,
but treatment with intralesional triamcinolone resulted in complete resolution of the
condition. Pyoderma gangrenosum in this setting can mimic infectious causes of
wound necrosis. Early recognition of its characteristic features may prevent
unnecessary and ineffective treatment, thereby avoiding frustration for both patient
and physician.

Les auteurs decrivent un cas de pyoderma gangrenosum qui est survenu dans la
zone operatoire a la suite d’une mammoplastie de reduction chez une femme de 37
ans. Le diagnostic fut retarde, mais Tinjection intralesionelle de triamcinolone
amena une resolution complete de l’affection. Dans ce contexte, la pyoderma
gangrenosum peut prendre les apparences des causes infectieuses de necrose
tissulaire. L’identification precoce de ses caracteristiques particulieres peut eviter
des traitements inutiles et inefficaces, evitant ainsi au patient et au medecin bien des
frustrations.

yoderma gangrenosum is an
uncommon necrotizing cutane
ous disease of unknown cause that
is often associated with underlying
systemic disease. The diagnosis is
one of exclusion, based on its char
acteristic appearance, failure to re
spond to local wound care and
antibiotics, and its often dramatic
response to appropriate therapy.
The histopathology is nonspecific
but helpful in excluding other
causes. The association of pyoder
ma gangrenosum and monoclonal
gammopathy is well recognized;
however, the relation between the
paraproteinemia and the ulcerative
lesion remains obscure.12 Several
cases have been reported recently of

P

pyoderma gangrenosum occurring
at surgical sites. In this situation
pyoderma gangrenosum often mim
ics infectious causes of wound ne
crosis.3-5 We report a case of pyo
derma gangrenosum occurring at
surgical sites in a patient in whom
an elevated immunoglobulin frac
tion was found incidentally and we
review the clinical aspects, patho
genesis and treatment of this dis
ease.

Case R eport

A 37-year-old woman was seen 6
weeks after bilateral reduction
mammoplasty because of open ul
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ceration at the inferior aspect of the
right areolar suture line. No suture
material was found upon probing so
the ulceration was treated with hy
drogen peroxide. Culture of the
ulceration was negative. Twelve
weeks postoperatively she had bilat
eral ulcerations measuring 18 X 7
mm on the right and 1 5 X 8 mm on
the left. Polysporin ointment was
added to the previous regimen. At
14 weeks central re-epithelialization
was noted despite progressive pe
ripheral ulceration (Figs. 1 and 2).
On referral to a dermatologist a
biopsy was done which revealed
acute and chronic inflammatory
cells and diffuse granulomatous in
flammation. This was considered
uncharacteristic of pyoderma gan
grenosum. The patient was given a
trial of betamethasone (1.5 m g/d
orally for 5 days) followed by a
tapering schedule, with Fucidin
(Leo Laboratories Canada, Picker
ing, Ont.) ointment applied weekly
beneath Duoderm (Convatec Cana
da, Montreal) to the lesions. There
was no improvement of either le
sion.
At 22 weeks postoperatively the
lesions had continued to enlarge,
and there was minimal serosanguineous discharge and mild dis
comfort (Fig. 3). Results of investi
gations performed on referral to an
allergist were as follows: leukocyte
count was 13.3 X 1 0 9/ L ; erythro
cyte sedimentation rate was 15
m m/h; the third and fourth compo
nents of complement (C3 and C4)
and lymphocyte and macrophage
function were normal; protein elec
trophoresis revealed hypergamma
globulinemia with a gammaglobulin
level of 20.7 g /L (normal range
CJS, VOL. 34, NO. 2, A P R IL 1991
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from 7 to 15 g /L ) and an immuno
globulin profile revealing an elevat
ed IgM fraction of 3.33 g /L (nor
mal range from 0.7 to 2.5 g/L).
Patch testing revealed a nickel
sensitivity, and the possibility of
cross-reactivity with adhesive tape
was considered, as was a contact
sensitivity reaction to polysporin.
Polysporin ointment was replaced
with flamazine, vibramycin was
started at 100 mg twice daily and a
nickel-free diet was instituted. After
2 weeks of this therapy the lesions
had not decreased in size, but a few
islands of granulation tissue were
noted centrally. It was therefore
suggested that the vibramycin be
continued. Gradual deterioration
was noted up to 30 weeks, and a

new lesion was present on the right
breast. Repeat cultures for bacteria,
fungi and Mycobacterium were neg
ative.
Because local measures had
failed and the lesions had gradually
progressed, split-thickness skin
grafts were applied at 48 weeks
postoperatively. Initially there was
excellent graft take; however, 2 to
3 weeks later, re-ulceration was
noted at the periphery (Fig. 4).
Donor sites healed well. Cultures
from the new lesions grew Sta
phylococcus epidermidis.
The patient was started on oral
cloxacillin, and garamycin ointment
was applied locally. Initially, there
was some improvement followed by
a steady state. Over the next year

FIG. 1. Patient’s right breast demonstrates ulceration inferior
to nipple-areolar complex and central areas of re-epithelialization.
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the patient failed to maintain fol
low-up, even though there was
slight improvement bilaterally. At
28 months postoperatively a second
dermatologic opinion led to the di
agnosis of pyoderma gangrenosum.
Treatment with intralesional triam
cinolone resulted in complete heal
ing of the lesions over the next 2
months (Fig. 5). At the last follow
up, 3.5 years postoperatively, the
lesions remained healed.

Characteristics of Pyoderma
Gangrenosum
As illustrated by this case, the
diagnosis of pyoderm a g an 
grenosum is not always obvious.

FIG. 2. Patient’s left breast shows ulcerating lesion with
erythematous “heaped-up” advancing edge.

PYODERMA GANGRENOSUM AFTER MAMMOPLASTY

Often there is considerable delay
between the onset of these lesions,
the correct diagnosis and subse
quent therapy. Treatment is empir
ic, because the cause is not clear.
Not all patients with pyoderma gan
grenosum respond well to treat
ment, and often high-dose oral cor
ticosteroids are required for a pro
longed period. The course is unpre
dictable and recurrences are not
uncommon.

Clinical Manifestations
The lesions typically occur on the
lower extremities or trunk, but may
occur anywhere, particularly at sites
of minor trauma. Pyoderma gan
grenosum usually begins as a vesiculopustular or nodular lesion that
ulcerates centrally. The advancing,
ulcerating edge becomes “heapedup,” undermined and violaceous
with a surrounding erythematous

border.2 The lesions are not always
this classic. The size of the lesions
may progress at a rate from mil
limetres to centimetres daily or re
main unchanged for months. Spon
taneous healing with atrophic crib
riform scarring can occur.2
The lesions are painful in 75% of
cases and there may be systemic
symptoms of fever and malaise.6
Recurrences are common and often
parallel the course of the associated
underlying disease, if one is identi
fied.

Histologic Features
Histopathologic features are un
fortunately nonspecific, with biopsy
of the advancing edge revealing an
inflammatory cell infiltrate of either
acute or chronic type.3 Centrally
there may be areas of thrombosis,
hemorrhage, necrosis or re-epithelialization. In lesions of prolonged
duration there can be giant cells
and marked fibrosis.3

FIG. 3. Condition of patient’s ulcerations bilaterally 22 weeks postoperatively.

Etiology and Epidemiology
Distribution between the sexes is
equal. A history of pathergy (the
development of new lesions follow
ing minor trauma) exists in 30% of
cases.2 There are findings that sug
gest altered host immunologic reac
tivity, although these are variable
and their importance is unknown.7'8
Pyoderma gangrenosum is associat
ed with an underlying disease in
50% to 60% of cases, the remainder
of the cases are idiopathic. There
has been one report of pyoderma
gangrenosum in a kindred.4

Associated Diseases

FIG. 4. Patient’s breast approximately 3 weeks after split-thickness skin grafting
shows initial re-ulceration at periphery of skin grafts.

The number of associated diseas
es is vast and of unknown impor
tance. Gastrointestinal, rheumatoCJS, VOL. 34. NO. 2, APRIL 1991
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logic and hematologic disorders
constitute the majority of systemic
illnesses associated with pyoderma
gangrenosum (Table I). Ulcerative
colitis accounts for 35% to 60% of
cases; however, only 1% to 5% of
patients with ulcerative colitis have
this skin disorder.5 The prevalence
in Crohn’s disease is 1.2%.9 Various
arthritides account for another
large group. Approximately 50% of
patients with pyoderma gan
grenosum have abnormal immuno
globulin levels, the most frequent
abberation being a diffuse hyper
gammaglobulinemia.2 Of the mono
clonal gammopathies, immuno
globulin A is the most frequent in
pyoderma gangrenosum.12

Diagnostic Evaluation
Patients must be thoroughly as
sessed to exclude other ulcerating
skin diseases and to identify any
possible associated underlying sys
temic illness. Investigations should
include biopsy, with the tissue
being sent for histologic examina
tion and cultures for bacteria
(aerobic/anaerobic), fungi and My
cobacterium, as well as rheumato-

logic, immunologic and gastrointes
tinal evaluations, as indicated by
the history and physical examina
tion.
The differential diagnosis is ex
tensive and includes vasculitis and
ischemic ulceration, infectious le
sions, ulcerating neoplastic lesions,
factitial lesions, erythema mul
tiforme, acute neutrophilic der
matoses and ulcerated necrobiosis
lipoidica.
Although the histologic charac
teristics of pyoderma gangrenosum
are nonspecific and at times mis
leading, they are extremely relevant
in excluding these other entities.
Often the presence of an underlying
systemic illness is not identified
until after the diagnosis of pyoder
ma gangrenosum is made.1 This is
often the case in patients with paraproteinemias as these patients are
usually otherwise well.1

ple of this is the case of pyoderma
gangrenosum in the setting of mul
tiple myeloma; treatment of the
latter with melphalan and plasma
pheresis has resulted in healing of
the cutaneous lesions.1
Although, no one therapeutic
protocol has near 100% efficacy,
high-dose corticosteroids and local
wound care to avoid secondary in
fection remain the mainstay of ther
apy.9 High-dose oral, intralesional
and massive intravenous pulse
doses of corticosteroids have been
effective.61011 In steroid-resistant
cases immunosuppressive agents
and other adjuvant agents such as
clofazimine and sulfapyridine have
been beneficial. Typically they are
used in combination with high-dose
oral corticosteroids.5 Administration
of hyperbaric oxygen, before and
after split-thickness skin grafting,
although labour intensive, has
shown promising results.12

Treatment
Discussion
The treatment remains empiric
because the cause is unclear. If
there is an associated systemic ill
ness, control of this can lead to
healing of the lesions.510 An exam

Pyoderma gangrenosum remains
an obscure entity of unclear etiolo
gy that often poses both a diagnos
tic and therapeutic challenge. The
Table I. Diseases Associated
With Pyoderma Gangrenosum
Gastrointestinal disease
Ulcerative colitis
Crohn’s disease
Chronic active hepatitis
Duodenal ulcer disease
Rheumatologic disease
Rheumatoid arthritis (RF .positive)
Rheumatoid arthritis (RF negative)
Systemic lupus erythematosus
Hematologic disease
Leukemias
Multiple myeloma
Polycythemia rubra vera
Paraproteinemias
Lymphoma
Miscellaneous
Sarcoidosis
Diabetes mellitus
Diverticulitis
Wegener's granulomatosis
RF = rheumatoid factor.

FIG. 5. Patient’s breasts 3.5 years postoperatively have healed completely.
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potential for this lesion to arise at
sites o f surgical trauma and its
ability to mimic superficial wound
necrosis of infectious etiology could
lead to a delay in diagnosis and
inappropriate management. Wound
debridement and skin grafting can
lead to further progression o f the
lesions or to new lesions at donor
sites, and they are therefore contra
indicated.
Review of the cases o f pyoderma
gangrenosum showed that they oc
curred at sites o f surgical trauma:
sternotomy, laparotomy, and Pfannenstiel and mammoplasty inci
sions, and sometimes at venipunc
ture sites in patients with primary
wound involvement.4'511 The time of
onset o f the condition after surgery
ranged from 4 days to 9 weeks. The
presence of low-grade fever and
leukocytosis is common and tends
to be more marked when the condi
tion appears early in the postopera
tive course.
Many systemic and local thera
pies have been tried with, at best,
variable results. The potential side
effects o f therapy with high-dose
steroids must be recognized and, if
possible, avoided. Hence, for single,
isolated lesions treatment with intralesional steroids offers an effec
tive treatment alternative associated
with low morbidy.
The significance o f immunologic
dysfunction and the presence of
systemic disease in this patient pop
ulation needs to be investigated
further to gain a better understand
ing of the underlying etiology and
to identify more specific therapy.
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SESAP VI Question
Item 47
Which of the following statements about the timing o f cholecystectomy
for patients with gallstone pancreatitis is NOT true?

(A) Most patients with mild disease can be safely operated on
within the first week
(B) If operation is performed after subsidence o f clinical symptoms,
common duct stones are found in 10% to 15% o f patients
(C) Operation should precede hospital discharge
(D) Operation should include cholecystectomy and exploration o f
the common bile duct
(E) Endoscopic papillotomy may obviate urgent operation

From the answers to the question above select the one that is best.
For the critique o f Item 47 see page 181
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NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS
TORADOL (ketorolac tromethamine) 10 mg tablets
TORADOL IM (ketorolac tromethamine) 15 mg/mL and 30 mg/mL intramuscular Injections
THERAPEUTIC CLASSIFICATION
Analgesic Agent
ACTION
Toradol (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug that exhibits analgesic activity. Its mode of
action is to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins, and is consid
ered to be a peripherally acting analgesic. At analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tromethamine israpidly and completely absoibed when administered by both the oral and intramuscular routes,
and pharmacokinetics are linear following single and multiple dosing.
Steady state plasma levels are attained after one day of Q.I.D. dosing. Based only on pharmacokinetic principles, a faster
attainm ent of the steady state plasma level might be achieved with a loading dose of about tw ice the maintenance
dose. This occurs when the dosing Interval is approximately equal to the drug's half-life.
Following oral administration, peak plasma concentrations of 0.52 to 1.31 mcg/ml occurred 35 minutes after a single 10 mg
dose. The terminal plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly sub
jects (m ean age: 72 years) it ranged between 3,0 dnd 6.1 hours. A high fat diet decreased the rate but not the extent
of absorption of oral ketorolac tromethamine, while antacid had no effect.
Following intramuscular administration, peak plasma concentrations of 2,2 to 3.0 m cg/m l occurred an average of 50
minutes after a single 30 mg dose. The terminal plasma half-life ranged between 3.8 and 6.3 hours in young adults and
between 4.4 and 8,6 hours in elderly subjects (mean age: 72),
The primary route o f excretion o f ketorolac tromethamine and its metabolites (conjugates and the p-hydroxy metabo
lite) is in the urine (91.4%) and the remainder is excreted in the feces.
More than 99% o f the ketorolac in plasma is protein bound over a wide concentration range.
INDICATIONS
Orally administered Toradol (ketorolac tromethamine) is indicated for the short-term management of mild to moderately
severe pain, including post-surgical pain (such as general, orthopedic and dental surgery), acute musculoskeletal
traum a pain and post-partum uterine cramping pain.
Intramuscular injection of Toradol is indicated for the short-term management of m oderate to severe pain, including pain
following major abdominal, orthopedic and gynecological operative procedures.
CONTRAINDICATIONS
Toradol (ketorolac tromethamine) should not be used where there is a known or suspected hypersensitivity to the drug.
Becouse of the possibility of cross-sensitivity, ketorolac tromethamine should not be used in patients in whom acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory agents induce acute asthmatic attacks, urticaria, rhinitis a other
allergic manifestations. Fatal anaphylactoid reactions may occur in such individuals.
Toradol (ketorolac tromethamine) also should not be used in patients with peptic ulcer or active inflammatory disease
of the gastrointestinal system,
WARNINGS
Long-term administration of ketorolac tromethamine oral formulation has shown th a t this drug shares the risks that other
non-steroidal anti-inflammatory drugs pose to patients when taken chronically. Peptic ulceration, perforation and gastrointestindl bleeding, sometimes severe and occasionally fatal have been reported during therapy with non-steroidal
anti-inflammatory drugs and may occur with ketorolac tromethamine, both in the presence or absence of previous symp
toms, Elderly d nd debilitated individuals are most susceptible to these complications, the incidence of which increases
with dose and duration of treatment. Close medical supervision is recom mended in patients prone to gastrointestinal
tract irritation, particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal
tract. In these cases the physician must weigh the benefits of treatment against the possible hazards.
Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to con
tact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding.
These reactions can occur at any time during the treatment, if peptic ulceration is suspected or confirmed, or if gastrointesM
bleeding occurs, ketorolac tromethamine should be discontinued and appropriate treatment instituted and the patient
closely monitored.
Ketorolac tromethamine is not recom mended for routine use with other non-steroidal anti-inflammatory drugs because
o f the potential for additive side effects.
Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy or lactation.
Ketorolac tromethamine is not recom mended for use as an obstetrical preoperative medication or for obstetrical anal
gesia because of the known effects of non-steroidal anti-inflammatory drugs on uterine contraction and fetal circulation.
Use in children: Safety and efficacy in children have not been established. Therefore, Toradol is not recom mended for
use in children under age 16.
Use in the elderty: Because ketorolac is cleared somewhat more slowly by the elderly (See PHARMACOKINETICS) who
are also more sensitive to the renal effects of non-steroidal anti-inflammatory drugs, extra caution and th e lowest effec
tive dose should be used.
PRECAUTIONS
Renal effects: As with other drugs th a t inhibit prostaglandin biosynthesis, elevations of blood urea nitrogen (BUN) and cre
atinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and its metabolites
are excreted primarily by the kidney, patients with significant impairment of renal function (serum creatinine values greater
than 5 m g/dL) should not receive ketorolac tromethamine unless the expected benefits outweigh the risks. In patients
with m oderately impaired renal function serum creatinine values ranging from 1.9 to 5.0 mg/dL, the rate of ketorolac
clearance was reduced to approximately half of normal. The total daily dose of ketorolac tromethamine should be reduced
by half in such patients. The disposition of ketorolac in dialysis patients has not been studied.
Patients who are volume depleted because of blood loss or severe dehydration may be dependent on renal prostaglandin
production to maintain renal perfusion and therefore glomerular filtration rate. In such situations the use of drugs which
inhibit prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised if ketorolac
tromethamine is used in such circumstances. Close monitoring of urine output, serum urea and serum creatinine is rec
om m ended until th e patient is normovolemic.
Hepatic effects: Meaningful elevations (greater than 3 times normal) of serum transaminases (glutamate pyruvate (SGPT
or ALT) and glutam ic oxalacetic (SGOT or AST)) occurred in controlled clinical trials in less than 1% of patients. If clinical
signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.),
ketorolac tromethamine should be discontinued. Patients with impaired hepatic function from cirrhosis d o not have any
clinically im portant changes in ketorolac tromethamine clearance. Studies in patients with active hepatitis or cholesta
sis have not been performed.
Fluid and electrolyte balance: Fluid retention and edema have been observed in patients treated with Toradol. Therefore,
as with m any other non-steroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in
elderly patients or those with compromised cardiac function should be borne in mind. Toradol should be used with cau
tion in patients with cardiac decompensation, hypertension or other conditions predisposing to fluid retention.
Hematologic effects: Ketorolac tromethamine inhibits platelet function and m ay prolong bleeding time. It does not affect
platelet count, prothrombin time (PT) or partial thromboplastin time (PTT), Patients who have coagulation disorders or
are receiving drug therapy that interferes with hemostasis should be carefully observed when ketorolac tromethamine
is administered. Unlike the prolonged effects from aspirin, the Inhibition of platelet function by ketorolac tromethamine
is normalized within 24 to 48 hours after the drug is discontinued.
Blood dyscrasias associated w ith th e use of non-steroidal anti-inflammatory drugs are rare, b u t could occur with
severe consequences.
Infection: in com m on with other anti-inflammatory drugs, ketorolac tromethamine may mask the usual signs of infection.

Drug Interactions: Toradol (ketorolac tromethamine) is highly bound to human plasma protein (mean 99,2%) and bind
ing is independent of concentration.
Prothrombin time should be carefully monitored in all patients receiving oral anticoagulant therapy concomitantly with
ketorolac tromethamine.
Ketorolac tromethamine does not alter digoxin protein binding.
In vitro studies indicated that at therapeutic concentrations of salicylates (300 mcg/mL), the binding of ketorolac
tromethamine was reduced from approximately 99.2% to 97.5%. Therapeutic concentrations of digoxin, warfarin,
acetaminophen, phenytoin, tolbutamide and piroxicam did not alter ketorolac flomethamine protein binding. Since ketoro
lac tromethamine is a highly potent drug and present in low concentrations in plasma, it would not be expected to displace
other protein-bound drugs significantly.
There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits the hepatic enzymes
capable of metabolizing itself or other drugs. Hence, it would not be expected to alter the pharmacokinetics of other
drugs due to enzyme induction or inhibition mechanisms.
Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhibition of rend Ithkm
clearance leading to an increase in plasma lithium concentration and potential lithium toxicity has been reported with some
non-steroidal anti-inflammatory drugs. The effect of ketorolac tromethamine on lithium plasma levels has not been studied.
Concomitant administration of methotrexate and some non-steroidal anti-inflammatory drugs have been reported to
reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine
on methotrexate clearance has not been studied
There is limited experience on concurrent administration with morphine. Available information shows no evidence of adverse
interactions. The extent of a possible narcotic-sparing effect of ketorolac tromethamine is currently under investigation.
ADVERSE EFFECTS
Toradol tablets: The incidence of adverse reactions in approximately 600 patients and subjects receiving short-term oral
therapy (less than 2 weeks) with Toradol (ketorolac tromethamine) are listed below. The most common adverse effects
include: Gastrointestinal: dyspepsia (2%), gastrointestinal pain (2%), nausea (2%). Central nervous system: headache (2%),
dizziness (2%),
The following adverse events are rare but have been reported (less than 1%): Gastrointestinal: flatulence, gastritis.
Respiratory: dyspnea. Dermatologic: urticaria, rash, pruritus. Metabolism/nutritional: edema. Body as a whole: asthenia.
Hemic and lymphatic: purpura. Musculoskeletal: myalgia.
Toradol IM: The adverse reactions listed below were reported to be probably related to Toradol IM in clinical trials in which
patients received up to 20 doses of 30 mg of intramuscularly administered Toradol over a period of up to five days.
Incidence between 3 and 9%: Gastrointestinal: nausea, dyspepsia, gastrointestinal pain. Central nervous system: drowsiness.
Incidence between 1 and 3%: Gastrointestinal: diarrhea. Central nervous system: dizziness, headache, sweating. Body as
a whole: edema. Injection site pain was repotted by 2% of patients in multi-drae studies (vs. 5% for morphine control group).
Incidence 1% or less: Gastrointestinal: constipation, flatulence, gastrointestinal fullness, liver function abnormalities,
melena, peptic ulcer, rectal bleeding, stomatitis, vomiting. Body as a whole: asthenia, myalgia. Cardiovascular: vasodi
latation, pallor. Hemic and lymphatic: purpura. Nervous system: dry mouth, nervousness, paresthesia, abnormal thinking,
depression, euphoria, excessive thirst, inability to concentrate, insomnia, stimulation, vertigo. Respiratory: dyspnea,
asthma. Urogenital: increased urinary frequency, oliguria. Dermatologic: pruritus, urticaria. Special senses: abnormal taste,
abnormal vision.
OVERDOSAGE
The absence of experience with acute overdosage precludes characterization of sequelae and assessment of antido
tal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
for each of five consecutive days (3 times the highest recommended dose) caused abdominal pain and peptic ulcers
which recovered after discontinuation of dosing,
DOSAGE AND ADMINISTRATION
Adults: Dosage should be adjusted according to the severity of the pain and the response of the patient.
Oral: The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every 4 to 6 hours for pain as required. “
ing 40 mg per day are not recommended.
Toradol is recommended f a short-term use only i.e. f a a maximum of a few weeks.
Parenteral: The recommended usual initial dose is 30 mg. Subsequent dosing may be 10 mg to 30 mg every 4-6 hours as
needed to control pain. A lower initial dose may be suitable f a patients under 50 kg in body weight, over age 65 years
and/or with less severe pain at baseline. In the initial post-operative period, m a e frequent dosing (e.g., every 2 hours)
may be employed, but the total daily dose should not exceed 120 mg. Dose above 120 mg could cause drug toxicity
(see Warnings 8t Precautions). If supplemental analgesia is required, a concomitant low dose of opiate can be used.
The administration of continuous multiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for more than 5 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time.
Directions lor use: Insert the plunger r t o the syringe barrel andthreaditontothescrew. WITHOUT REMOVING THENEEDLE GUARD,
apply quick, firm pressureto the plunger to break the m e t seal (you will feel it let go). Pull back on the plunger slightly to relieve
pressure. Remove the needle guard by twisting as you pul. Use the unit as you would a normal syringe. Dispose of property.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets may be used either as monotherapy or as follow-on therapy to parenteral ketorolac. In the latter case,
the total combined daily dose of ketorolac should not exceed 120 mg on the day the change of formulation is made,
this includes a maximum of 4 of the 10 mg tablets.
Toradol (ketorolac tromethamine) is a Schedule F drug.
COMPOSITION
Toradol Tablets: Each Toradol tablet contains ketorolac tromethamine, the active ingredient, with microcrystaltine cel
lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyl-methylcellulose, titanium
dioxide and polyethylene glycol.
Toradol IM: Toradol IM is available for intramuscular administration as: 15 mg in 1 r r t (1.5%), or 30 mg in 1 mL (3%) of ketoro
lac tromethamine in sterile solution. The 15 mg/mL solution contains 10% (w/v) alcohol, USP, and 6.68 mg sodium chloride
in sterile water. The 30 mg/mL solution contains 10% (w /v) alcohol, USP and 4.35 mg sodium chloride in sterile water. The
pH Is adjusted with sodium hydroxide or hydrochloric acid. The sterile solutions are d e a r and slightly yellow in colour.
STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store at room temperature. The blister package tablets should be protected from light.
Toradol IM: Store a t room temperature with protection from light.
AVAILABILITY OF DOSAGE FORMS
Toradol (ketorolac tromethamine) is available as 10 mg white round film coated tablets with one side printed in red with
TORADOL inside a bold T and the other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available
in bottles of 100 tablets.
Toradol IM is available in 1 mL syringes containing 15 or 30 mg/mL of ketorolac tromethamine.
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Comparison of Topical Xylocaine
With Placebo As a Local Anesthetic
in Colposcopic Biopsies
Michel Prefontaine, MD, FRCSC;* Michael Fung-Kee-Fung, MD, FRCSC;t David Moher, MScrf
Colposcopically directed biopsies cause discomfort for the patient. Topical lidocaine
(Xylocaine) had routinely been applied to the cervix before biopsies performed at the
colposcopy clinic of the Ottawa General Hospital. A prospective, single-blind trial
was performed to compare the effect of topical Xylocaine with that of a placebo.
Patients in both groups experienced discomfort; the median pain score in both
groups was equal, and statistical analysis of the results by the Mann-Whitney test
showed no difference between the two treatment groups.

Les biopsies pratiquees sous colposcopie sont une source d’inconfort pour le
patient. La lidocaine topique (Xylocaine), en application sur le col, avait ete d’usage
courant lors des biopsies pratiquees a la clinique de colposcopie de l’Hopital General
d’Ottawa. Une etude prospective, a simple insu, a ete effectuee pour comparer les
effets de la Xylocaine topique a celle d’un placebo. Les patients des deux groupes
ont subi des malaises; les cotes medianes de la douleur des deux groupes furent
egales et l’analyse statistique des resultats par la methode de Mann-Whitney n’a
revele aucune difference entre les deux groupes therapeutiques.

W

omen attending colposcopy
ic of the Ottawa General Hospital
clinics have apprehensions
had been to apply topical lidocaine
before and during the examination.(Xylocaine; Astra Pharma Inc., Mis
These include fear of a diagnosis of
sissauga, Ont.) to the cervix before
cancer of the cervix and fear of pain
performing biopsies, in an attempt
during the procedure.1 Cervical col
to decrease the pain associated with
poscopy with biopsies can induce
this procedure.
measurable pain.
To assess the value of topical
Standard practice in most colpos
Xylocaine in colposcopically direct
copy clinics does not include the
ed cervical biopsies, a randomized
use of topical anesthetics during
prospective trial was conducted to
the performance of cervical biop
compare the effect of 2% Xylocaine
sies.2-4 Despite the lack of relevant
with that of a placebo on the degree
studies in the literature, the stan
of pain perceived by the patient
dard practice at the colposcopy clin
during colposcopic biopsies. We hy
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pothesized that topical Xylocaine
reduced the pain associated with
colposcopic biopsies, and we tested
this hypothesis by a randomized,
single-blind trial. We also investi
gated the association between the
patient’s level of anxiety before the
colposcopic examination and the
degree of pain perceived.
Since we conducted our trial, a
study has been published5 that eval
uated the effectiveness against pain
of a topical anesthetic applied to the
cervix for different procedures, in
cluding cervical biopsies. That
study reported a significant reduc
tion in the degree of pain in the
treatment group compared with the
placebo group.

Patients and Methods
A randomized, prospective trial
was performed to compare the per
ceived degree of pain relief obtained
from topical Xylocaine with that
from a placebo applied to the cervix
before colposcopic biopsies. The
study population comprised 50 con
secutive patients who underwent
cervical biopsies at the colposcopy
clinic of the Ottawa General Hospi
tal. Women were eligible if they had
no known allergy to Xylocaine or
other topical anesthetics. Patients
were allocated to the study or con
trol groups according to a list of
random numbers. The study group
had 2% topical Xylocaine and the
control group had topical Muko
lubricating jelly (Ingram & Bell
Medical, Don Mills, Ont.) applied to
the cervix.
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All colposcopic examinatigns and
biopsies were performed by one
investigator (M.P.). The clinic nurse
explained the procedure and the
study to the patient and obtained an
informed consent. After insertion of
a medium-sized Graves’ vaginal
speculum, the cervix was inspected.
Specimens for cytologic examina
tion were obtained from the exocer
vix and endocervical canal. The cer
vix was treated with 3% acetic acid,

and colposcopy was performed
using a Carl Zeiss OPMI-1FC colposcope. The cervix was treated
with either 2% Xylocaine or Muko
lubricating jelly, applied with a cot
ton-tipped swab according to the
randomization list. The interval be
tween the application and the biop
sy was the same for both groups.
Before the biopsy, patients in
both groups were informed that
they might experience mild discom

fort. Biopsies were performed with
Kevorkian punch biopsy forceps.
After the procedure, the patients
answered a short questionnaire, in
dicating the degree of anxiety they
experienced about the procedure
(rated from 0 to 3, not at all to very
anxious) and of pain (rated from 0
to 5, no pain to very severe pain).
The anxiety scores were correlated
with the pain scores.
The Mann-Whitney test for com
parison of rank-independent varia
bles and Fisher’s exact test were
used to analyse any differences.

Results

FIG. 1. Level of pain reported by patients in study (Xylocaine) (black bars) and
control (placebo) (hatched bars) groups after colposcopically directed cervical
biopsies.

FIG. 2. Correlation of degree of pain experienced by patients during procedure
correlated with their anxiety level before undergoing colposcopically directed
cervical biopsies. Black bars = not anxious at all, light hatched bars = not very
anxious, white bars = moderately anxious, dark hatched bars = very anxious.
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Of the 50 patients studied, 26
were randomized to the treatment
group and 24 to the placebo group.
Patients in both groups were com
parable with regard to age, parity,
cervical disease and number of biop
sies. All 50 patients were able to
evaluate the degree of pain experi
enced during the colposcopic biopsy
(Fig. 1). Data on the level of anxiety
before colposcopic examination
were available for 49 patients.
The median pain score for both
groups was 2. When the MannWhitney test was used to compare
the degree of pain perceived by the
study group with that perceived by
the control group, there was no
significant difference (U = 335, p =
0.6466). The ratio of pairs gave a
value of 0.54, which means that
there is a 0.54 probability that a
patient will perceive less pain with
Xylocaine than with the placebo.
This value is only slightly better
than the “by chance” value (0.50),
indicating that Xylocaine was virtu
ally no more effective than the
placebo in relieving the pain associ
ated with cervical biopsy.
Thirty-five (71%) of 49 patients
indicated that they were moderately
or very anxious about the proce
dure (Fig. 2) (Fisher’s exact test,

XYLOCAINE IN COLPOSCOPIC BIOPSIES

p = 0.74). There was no correlation
between the degree of anxiety and
the level of pain reported, as shown
by the even distribution of anxiety
levels for all pain ratings.

Discussion
Although only a few patients re
ported feeling severe pain during
biopsy, the majority reported some
pain. The pain scores reported by
patients in the Xylocaine-treated
group and in the placebo group
were not significantly different. Al
though one could speculate that
there might be a significant differ
ence between the study and the
control groups if a larger number of
patients was evaluated, we would
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not expect to find a statistically
significant difference with a larger
group on the basis of our findings
in these 50 patients.
Our findings differ from those of
Rabin and associates,5 who noted a
significant reduction in pain when
20% topical benzocaine was used
for cervical biopsies. This difference
may be explained by the use of a
different drug and a much stronger
concentration of the topical anes
thetic in the gel in that study.
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of this study, topical Xylocaine is
no longer used for cervical biopsies
in the colposcopy clinic at the Otta
wa General Hospital.
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ORIGINAL ARTICLES

Functional Testing of Braces for Anterior
Cruciate Ligament-Deficient Knees
H.J. Marans, MD, MSc, FRCSC; R.W. Jackson, MD, MS, FRCSC; J. Piccinin, PT; R.L. Silver, MD; D.K.
Kennedy, MD
Previous studies into the efficacy of bracing anterior cruciate ligament
(ACL)-deficient knees have lacked objective functional testing. In this study of
function the authors compare the effectiveness of three custom-made and three
off-the-shelf braces in stabilizing symptomatic, unilateral, chronic,
non-reconstructed, ACL-deficient knees. Ten subjects randomly performed six
functional tests with each of the six test braces. Knee function was evaluated both
objectively and subjectively. Two customized functional braces (Generation II
Polyaxial Knee Cage and Lenox Hill Derotation Brace) provided the most objective
improvement during ACL-dependent activities and also the most subjective stability.
Laterally hinged braces were as effective as the more commonly used double-hinged
models. Based on this study, the authors recommend the use of laterally hinged
customized functional braces in the nonoperative treatment of the symptomatic
ACL-deficient knee.

Les etudes anterieures sur l’efficacite des supports du genou pour corriger les
deficits du ligament croise antero-externe etaient depourvues de tests fonctionnels
objectifs. Dans la presente etude, les auteurs ont compare l’efficacite de trois
supports personnalises et celle de trois supports commerciaux pour stabiliser le
genou, lors de deficits symptomatiques unilateraux chroniques du ligament croise
antero-externe qui n’avaient pas fait l’objet d’une reconstruction ligamentaire. Dix
sujets pris au hasard ont effectue six tests fonctionnels avec chacun des six
supports. La fonction du genou fut evaluee objectivement et subjectivement. Deux
des supports personnalises (la cage polyaxiale Generation II et le support de
derotation Lenox Hill) ont offert la meilleure amelioration fonctionnelle objective au
cours d’activites faisant appel au ligament croise antero-externe du genou. Ils
procuraient egalement le plus de stability a revaluation subjective. Les supports a
articulation laterale etaient aussi efficaces que les modeles a double articulation plus
courants. Compte tenu des resultats de cette etude, les auteurs recommandent
l’emploi de supports fonctionnnels personnalises a articulation laterale pour le
traitement non chirurgical des deficits du ligament croise antero-externe du genou.

xternal bracing is a common
method for conservative man
agement of the anterior cruciate
ligament (ACL)-deficient knee. De
spite the increased use of these

E

braces for nonoperative treatment
and for postoperative protection,
previous studies of their effective
ness have lacked objective function
al testing. All previous testing has

been subjective,12 subjective and
objective, using the clinical tests
(anterior drawer, Lachman, pivot
shift) for anterior cruciate in
stability3-7 or cadaveric, using bi
omechanical testing or the clinical
tests for ACL insufficiency noted
previously.8-9 The problem common
to all these studies is the lack of
testing of the ACL-deficient knee in
a dynamic setting. The degree of
objective instability found by clini
cal testing has never been correlat
ed to the degree of functional insta
bility (defined as instability during
sporting activities or activities of
daily living) that the patient may
suffer from. Moreover, most studies
have concentrated their evaluation
on one type of brace in an effort to
prove its effectiveness. We are un
aware of any studies that compare
several knee braces during activities
that place the ACL under appropri
ate stress and therefore potentially
precipitate the symptoms we asso
ciate with ACL insufficiency.
The purpose of this study is to
evaluate and compare the effective
ness of six commonly used func
tional and prophylactic knee braces
in stabilizing the symptomatic nonreconstructed ACL-deficient knee
during dynamic functional testing.

Patients and Methods
From the Orthopaedic and A rthritic Hospital, Toronto, Ont.
Accepted for publication Mar. 26, 1990
Reprint requests to: Dr. R. W. Jackson, 43 Wellesley St. E, Toronto, O N M 4 Y 1 H 1

Our subject group consisted of
10 subjects (4 men, 6 women) with
symptomatic and arthroscopically
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proven ACL-deficient knees on one
side only. They ranged in age from
17 to 28 years (mean 24.8 years).
All subjects were athletically active
at the time of the study and had
symptoms of functional instability
during athletic activities but not
during activities of daily living. All
subjects possessed a strongly posi
tive pivot shift sign and had their
untreated ACL lesion confirmed arthroscopically. Coexistent disease
was seen in five of the subjects:
three patients had meniscal disease
(two medial, one lateral) and two
had partial-thickness medial femoral
condylar lesions. All unstable intraarticular disease was treated by
closed means at the time of arthro
scopic diagnosis. The other five
presented with isolated ACL insuffi
ciency. No other ligament instability
patterns were present. All of these
patients had been advised to under
go ligament reconstruction; howev
er, all had declined a surgical proce
dure. None had worn any type of
knee brace before.
Six commonly used braces were
chosen for the study (Table I). The
braces were classified as either
functional or prophylactic,10 custom
made or off the shelf, and were
either laterally hinged or double
hinged. The three custom-made
braces (Don Joy Rotational Knee
Stabilizer [RKS], Generation II Polyaxial Knee Cage and the Lenox
Hill Derotation Brace) were made to
a mould of the subject’s leg and
supplied without charge by the ma
nufacturers. The three off-the-shelf
braces (Don Joy Four-Point ACL
Brace, McDavid Knee Guard, Zim
mer Double-Hinged Neoprene
Sleeve) were also supplied by the
manufacturers in all sizes so that
each subject could be appropriately
fitted. Therefore, each subject was
provided with six braces, three cus
tom made to the patient’s leg and
three suitably fitted off the shelf.
All four functional braces (Table I)
168
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were equipped with 15° extension
stops.
An activity program was de
signed, based partially on previous
work by Tegner and colleagues11
and supplemented with activities
that we felt would stress the ACL
(Table II). These functional activi
ties could be quantified by measur
ing the time to perform a test or the
distance achieved during the test.
Although straight-ahead running
does not specifically stress the ante
rior cruciate ligament, it was con
sidered important as an objective
measure of the possible “restriction
factor’’ the braces might impose on
the athlete’s ability to perform at
full capacity. It has been our experi
ence, as well as that of others,1213
that knee bracing can impede the
performance of an athlete. This may
well be a major factor in the noncompliance often seen in highcalibre athletes. Both figure-ofeight running and acute-angle cut
ting place an unstable ACL-deficient
knee under maximal stress and are
considered to be the most important
tests in this study. In the figure-of-

eight test, the end pylons were 14
m apart, with the outside pylons
3.5 m on each side of the midline.
The acute-angle cutting test in
volved pylons placed 2 m distant
from each other, but alternately 3
m to each side of midline. An agility
drill, simulating running through
tires, and the forward and lateral
jumps with the affected leg all
stress the ACL deficient knee in a
dynamic method and represent gen
eral activity that athletes are likely
to encounter during participation in
their sport.
Each subject performed all six of
the functional tests, first unbraced
and then wearing each of the six
braces in random order. Therefore,
all activities were performed by all
subjects, wearing all the braces.
Random ordering was necessary so
as not to bias our results in favour
of the braces worn in the early part
of the testing before fatigue became
a factor. Each brace was then evalu
ated both subjectively and objec
tively with the unbraced perfor
mance acting as a control for each
subject. The subjects were asked to

.

T a b le 1 K ne e -B ra ce C la s s ific a tio n

B race
D o n J o y F o u r-P o in t
A C L B ra ce
D o n J o y R o ta tio n a l
Knee S ta b iliz e r
G e n e ra tio n II P o ly a x ia l
Knee C age
L e n o x H ill D e ro ta tio n
Brace
M cD a vid K nee G uard
Z im m e r D o u b le -H in g e d
N e o pren e S le e ve

Functional or
prophylactic

C ustom m a d e or
o ff th e s h e lf

T yp e of
hinge

F u n ctio n a l

O ff th e s h e lf

D o u ble

F u n ctio n a l

C u s to m m ad e

D o u ble

F u n ctio n a l

C u s to m m a d e

L a tera l

F u n ctio n a l
P ro p h y la c tic

C u s to m m ad e
O ff th e s h e lf

D o u ble
L a tera l

P ro p h y la c tic

O ff th e s h e lf

D o uble

A C L = a n te rio r c ru c ia te lig a m e n t.

T a b le II. D y n a m ic F u n c tio n a l A c tiv itie s T e s tin g
A ctivity

Test

S tra ig h t-a h e a d run
F ig u re -o f-e ig h t run
A cu te -a n g le c u ttin g
A g ility d rill
F o rw a rd ju m p
L a tera l ju m p

40 m
A ro u n d p y lo n s
B e tw e e n p y lo n s
S im u la te d ru n n in g th ro u g h tire s
One leg h o p o n a ffe c te d leg
One leg h o p o n a ffe c te d leg
to w a rd a ffe c te d sid e

FUNCTIONAL TESTING OF KNEE BRACES

rate each brace for stability, com
fort and the feeling of restriction of
normal knee motion. All of these
were graded by the subject on a
scale of I to 5, for each brace,
during each activity.
Subjective stability is defined as
the perception that the brace makes
the knee more stable and therefore
gives confidence that the knee is
less likely to give way. Although
this is not an objective measure, the

athlete’s sensation of knee stability
may well be a sensitive assess
ment.10 Performance measurement
was chosen as the method of objec
tive assessment in this study. Al
though several objective means of
evaluating static knee-joint stability
by clinical examination exist, these
were not performed in our study.
Performance measurements, al
though not providing specific infor
mation relating to knee kinematics,

are a useful guide to the effective
ness of knee bracing in controlling
instability, by recording the effect
on the final end point in athletics,
which is performance.
Each of the nine subjective and
objective criteria were statistically
analysed by two-way analysis of
variance with the subjects as blocks
(or controls) for themselves. When
a statistically significant difference
was found, the Student-NeumanKeuls test was used to determine
the specific differences between the
braces for the given criterion being
analysed. Since this analysis re
quired multiple statistical testing,
appropriate corrective measures
were necessary. In this case, de
creasing the p level for each test to
0.005, gave us an overall level of
significance for the study less than
0.05.

Results
Subjective

FIG. 1. Subjective stability of six knee braces, three custom made (Don Joy
Rotational Knee Stabilizer [RKS], Generation II Poly axial Knee Cage and Lenox
Hill Derotation Brace) and three off the shelf (Don Joy Four-Point ACL Brace,
McDavid Knee Guard, Zimmer Double-Hinged Neoprene Sleeve), p < 0.005.

Zim m er D o u b le-H in g e
McDavid Knee Guard

G en eratio n II
Lenox Hill
Don Joy RKS
Don Joy 4 -P o in t

1

2

3

4

5

1 = very re s tric tiv e , 5 = no re s tric tio n

FIG. 2. Subjective restriction of normal knee movement with six knee braces, p <
0.005.

Statistically significant differ
ences, at the 0.005 level, were
found when analysing two of the
three subjective criteria — stability
and restriction of normal knee
movement — and there was no
difference in overall comfort (Figs.
1 and 2). It can be seen in Fig. 1
that the Lenox Hill, Generation II
and the McDavid Knee Guard
braces provided significantly more
subjective stability than the other
three braces. With respect to restr
iction of normal knee movement,
the two prophylactic braces (McDa
vid Knee Guard, Zimmer Double
Hinge) appeared to be the least
restrictive.
Objective
When the objective performance
measurement data were analysed,
statistically significant differences
CJS, VOL. 34. NO. 2, APRIL 1991
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were found with respect to straight
ahead running, figure-of-eight run
ning and acute-angle cutting. No
significant differences were found
with respect to agility testing, for
ward jumping or lateral jumping.
Three graphic representations of
the statistically significant data are
presented (Figs. 3 to 5). When
interpreting these graphs, we found
three groups of braces in each case.
In all cases the top group of braces
significantly improved performance
when compared with the bottom
group; the middle groups were not
significantly different from the
other two. In the case of straight
ahead running, the two ACL-specific Don Joy braces were found to
adversely affect performance, com
pared with unbraced knees, and the
two laterally hinged braces, the
Generation II and McDavid, had the
least effect on straight-ahead run
ning. Although all six braces im
proved performance in the figureof-eight running and acute-angle
cutting compared with unbraced
knees, only the ACL-specific Gener
ation II and Lenox Hill braces did
so with statistical significance (Figs.
4 and 5).

As one would expect, the two less
cumbersome prophylactic braces
gave the least feeling of restriction.
The objective differences found can
be placed into two categories:
straight-ahead running to assess
the potential negative effects of the
braces on performance and figureof-eight running and acute-angle
cutting to assess the positive effects
of providing stability. Houston and
Goenans12 assessed the effect of
wearing and not wearing knee sup
port braces on levels of perfor
mance during isokinetic knee exten-

date that assess knee braces do so
in this fashion. This study was
designed to provide objective infor
mation on a variety of braces.
We found that two of the func
tional custom-made braces (Lenox
Hill and Generation II) provided the
most subjective stability. Of interest
is that the McDavid Knee Guard,
which is a laterally hinged off-theshelf prophylactic brace, provided
subjective stability equivalent to
that of the Lenox Hill and Genera
tion II braces and was statistically
better than the other three braces.

6.5

7.0

7.5

8.0

8.5

Seconds

FIG. 3. Stability provided by six knee braces in straight-ahead running, p < 0.005.

Discussion
Functional knee braces are de
signed and prescribed to supply
stability for knees that are unstable
secondary to ligament abnormali
ties. In analysing the effectiveness
of these braces, the simplest meth
od is to stress the involved knee
both with and without a brace in a
non-weight-bearing situation, such
as the usual physical examination
for ACL instability. Although this
may provide some potentially useful
information, it cannot help us to
define the knee braces that are
most effective in controlling func
tional instability. Unfortunately, all
of the studies in the literature to
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Seconds

18.5

19.0

FIG. 4. Stability provided by six knee braces in figure-of-eight running, p < 0.005.

FUNCTIONAL TESTING OF KNEE BRACES

sion contractions and during a
short maximal sprint. They con
cluded that the potential benefits of
support braces for knee instability
come at the expense of impaired
performance. Zetterlund, Serfass
and Hunter13 studied the effect of
wearing a Lenox Hill Derotation
Brace during horizontal treadmill
test. They found that when the
subjects wore the brace, there was a
significant increase in energy ex
penditure while running.
We found that during straight
ahead running, in which ACL insta
bility is not considered to 'be a
detriment, performance was im
paired whenever the subject was
wearing a brace; however, in the
case of the Generation II and McDavid Knee Guard braces, the two
laterally hinged braces, the adverse
effects appeared to be inconsequen
tial. Of interest is that the two Don
Joy braces, which were considered
to be the most restrictive subjec
tively, also impaired the perfor
mance of straight-ahead running to
the largest degree. In the second
objective category (Figs. 4 and 5)
the custom-made ACL-specific Gen
eration II and Lenox Hill braces
improved performance in these
ACL-dependent activities to a statis

tically significant degree, and al
though the remaining braces all
improved performance to a lesser
degree none of the differences was
statistically significant. In our opin
ion these two objective graphical
representations form the corner
stone of this study. The effective
ness of these braces in controlling
knee instability in this ACL-deficient patient population was of a
sufficient degree to allow improved
performance during both of these
demanding functional activities.
An interesting point that has not
been discussed in any of the previ
ous studies is that of the need for a
double-hinged brace compared with
a laterally hinged brace. Through
out the study it can be seen that the
laterally hinged braces were found
to be at least as effective as their
potentially more cumbersome dou
ble-hinged counterparts and also
had the least effect on performance
during straight-ahead running.

Conclusions
Functional testing of chronic
symptomatic ACL-deficient knees
revealed that two custom-made
braces (Generation II and Lenox

Hill) provided the most subjective
stability, demonstrated the least ad
verse effect on straight-ahead run
ning and produced the most im
provement in performance during
functional tests. On the basis of the
comparison results with the un
braced knee, these two braces have
been shown to be effective in deal
ing with the functional instability
associated with ACL insufficiency.
An attractive alternative, which is
less restrictive and less costly, yet
provides excellent subjective stabili
ty, is the McDavid Knee Guard.
Laterally hinged braces were found
to be at least as effective, from all
points of view, as their potentially
more cumbersome double-hinged
counterparts. Further studies into
these and other brace designs using
dynamic, functional test methods
and with improved objective meth
ods of evaluation as they become
available, are needed to define bet
ter the role of bracing.
We thank the manufacturers who will
ingly, without restriction, supplied the
braces for this study. None of the
authors have received any financial or
other benefits from the conduct of this
study. The Don Joy Brace Company
has changed the design of its sports
brace substantially since the study was
concluded, and the results reported
here do not reflect its latest product.

G e n e ra tio n II
Lenox Hill
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MARANS ET AL
Nursing Mothers

Studies performed in lactating rats have shown that
PEPCID® is secreted in breast milk. It is not known
whether this drug is secreted in human milk.
Nursing mothers should either stop this drug or
should stop nursing.
Pediatric Use

Lenox Hill brace: an evaluation of effec
tiveness in treating knee instability. Ibid:
2 5 7 -2 6 1

Safety and effectiveness in children have not been
established.
Use In Elderly Patients

No dosage adjustment is required based on age (see
HUMAN PHARMACOLOGY, Pharmacokinetics).

ADVERSE REACTIONS
6 . C oughlin L, Oliver J, B erretta G: Knee

bracing and anterolateral rotatory insta
bility. Am J Sports Med 1987; 15: 16 1 —
163

Histamine H2 Receptor Antagonist
7. R oser LA, Miller S J, Clawson DK:
Effects of taping and bracing on the
unstable knee. Northwest Med 1971;
70: 5 4 4 -5 4 6

8. H ufmann AA, W yatt RW, B ourne MM
et al: Knee stability in orthotic knee
braces. Am J Sports Med 1984; 12:
3 7 1 -3 7 4

ACTIONS AND
CLINICAL PHARMACOLOGY
PEPCID® (famotidine) is a competitive inhibitor of
histamine H2-receptors. The prim ary clinically
important pharmacologic activity of PEPCID® is
inhibition of gastric juice secretion. PEPCID®
reduces the acid and pepsin content, as well as the
volume, of basal, nocturnal, and stimulated gastric
secretion.

INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment
of the following conditions where a controlled
reduction of gastric secretion is required for ulcer
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;

9. W o jtys EM, Goldstein SA, R edfern M
et al: A biomechanical evaluation of the
Lenox Hill brace. Clin Orthop 1987;
2 2 0 :1 7 9 - 1 8 4

4. Treatment of pathological hypersecretory
conditions (e g., Zollinger-Ellison syndrome).
PEPCID® I V. is indicated in some hospitalized
patients with pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage forms for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
10. D rez D: Knee Braces. Seminar Report
Based on Knee Brace Symposium, Chi
cago, June 1984, American Academy of
Orthopaedic Surgeons, August 1984

1 1 . T ecner Y, Lysholm J, L ysholm M et al:

A performance test to monitor rehabili
tation and evaluate anterior cruciate
ligament injuries. Am J Sports Med
1986; 14: 1 5 6 -1 5 9

12. Houston ME, Goenans PH: Leg muscle
performance of athletes with and with
out knee support braces. Arch Phys
Med Rehabil 1982; 163: 4 3 1 -4 3 2

H y p e rs e n s itiv ity to any c o m p o n e n t o f th is
medication.

PRECAUTIONS
Patients with Severe Renal Insufficiency

Dosing intervals may need to be prolonged in
pa tie n ts w ith advanced renal in s u ffic ie n c y
(creatinineclearanceOO mL/min.) toadjustforthe
longer elimination half-life of fam otidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION.)
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( 1. 6% ) .

Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.
Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychlatric

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory

Bronchospasm

4.4%

<0.1%

Body as a Whole

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1-7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Skin

1.7%

Studies with famotidine in man, in animal models,
and
have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e g., cytochrome
P450 system. Compounds tested in man have
includ ed w a rfa rin , th e o p h y llin e , p h e n yto in ,
diazepam, am inopyrine and antipyrine. Indo
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

in vitro

Use In Gastric Ulcer

Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.
Reproductive studies have been performed in rats
and rabbits at oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of impaired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or wellcontrolled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.
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The following adverse reactions have been reported
at a rate of greater than 1% in patients on therapy
with PEPCID® in controlled clinical trials, and may
be causally related to the drug: headache (4.6%),
dizziness (1.2%), constipation (1.2%) and diarrhea

Drug Interactions

Use In Pregnancy

13. Z etterlund AE, S erfass RC, Hunter
RE: The effect of wearing the complete
Lenox Hill Derotation Brace on energy
expenditure during horizontal treadmill
running at 161 meters per minute. Am J
Sports Med 1986; 14: 7 3 -7 6

PEPCID® (famotidine) is usually well tolerated;
m ost adverse reactions have been m ild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema
Urogenital

0.1%
0.1%
<0.1%
0.9%

The adverse reactions reported for PEPCID®
Tablets may also occur with PEPCID® I V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
Laboratory Abnormalities

Laboratory parameters may be affected during
treatment with PEPCID®, but the changes are
u su ally not considered serious. Among the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.

Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

Parenteral Products

The oral LDS0 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy

The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for
4-8 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy

For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtime, fo r a duration o f up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy

Other effects

Dilution of PEPCID® I.V.
for Infusion

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 640 mg/day have been
employed in patients w ith pathological hyper
secretory conditions w ith no serious adverse
effects. In the event of overdosage, treatment
should be sym ptom atic and supportive. Un
absorbed material should be removed from the
ga strointestina l tra c t, the p a tie n t should be
monitored, and supportive therapy should be
employed.

emptying and exocrine pancreatic function are not
affected by PEPCID®.

R ECO NSTITUTION

P E P C ID * I.V .
Solution

V 0 L ...4 of
C om patible
I.V . S olution

Final
Volum e

Final
C oncentration

R ate o f
In fu sio n

2 mL

3 mL

5m L

4 m g /m L

N o t le s s th a n

2m L

8m L

10 m L

2 m g /m L

N o t le s s th a n

2 m in u t e s

2 m in u t e s
2 mL

100 m L

102 m L

0 . 1 9 6 m g /m L

1 5 - 3 0 m in u t e s

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer’s Injection
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution

Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
a llo w s u ffic ie n t tim e to s o lu b iliz e a ll th e
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: P are nteral drug p ro d u c ts s h o u ld be
inspected visually for particulate matter and
d is c o lo u ra tio n p rio r to a d m inistra tion
whenever solution and container permit.

DOSAGE FORMS AND AVAILABILITY

The recommended adult oral dosage for acute
benign gastric ulcer is 40 mg once a day at bedtime.
Treatment should be given for 4 to 8 weeks, but the
duration of treatment may be shortened if healing
can be documented.

T a b le ts PEPCID® (fa m o tid in e ta b le ts ) are
D-shaped, film-coated tablets supplied as follows:

P A T H O L O G IC A L H Y P E R S E C R E T O R Y C O N 
D IT IO N S (S U C H AS Z O L L IN G E R -E L L IS O N
SYNDROME)

No. Ca 8103 - 40 mg lig h t brownish orange,
coded 964. Available in bottles of 100 tablets.

The dosage o f PEPCID® in p a tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose fo r pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required.
Doses should be adjusted to individual patient
needs and should continue as long as clinically
indicated. Doses up to 160 mg q6h have been
adm inistered to som e p a tie n ts w ith severe
Zollinger-Ellison syndrome.
Intravenous Administration

In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I.V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids

Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal
Insufficiency

In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min.,
the elimination half-life of PEPCID® may exceed
12 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient's clinical
response.

PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets

Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection

Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
in a c tiv e in g re d ie n ts : L -a s p a rtic a c id 4 mg,
mannitol 20 mg, and Water for Injection, q.s., 1 mL.
The multidose injection also contains benzyl
alcohol 0.9% added as preservative.

No. Ca 8102 - 20 mg b e ig e c o lo u re d ,
coded 963. Available in bottles of 100 tablets.

No. Ca3539 - PEPCID® I.V., 10 mg per 1 m L .isa
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 10 x 2 mL vials.
No. Ca 3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
preserved m u ltip le dose c o n ta in in g 4 mL of
injectable solution. Available in 4 mL vials.

HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the antisecretory effect occurred w ithin one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of 10
and 20 mg inhibited basal nocturnal secretion fo ra
period o f 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhibited basal nocturnal acid secretion in all
subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, for a period of at least
10 hours. S im ilar doses given in the m orning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after drug, and of 25% and
30%, re sp e ctive ly, 8 to 10 hours a fte r drug;
however, in some subjects who received the 20 mg
dose, the antisecretory effect was dissipated earlier,
within 6-8 hours. There was no cumulative effect
with repeated doses. The basal nocturnal intragastric pH was raised by evening doses of 20 and
40 mg of PEPCID® to mean values of 5.0 and 6.4,
respectively. When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be s lig h tly elevated d u rin g periods o f drug
antisecretory effect, and with chronic therapy an
increase in gastric bacterial flora may occur. Gastric

Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory or endocrine
system s have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics

PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may be
slightly increased by food, or slightly decreased by
acntacids; however, these effects are of no clinical
consequence. PEPCID® undergoes minimal firstpass metabolism. After oral doses, peak plasma
levels occu r in 1-3 hours. Plasma levels after
multiple doses are sim ilar to those after single
doses. Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3.5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 m L/m in., indica ting some
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an
intravenous dose are recovered in the urine as
un chang ed co m poun d. The o n ly m e ta b o lite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
w ith severe renal insufficie ncy, i.e., creatinine
clearance less than 10 mL/min., PEPCID® elim i
n a tio n h a lf - life m ay e xce e d 20 h o u rs and
adjustment of dosing intervals may be necessary
(see PRECAUTIONS, DOSAGE AND ADMINIS
TR A TIO N ). In e ld e rly pa tients, th e re are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.
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Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of
restoring impaired immune responses preferentially of
the cell mediated type in compromised hosts. Therapeutic
doses of levamisole restore to normal the functions of
monocytes (phagocytes) and T lymphocytes but do not
directly influence B cells.
Levamisole is rapidly absorbed from the gastrointestinal
tract follow ing a single oral ingestion of 150 mg. In
patients with neoplastic disease, a mean peak blood level
of 0.86 mcg/mL is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between
3-4 hours. The metabolites are eliminated more slowly
with a term inal half-life of approximately 16 hours.
Levamisole is extensively metabolized by the liver in man
and excreted mainly by the kidneys (70% over 3 days).
Approximately 5% is excreted in the feces. Less than 5%
of the unchanged dose is excreted in the urine and less
than 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as
adjuvant therapy in poor prognosis malignant melanoma
following complete surgical excision and exclusion of
metastatic disease. In such patients, levamisole has been
shown to produce an improvement in relapse free survival
and overall survival when compared to observation alone,
particularly in patients aged 55 years or older.
ERGAMISOL is also indicated as adjuvant therapy, in com
bination with 5-fluorouracil, in patients with completely
resected Dukes’ stage C colon cancer. Evidence of
metastatic disease must be excluded before initiating
therapy. In patients with Dukes' stage C carcinoma of the
colon, a regimen of levamisole plus 5-fluorouracil has
been shown to produce significant reductions in both
cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known
hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been asso
ciated with reversible leukopenia and agranulocytosis,
therefore it is essential that appropriate hematological
m on ito rin g be done ro u tin e ly during therapy w ith
ERGAMISOL.
Patients should be instructed to report immediately any
sudden change in their state of health which may be man
ifested by influenza-like symptoms (fever, lassitude, sore
throat, shivering or sweating) so that appropriate hema
tological testing can be done.
Leukopenia (total WBC below 3000/mm3) is not neces
sarily a sign of impending agranulocytosis; recovery is
possible w ithout withdrawal of the drug. However, with
a reduced neutrophil count (less than 20% of the total
white blood cell count) levamisole should be discontinued
permanently. (Agranulocytosis is attributed to antibody
formation and absorption of immune complexes. This
process initiates complement activation and cell lysis; lev
amisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development
of agranulocytosis, particularly in females with concomi
tant rheumatoid arthritis. The onset is frequently sudden
and may be asymptomatic. Following discontinuation of
levamisole, neutrophil counts normalize within a week to
10 days. There is no evidence that steroids or WBC trans
fusions are of significant therapeutic value; prophylaxis
of infection during the acute phase of agranulocytosis
should be an important consideration.

PRECAUTIONS
Drug Interactions: The therapeutic effect of levamisole
may be antagonized by concomitant administration of cor
ticosteroids.
Additional caution is necessary when levamisole is used
in combination with other drugs potentially affecting
hemopoiesis.
Levamisole has been reported to produce “ANTABUSE™”like side effects when given concomitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL
(levamisole hydrochloride) experience adverse effects of
the medication. Due to the interm ittent nature of the
dosage schedule, drug discontinuation may not be nec
essary for successful resolution.
The adverse reactions observed when levamisole is used
in combination with 5-fluorouracil are consistent with
those anticipated if 5-fluorouracil is given alone in a com
parable dose and schedule.
The incidence of adverse reactions for levamisole alone
in malignant melanoma patients and for levamisole plus
5-fluorouracil in colonic cancer patients is presented in
Table I.
An encephalopathy-like syndrome has been reported.
TABLE I: INCIDENCE OF ADVERSE REACTIONS
IN PATIENTS TREATED WITH LEVAMISOLE FOR
MALIGNANT MELANOMA OR COLONIC CANCER.
INCIDENCE (%)
LEVAMISOLE LEVAMISOLE+5-FU
COLONIC
MELA
INDUC MAINTE
NOMA
TION
NANCE

ADVERSE REACTIONS
GASTROINTESTINAL
nausea
24
vomiting
6
diarrhea
taste change
10
anorexia
1
MUCOCUTANEOUS
stomatitis
1
4
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
10
2000 to 4000/mm1
less than 2000/mmJ
thrombocytopenia
50000 to 130000 /mm1
less than 50000 /mm3
agranulocytosis
1.4
MUSCULOSKELETAL
arthralgia/myalgia
8
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo
ataxia
anxiety/irritability
depression
insomnia
somnolence
impaired thinking
OTHER
fatigue/weakness
fever
8
impaired liver function

37
8
25
2

56
17
47
7

27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

1

2
2
5
4
3
2
2
1
1
2

5

11

1

2

1
1
1
2
1

SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL
(levamisole hydrochloride). At high doses ERGAMISOL
exhibits positive inotropic and chronotropic properties on
heart muscle as well as convulsant properties. General
supportive measures are recommended.
DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be admin
istered at a dose of 2.5 mg/kg given as a single daily dose,
preferably at night, on 2 consecutive days every week.
Higher doses are not recommended as they are associated
with increased toxicity and have not been shown to
provide any additional therapeutic benefit.
In patients with Dukes’ stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered
only by or under the supervision of qualified physicians,
experienced in cancer chemotherapy, and well versed in
the use of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after
resection as patients are able to tolerate oral medication,
but no sooner than one week and no later than five weeks
after surgery.
ERGAMISOL should be administered orally at a dose of
50 mg t.i.d., for three consecutive days, every two weeks.
This therapy should be continued for at least one year.
Administration of 5-fluorouracil should be timed to begin
concomitantly with the second three day course of lev
amisole. The initial dosage of 5-fluorouracil should be 450
mg/m7day, given intravenously, for five consecutive days.
Four weeks following the initial five day course of 5-flu
orouracil, patients should begin maintenance therapy on
a once weekly basis with an intravenous injection of 5fluorouracil at a dose of 450 mg/m!. Treatment should
continue fo r as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukope
nia, the weekly 5-fluorouracil administrations should be
deferred until these side effects have subsided. If these
side effects are moderate to severe in intensity, 5-flu
orouracil should be resumed with a 20% reduction in
the dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in
blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored
at room temperature and protected from
moisture and light.
Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adju
vant therapy of resected colon carcinoma.
1990;322:352-8.
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Gastric Perforation As a Complication
of Splenectomy: Report of Five Cases
and Review of the Literature
James H. McClenathan, MD
A rare complication of splenectomy is gastric perforation and fistula. Patients with
this complication often complain of pain in the left upper quadrant and left shoulder,
and of fever, tachycardia and upper abdominal tenderness. Chest radiographs often
show a pleural effusion in the left hemithorax. Patients usually exhibit increased
drainage from the tube in the left upper quadrant or a collection of fluid in the left
subphrenic space. The diagnosis can be confirmed by radiography after ingestion of
meglumine diatrizoate (Gastrografin). Treatment by nasogastric suction and
adequate drainage of the left subphrenic space allows some of these fistulas to close.
In some cases operative closure is necessary. With appropriate treatment, 75% of
these patients can be expected to recover.

La perforation gastrique avec formation de fistule est une complication rare de la
splenectomie. Les patients qui presentent cette complication se plaignent souvent de
douleur dans le quadrant superieur gauche de l’abdomen et dans l’epaule gauche, de
fievre, de tachycardie et de sensibilite a la partie superieure de l’abdomen. Les
radiographies thoraciques revelent souvent un epanchement pleural dans
l’hemithorax gauche. La plupart du temps, les patients montrent un drainage
croissant provenant du catheter place dans le quadrant superieur gauche ou une
accumulation de liquide dans l’espace sous-diaphragmatique gauche. Une
confirmation du diagnostic peut etre obtenue par radiographie apres ingestion de
diatrizoate de meglumine. Le traitement par aspiration gastrique par voie nasale et
drainage adequat de l’espace sous-diaphragmatique gauche permet a quelques unes
de ces fistules de se refermer. Dans certains cas une fermeture chirurgicale est
necessaire. Avec un traitement approprie, on peut s’attendre a ce que 75% de ces
patients guerissent.

astric fistula, although a rare
complication of splenectomy, is
associated with substantial morbidi
ty and mortality. The possibility of
injuring the stomach during sple
nectomy has been recognized since
the work of Mayo1 in 1913. Al
though gastric fistula is often listed
as a potential complication of sple
nectomy, few cases have been re
ported. During the past 15 years,
five patients were treated at our
hospital for delayed gastric perfora
tion after splenectomy. In this re
port we summarize our experience

G

with this serious complication and
review cases that have been report
ed previously in the English litera
ture.

bucil and prednisone. Multiple petechiae were noted, but there was no
indication of splenomegaly. A sple
nectomy, with sump drainage, was
performed. Review of the operative
specimens showed a leukemic sple
nic infiltrate. Steroids were adminis
tered perioperatively. The patient
was discharged 9 days after the
operation but was readmitted 1
week later because of pain in the
left upper quadrant, fever and leu
kocytosis. Upper gastrointestinal ra
diographs obtained after the inges
tion of meglumine diatrizoate (Gas
trografin) showed a gastric fistula
that communicated with a left
subphrenic abscess. The abscess
was drained, but the gastric defect
was not identified. Drainage contin
ued, and the patient’s postoperative
course was marked by continued
sepsis, thrombocytopenia and neu
rologic changes. He died 4 months
after drainage of the abscess. At
autopsy a 3- to 4-mm fistula was
identified high on the gastric fun
dus.
Case 2

Case Reports
Case 1

In 1974 thrombocytopenia devel
oped in a 70-year-old man who had
chronic lymphocytic leukemia. His
platelet count was 12 000 X 109/L .
He had been treated with chloram
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A 30-year-old man with peptic
ulcer disease who underwent over
sewing of a perforated duodenal
ulcer in 1973 was referred to our
clinic with intractable pain and re
current episodes of bleeding from a
duodenal ulcer. He underwent va
gotomy, antrectomy, Billroth II re
construction and incidental splenec
tomy. One week later, leakage from
a duodenal stump was repaired.
Four weeks later, a left subphrenic
abscess was drained. A stormy post
operative period continued with re
peated efforts to drain the left
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subphrenic space. Two months lat
er, a charcoal meal was passed
through the subphrenic drains. The
patient was discharged 1 month
later with persistent drainage and
he was readmitted after 4 months
because of acute cholecystitis. Dur
ing cholecystectomy, the gastric fis
tula was isolated and repaired. The
patient slowly recovered, and there
was no further drainage.

mography scan of the abdomen was
normal. Ten days postoperatively, a
dose of methylene blue was given
through the nasogastric tube and
was seen promptly in the left upper
quadrant drain. At reoperation, a
1-cm defect in the greater curve of
the gastric fundus was debrided and
closed in two layers. The patient’s
recovery was uncomplicated.
Case 5

Case 3

An 18-year-old woman had sple
nectomy for idiopathic throm
bocytopenic purpura. Steroids were
used perioperatively. Blood loss was
minimal. The patient was treated
with antibiotics and local wound
care and was discharged 5 days
later, but she continued to have
small amounts of drainage from her
wound. She was readmitted 3 weeks
later because of fever and because
ultrasonography demonstrated a
collection of fluid in the left subph
renic space. An abscess was drained
of 400 mL percutaneously. A sino
gram revealed communication with
the stomach. Nasogastric suction
and peripheral alimentation were
started, and the fistula closed with
in 1 week.
Case 4

A 47-year-old woman who had
autoimmune hemolytic anemia was
referred for a splenectomy. Her re
sponse to corticosteroid therapy
was incomplete. She had previously
undergone cholecystectomy and
pancreatic debridement for pancre
atic necrosis. Splenectomy was per
formed. Blood loss was 1300 mL. A
drain was used. The patient had
persistent postoperative tachycar
dia, left upper quadrant pain, and
left shoulder pain. Moderate
amounts of drainage were collected
and were found to have a high
amylase content. A computed to
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A 57-year-old man with Hodg
kin’s lymphoma underwent splenec
tomy. One week after the operation
an abscess in the left upper quad
rant required drainage. Injection of
methylene blue demonstrated a
gastric fistula. He was treated with
antibiotics and omeprazole, but the
fistula failed to close and required
surgical repair 3 weeks later. The
patient recovered.

Discussion
The incidence of gastric perfora
tion or fistula as a complication of
splenectomy is less than 1%. Sever
al large series of splenectomies have
been reported without a single
gastric injury, including reviews by
Taylor, Kaplan and Nelsen2 of 825
staging laparotomies, by Musser
and associates3 of 306 splenecto
mies in patients with hematologic
disease, by Danforth and Thorbjarnson4 of 185 incidental splenecto
mies and by Schwartz5 of 223 sple
nectomies in patients with throm
bocytopenia. Daoud, Fischer and
Hafner6 reported one case of gastrocutaneous fistula among 106 pa
tients who underwent splenectomy.
Among 310 splenectomies reported
by Hodam,7 13 associated fistulas
arose from the colon, small bowel,
stomach and esophagus.
In contrast, Tarazi and col
leagues8 reviewed 18 patients with
gastrocutaneous fistulas and found

that none of the fistulas had oc
curred after splenectomy. In our
experience, five gastric fistulas were
seen among 540 patients who had
their spleens removed, a rate of 1%.
Although gastric perforation is
frequently mentioned as a potential
complication of splenectomy,910 ac
tual reports of this problem have
appeared sporadically over the
years. Fourteen cases, described
since 1967, are summarized in
Table I.11-14 In addition, Warshaw,
Moncure and Rattner15 recently re
ported a series of six patients with
gastrocutaneous fistulas associated
with pancreatic abscesses. Three of
these patients had also had a recent
splenectomy and a gastrocutaneous
fistula was diagnosed between 5
and 9 weeks postoperatively.
Gastric perforation has occurred
after splenectomy performed for a
variety of indications. None of the
patients was suspected of having a
gastric injury at the time of splenec
tomy. Because drains had been
placed in most of the patients at
operation, the most common pre
sentation of gastric perforation was
an increased volume of drainage
during the first week after splenec
tomy. In several other patients, the
fistula was diagnosed only after a
left subphrenic abscess was recog
nized.
The diagnosis was established
during the first week after splenec
tomy in several patients, but in
others the diagnosis was not made
for weeks or even months postoper
atively. Clinically, patients often
had pain in the left shoulder, pain
and tenderness in the left upper
quadrant, fever and tachycardia. A
pleural effusion was often seen in
the left hemithorax. Several pa
tients had a sentinel gastrointestinal
hemorrhage before perforation.11
The diagnosis may be confirmed
by radiologic studies obtained after
the ingestion of Gastrografin, char
coal or methylene blue, or by injec-

GASTRIC PERFORATION AFTER SPLENECTOMY

tion of a contrast medium through
a catheter or drain into the left
upper quadrant. The perforation
typically occurs in the gastric fun
dus near the site where the short
gastric arteries are clamped, divided
and ligated.
Several etiologic mechanisms
have been proposed for gastric per
foration. Ballinger and Erslev10 and
Jordan16 speculated that gastric ne
crosis was the direct result of a
technical error in which a portion of
the gastric wall was included in a
ligature of a short gastric vessel.
Several technical aspects of splenec

tomy may help prevent this compli
cation. First, the short gastric ves
sels should be identified individual
ly, dissected and ligated away from
the gastric wall. If a portion of the
greater curvature of the stomach is
denuded, or if any of the ties are
thought to be too close to the
gastric wall, the area can be imbri
cated by placing several Lembert
sutures . 13 We also believe that post
operative nasogastric decompres
sion should be continued until gas
trointestinal function resumes. If
gastric injury is suspected, drainage
should be considered.

T a b le

Age,
y r Sex

Although it is recognized that
there is a generous intramural col
lateral blood supply in the stomach,
some have suggested that dividing
the short gastric vessels may cause
ischemic gastric necrosis in some
patients, especially those with ath
erosclerosis. 1 3 1 6 In some patients a
gastric fistula is diagnosed only
after treatment of a subphrenic or
lesser sac abscess, sometimes weeks
or months after splenectomy. This
situation has led us to postulate
that in some patients gastric necro
sis and perforation may develop
from the combination of the relative

1. Summary of Cases of Gastric Perforation After Splenectomy
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gastric ischemia caused by ligation
of short gastric vessels and local
alterations in blood flow caused by
an adjacent abscess.
Corticosteroid therapy has also
been implicated as contributing to
formation of gastric necrosis.12
Other factors that may predispose
to gastric necrosis include chemo
therapy, malignant disease, sepsis
and multiple previous operations.
Although drains were used in 11
of the 15 patients who later had
fistulas (Table I), it is doubtful that
drainage was a causative factor. In
fact, drainage probably assisted in
the early detection of the fistula in
many patients.
Once a gastric fistula has been
recognized, adequate drainage must
be established, appropriate antibiot
ic therapy started and nutritional
support begun. The use of naso
gastric suction and H2 blockers may
help to reduce output from the
fistula.
Several newer pharmacologic
agents can dramatically reduce
gastric secretion. Octreotide acetate
is a synthetic peptide that is similar
to somatostatin in its ability to
suppress secretion of gastrin and
other gastrointestinal peptides.
Omeprazole, which has been char
acterized as a gastric add pump
inhibitor, has been shown to reduce
markedly the production of gastric
acid. Theoretically, use of such
medications to reduce gastric secre
tion in patients with gastric fistulas
could be a valuable adjunct in the
conservative management of these
patients. However, in the patient we
treated with omeprazole the fistula
did not close during a 3-week trial
of nonoperative management, al
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though fistula output was markedly
decreased.
In patients in whom the fistula
fails to close or in whom sepsis
occurs, an operation should be per
formed to provide better drainage of
the subphrenic space. All areas of
devitalized gastric wall should be
debrided, and the defect should be
closed in layers. Because the defect
in the gastric wall may be quite
small and adhesions may make dis
section difficult, it may be necessary
to instil air or methylene blue into
the stomach to identify the fistula
defect. Although recovery often
takes several months, more than
75% of these patients can be ex
pected to survive.

Summary
Gastric necrosis, perforation and
fistula are rare complications of
splenectomy, occurring in fewer
than 1% of patients. It is usually
felt to be a result of iatrogenic
injury to the greater curvature of
the stomach during mobilization of
the spleen. Segmental ischemia of
the greater curvature of the stom
ach after ligation of the short gastr
ic vessels, aggravated by the pres
ence of an abscess in the subphren
ic space, may also cause this com
plication. Once recognized, it
should be treated with prompt
drainage, aggressive nutritional
support and timely surgical repair if
necessary.
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Post-traumatic Compartment Syndrome
of the Foot
Drew A. Bednar, MD, FRCSC
Post-traumatic compartment syndrome in the foot is an unusual but well-recognized
entity. If there is an awareness of the condition at the time of presentation it can be
diagnosed and treated effectively. A case of compartment syndrome in the foot of a
17-year-old boy after massive lower-extremity trauma is described. The simple and
readily available diagnostic techniques are emphasized and an alternative approach
to plantar decompression, which avoids exposure of and potential damage to the
posterior tibial neurovascular bundle, is presented.

Le syndrome post-traumatique des loges du pied est une entite peu frequente mais
bien connue. Si Ton soupfonne cette affection lors du diagnostic, il est possible de
traiter efficacement. On decrit un cas de syndrome des loges du pied chez un garfon
17 ans apres un traumatisme grave des membres inferieurs. Les techniques
diagnostiques simples et courantes sont soulignees et on decrit une alternative a la
methode de decompression plantaire qui permet d’eviter l’exposition du paquet
vasculonerveux sciatique poplite posterieur et les dommages qui peuvent en
resulter.

cute compartmental ischemia
has emerged as a frequently
recognized post-traumatic condition
that is well treated by thorough
surgical decompression. I report a
second case of acute compartment
syndrome, involving the plantar
compartment of the foot, and re
view previously undescribed meth
ods of assessing tissue perfusion
and compartmental pressure. The
equipment used is immediately
available and involves minimal in
cremental cost in most hospital op
erating rooms. An alternative surgi
cal approach to plantar decompres
sion in the foot, avoiding exposure
of and potential damage to the
posterior tibial neurovascular bun
dle, is also presented.

A

Case Report
A 17-year-old boy suffered mas
sive trauma to the left lower ex
tremity when his motorcycle ran off
the road into a ditch. Assessment of
his condition in the emergency de
partment shortly after injury re
vealed trauma largely limited to the
left leg; there was an open distal
diaphyseal fracture of the left femur
with 10 cm of bone loss but intact
soft-tissue coverage, an open and
minimally comminuted mid-dia
physeal fracture of the tibia with
skin and partial-thickness muscle
loss ventrally, and an obvious crush
injury to the foot with heavy bruis
ing and extensive tense swelling of
the soft tissues. The foot was cool
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but sensate; there was minimal ac
tive plantar flexion of the toes with
pain. Passive plantar or dorsiflexion
of the toes caused increased pain in
both the foot and mid-calf.
A vascular surgeon suggested
that angiography and Doppler vas
cular assessment were not neces
sary in the presence of palpable,
though thready, pedal pulses. Sug
gested management included reas
sessment after fracture stabilization
with microvascular intervention for
foot salvage as indicated.
The patient underwent immediate
thorough debridement and primary
stabilization of both long-bone frac
tures. Reassessment of the foot re
vealed progressive tense swelling
with capillary refill time in the
range of 3 seconds.
A digital transcutaneous oxygen
tensiometer (Biox 3700; Ohmeda
Inc., Boulder, Colo.) recorded a
transcutaneous oxygen tension
through the plantar surface of the
left second toe of 50 mm Hg com
pared with 90 mm Hg on the
control side.
A standard 18-gauge injection
needle was connected through a
short length of sterile intravenous
tubing to the same pressure moni
toring dome (DTMS 7 2 /1 2
#36-8084-1; Deseret Medical,
Sandy, Utah) that had been used
throughout the procedure to moni
tor the patient’s arterial blood pres
sure. After flushing of the system
with normal saline solution the nee
dle was inserted dorsally into the
first metatarsal space and flushed
with approximately 0.5 mL of nor
mal saline; the tissue pressure was
CJS, VOL. 34, NO. 2, APRIL 1991

179

BEDNAR

measured through the pressure
dome on a standard arterial pres
sure monitor (HP 78354A; Hewlett
Packard, Palo Alto, Calif.); it was
58 mm Hg. The lateral-most inter
metatarsal compartmental pressure
was then similarly measured and
found to be 38 mm Hg, and the
plantar compartment pressure was
measured at 68 mm Hg after inser
tion of the needle from the indirect
plantar approach in the mid-foot.
Decompression of the intermeta
tarsal compartments was then per
formed by two dorsal incisions, as
suggested by Mubarak and Hargens.1 The plantar compartment
was approached through a straight
lateral incision, extending from the
peroneal tubercle along the length
of the fifth metatarsal to the fifth
metatarsophalangeal joint (Fig. 1).
A curved Kelly forceps was used to
dissect bluntly across the sole of
the foot, effectively decompressing
all layers.
Tissue pressure measurements
after decompression were 34 mm
Hg in the intermetatarsal compart
ments and 38 mm Hg on the sole.
Clinically there was impressive
blushing of the foot after tissue
decompression and a reduction in
capillary refill time to just over 1
second. Transcutaneous oximetry
on the second toe delineated a
transcutaneous oxygen tension of
92 mm Hg immediately after de
compression.
All wounds were packed open,
and the foot was supported postoperatively in a posterior plaster splint
at the ankle-neutral position. The
patient was brought back to the
operating room on postoperative
day 6 for wound debridement and
uncomplicated closure of his fasciotomy incisions.
After three further procedures for
bone grafting and soft-issue cover
age the patient was bearing weight
without restriction, and all fractures
were healed 6 months after opera
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tion. Clinically the range of motion
in the hip, knee and toes was
normal as was the neurovascular
status of the left foot.

Discussion
A review of the literature revealed
only two previously reported cases
of compartmental ischemia involv
ing the plantar compartments of the
foot. One occurred in an infant
suffering from sclerema neonato
rum without trauma,2 the other was
associated with trauma.3 The poten
tial for sustained elevation of myo
fascial pressure in the plantar com
partment has been well investigat
ed, and optimal decompression
would seem to be afforded through
a direct plantar approach.45
The compartmental anatomy of
the foot, and particularly that of the
plantar compartments has been well
described.1'4'6-7 Surgical approaches
to the plantar compartment have
been described from a dorsal ap
proach by Myerson,6 from the medi
al approach by Henry8 and Myer
son6 and the plantar approach by
Loefflor and Ballard4 and Heckman
and Champine.9
A concern in the medial approach
of Henry8 for access to the plantar
compartment of the foot, is the
potential for damage to the posteri
or tibial neurovascular bundle. The

approach used in the case reported
is a mirror image of this access and
avoids direct exposure of and poten
tial trauma to the neurovascular
pedicle.
Well-described methods of quan
tifying interstitial tissue pressure
include those pioneered by Whitesides and colleagues10 and Mubarak
and Hargens.1 The simple, univer
sally and immediately available,
cost-effective method used in this
case is inherently inaccurate as de
scribed by Brace;1112 needle assess
ment of interstitial compartmental
pressure lies in artificially elevated
pressure assessment in the range of
5 to 10 mm Hg at the initial
assessment, gradually normalizing
over 30 to 40 minutes. Certainly
the recording of a marginally elevat
ed tissue pressure by this technique
would provide only equivocal indi
cation for surgical decompression,
but the production of such marked
ly elevated compartmental pressures
as reported here certainly provides
clinically relevant information.
Transcutaneous oximetry is a
well-recognized technique for moni
toring the adequacy of ventilation
and tissue oxygenation. It is not
commonly applied to the assess
ment of peripheral tissue perfusion
but is used to reflect systemic oxy
genation in the ventilated patient. It
is a readily available method and
carries no incremental cost.

FIG. 1. Lateral view of foot showing line of lateral incision.

COMPARTMENT SYNDROME OF FOOT

It is certainly well accepted that
cutaneous blood flow and oxygena
tion may be normal in compartment
syndromes and that confirmation of
adequate cutaneous perfusion does
not rule out the possibility of un
derlying compartmental ischemia in
a damaged limb.1 The foot differs
anatomically from the upper ex
tremity in that there is no major
afferent blood supply to the toes
traversing the myofascial compart
ments of the foot;7 certainly in this
situation transcutaneous oximetry
may be helpful in assessing clinical
ly the adequacy of compartment
decompression and tissue reperfu
sion, as described. Application of an
unsterile oximetry clamp in the op
erative setting does require some
minor delay for the isolation of the
field from the monitored toe and

repreparation of the contaminated
toe after monitoring, but the time
involved is minimal; these delays
could be avoided by sterilizing the
unit as required.
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SESAP VI Critique
Item 47
Gallstone pancreatitis is secondary to passage of a gallbladder stone into the common bile duct with subsequent
blockage of the main pancreatic duct. In over 90% of patients with gallstone pancreatitis, the stone will pass
promptly into the duodenum, and clinical symptoms and hyperamylasemia will resolve within a few days.
Numerous studies have demonstrated that operation is safe at this time, and that only 10% to 15% of patients
will have residual common bile duct stones demonstrated by operative cholangiography, thus requiring
exploration of the common bile duct in addition to cholecystectomy.
Although emergency cholecystectomy during the attack has been advocated to avoid the uncommon situation
of smoldering pancreatitis, this approach is not recommended. Several studies have shown significantly increased
operative mortality. At least 60% of such patients will require common bile duct exploration for stones that have
not yet passed into the duodenum. For the uncommon patient whose symptoms and hyperamylasemia do not
promptly improve during medical management, endoscopic papillotomy can be performed, followed by
cholecystectomy several days later after subsidence of symptoms. Cholecystectomy should precede hospital
discharge in all cases, because pancreatitis recurs in up to 50% of patients within three months if
cholecystectomy is not performed.
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PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute Rocephin® powder with the appropriate diluent:
• Sterile Water for Injection
• Bacteriostatic Water for Injection
• 0.9% Sodium Chloride Injection
• 1% Lidocaine Solution
• 5% Dextrose Injection
Reconstitute as follows:
Reconstitution Table (IM)
Vial
Size

Volume to be
added to vial
mL

Approximate available
volume
mL

11I

0.25 g

0.9 ;

0.5 g

1.8 i i

1.0g

3.6

20g

7.2

Approximate average
concentration
g/mL
0.25
0.25

,

4p ;

H25

8

0.25

Shake well until dissolved.
NOTE: SOLUTIONS PREPARED FOR INTRAMUSCULAR USE OR ANY SOLUTION CONTAINING Lll
BACTERIOSTATIC WATER FOR INJECTION SHOULD NEVER BE ADMINISTERED INTRAVENOUSLY.

OR

For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute as follows:
Reconstitution Table (IV)
Vial
Size

Volume to be
added to vial
mL

Approximate available
volume
mL

Approximate average
concentration
g/mL

0.25 g

2.4

2.5

0.1

0.5 g

4.8

5.0

0.1

1.0 g

9.6

10.0

0.1

2.0 g

19.2

20.0

0.1

Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the “Solutions
for IV Infusion” listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection
5% Dextrose Injection
Dextrose and Sodium Chloride Injection
0.9% Sodium Chloride Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL
5% Dextrose Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable sterile transfer
device or dispensing set which allows measured dispensing for the contents.
Reconstitution Table for Bulk Pharmacy Package
Vial
size

Volume to be
added to vial
mL

Approximate
available volume
mL

Approximate
average concentration
g/mL

10 g

95

100.0

0.1

Shake well until dissolved. Withdraw the required amount and dilute with one of the “Solutions for IV Infusion” . Any
unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
Rocephin® should not be physically mixed with other antimicrobial agents.
Rocephin® should not be added to blood products, protein hydrolysates or amino acids.
Rocephin® should not be added to solutions containing calcium.
DOSAGE FORM
Availability:
1.Rocephin* Vials containing sterile powder equivalent to 0.25 g, 1 g and 2 g of ceftriaxone.
2. Rocephin® Vials containing sterile powder equivalent to 1 g and 2 g of ceftriaxone for use only with Abbott Laboratories
Limited ADD-VANTAGE (Abbott) 0.9% Sodium Chloride Injection U.S.P. or 5% Dextrose Injection U.S.P. in 50 mL and
100 mL containers.
3. Rocephin® Pharmacy Bulk Vials containing sterile powder equivalent to 10 g ceftriaxone (not for direct administration).
The availability o f the pharmacy bulk vial is restricted to hospitals with a recognized intravenous admixture programme.
Storage:
Rocephin® sterile powder should be stored at a controlled room temperature (between 15° and 30°C) and protected from
light.
Product Monograph available on request.
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HISTORY OF SURGERY

T h e Le Fort Fractures: Rene Le Fort
and His Work in Anatomical Pathology
Robert Patterson, MD
Rene Le Fort (1869-1951) was a French army surgeon who conducted a series of
thorough, if somewhat macabre, experiments on the heads of cadavers. The results
of his work gave rise to a system of classifying facial fractures, now known as Le
Fort types I, II and III. Le Fort had a distinguished career in surgery and teaching
and served in both world wars.
Rene Le Fort (1869-1951) fut chirurgien dans l’armee franfaise. II mena une serie
d’experiences approfondies, bien qu’un peu macabres, sur la tete de cadavres. Les
resultats de ses travaux ont donne naissance a une classification des fractures du
visage connue sous les appellations de types I, II ou III de Le Fort. Le Fort connut
une carriere enviable en chirurgie et dans l’enseignement et il servit au cours des
deux guerres mondiales.

he name Le Fort is associated
in surgery with a series of
facial fractures. Few physicians,
however, know much about the
man and how he developed his
classification. Haphazard guesses at
one debate included observation of
wounded soldiers, dropping cannon
balls on corpses and pitching the
heads of cadavers down a mine
shaft. The real story unfolds in
Paris at the turn of the century
when a young military doctor with
an interest in skulls had time on his
hands.
Rene Le Fort was an exceptional
ly bright, energetic physician whose
surgical talents covered a wide
range of present-day subspecialties.
He was born in 1869 in Lille,
France, into a family rich with
medical tradition: his great uncle
was the reknowned surgeon Joseph
Malaigne; his uncle was Leon Le
Fort, a distinguished anatomist and
surgeon; and his father and older
brother were also doctors. From
childhood Rene was guided toward

T

medicine and toward surgery in
particular. In 1887 he joined the
Ecole du service de sante militaire
at Strasbourg and placed first in the
entrance examinations of the Inter
nal des hopitaux de Lille. At the
age of 21 years he became the
youngest person in France to re
ceive a medical degree. His graduat
ing thesis addressed the subject,
“Topographie cranio-cerebrale avec
applications chirurgicales.”
Le Fort served at the Val-deGrace military hospital in Paris until
1899, when he became ill and was
removed from the active service list.
During his recuperation he turned
his attention to anatomic pathology
and facial trauma. In 1901 he pub
lished in three parts an “ Etude
experimentale sur les fractures de la
machoire superieure.” 1
Le Fort experimented on a total
of 35 cadavers, some of which he
first decapitated. He inflicted trau
ma to the faces of his subjects
using a variety of methods, al
though no mine shafts or cannon
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balls were involved. He then boiled
the heads to help in removing the
flesh, and observed in meticulous
detail the presence of any fracture
lines. Here is a sampling of his
trials:
Experiment I: Female, approximately
50 years old. Entire cadaver, supine,
face turned up. Three blows with a club
were applied directly to the front of the
upper maxilla, with moderate force.
Experiment III: Male, about 45 years
old. Decapitated specimen. The head
was hurled against the rounded edge of
a table.
Experiment XIII: Very old woman, com
pletely edentulous. The cadaver being
supine on the ground with the face
looking up, it was kicked violently on
the lower part of the face.
Experiment XXIII: Man, about 60. The
head, taken off and held solidly in the
hands, was violently projected toward
the padded edge of the autopsy table.
Experiment XXVIII: Old woman. The
head was placed between the jaws of a
large vise and held, as much as possi
ble, while applying compression on both
sides at the level of the cheekbones.2

In his conclusions Le Fort noted
that fractures tended to occur in
three places (Fig. 1). “ La premiere
grande ligne de faiblesse, c’est la
barriere de protection de la boite
cranienne.” This type of fracture,
resulting in craniofacial dysjunction, is now referred to as a Le Fort
type III fracture. The second great
line of weakness, causing a pyrami
dal fracture of the maxilla, is
known as a Le Fort type II fracture
and the third line of weakness, a
transverse fracture of the lower
maxilla, is termed Le Fort type I or
Guerin’s fracture. With these de
scriptions, Le Fort unwittingly seCJS, VOL. 34, NO. 2, A P R IL 1991
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cured a place for his name in the
eponyms of surgery.
Most of Le Fort’s working life
still lay ahead. In 1902 he resigned
his commission and returned to
Lille to pursue academic medicine,
with an interest in orthopedics. At
the outbreak of the Balkan War in
1912, he rejoined the army to prac
tise battlefield surgery. During
World War I he initially served at
the front lines and received a cita
tion for bravery. For the last 2
years of the war he was stationed at
a military hospital in Versailles,
where he performed chiefly thoracic
and cardiac surgery.
Soldiers at war are exposed to
numerous forms of trauma not
common in civilian life. Le Fort
provided a colourful description of a
case that illustrated his skills as a
surgeon as well as the difficulties
and uniqueness of practising mili
tary medicine. He operated on a
soldier who had a grenade fragment
lodged in his lower left ventricle. Le
Fort attempted to hold the shard of
metal in place to prevent hemorrh
age while suturing the wound it
had caused:

J’avais place quatre anses de fils en
arriere de l’eclat metallique, j ’avais in
cise le ventricule jusqu’au niveau de
l’eclat, extrait ce dernier par l’incision,
et toujours sans lacher la striction de
mes deux doigts qui empechaient toute
hemorrhagie par la breche ouverte, je
serrais les fils pour fermer le ventricule,
quand le dernier d’entre eux se rompit
au moment du serrage. Un terrible jet
de sang s’echappe du coeur; j ’en reprends vivement la pointe et la pince a
nouveau pour arreter l’hemorrhagie.
Mon aide, frappe de stupeur, avait les
bras ballants et je ne pouvais en esperer
aucun secours. Le Docteur X . . . etait
vert; les nombreux assistants, angoisses, attendaient la fin du drame. De
la seule main restee libre, je dus placer
et serrer de nouveaux fils. Je parvins a
les lier. Hergaut vit toujours.3

In 1918, at the end of the war,
Le Fort was asked by Clemenceau
to reorganize the Hopital des Invalides. He used this time to devote
himself to neurosurgery. In 1920
he returned to Lille and resumed
his duties as professor of operative
medicine and later was appointed
professor of children’s surgery and
orthopedics. An avid traveller, he
voyaged widely throughout the

world and for a time was vice
president of the Societe de Geographie. He retired in 1937, but at the
outbreak of World War II he again
served briefly in the French Army.
Rene Le Fort died in 1951 at his
home in Lille. Among the many
pearls of wisdom he left behind was
the observation that, “le chirurgien
d’aujourd’hui est bien le meme
homme que celui des siecles pass
es.”4
I thank Dr. Peter Cruse for his sugges
tions.

References
1. Le F ort R: Etude experimental sur les
fractures de la machoire superieure. Rev
Chir Paris 1901; 23: 208-227, 360-379,
479-507
2. T essier P: The classic reprint. Experi
mental study of fractures of the upper
jaw. Rene Le Fort M.D. Plast Reconstr
Surg 1972; 50: 497-506, 600-607
3. P ons J, D uboscq JC, S adania JB: Rene Le
Fort de Lille. Ann Chir Plast Esthet
1988; 33: 199-200
4. Vetter T: Une famille lorraine au service
de la chirurgie: les Malgaigne et les
heritiers de la tradition. Ann Med Nancy
1966; 5: 763-779

FIG. 1. Computer-generated illustrations of Le Fort fractures: (A) Le Fort type I, (B) Le Fort type II, (C) Le Fort type III.
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SURGERY OF THE THYROID AND
PARATHYROID GLANDS. 3rd ed. Ed
ited by Blake Cady and Ricardo L.
Rossi. 348 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1990. $75 (US).
ISBN 0-7216-3462-1
The late William Halsted, the great
father figure of North American sur
gery, viewed thyroidectomy as the pen
ultimate example of surgical expertise.
This was personified in the award of the
Nobel Prize in Medicine to Professor
Kocher of Switzerland at the turn of
the century. Since then much has oc
curred to diminish this exalted view of
thyroid surgery, which is currently
showing modest but definite signs of
expansion. Thyroid surgery could be
said to have established such current
well-known institutions as the Mayo
Clinic, Cleveland Clinic and the Lahey
Clinic. Drs. Cady and Rossi, long-time
associates of the Lahey Clinic, have
edited a book that is in its third edition
and represents an achievement in the
succinct but comprehensive presenta
tion of material on this area of surgery.
Both Cady and Rossi have an estab
lished reputation in thyroid and para
thyroid surgery, which represents a
significant part of their genera! surgical
activity within the broad network of
Boston’s Harvard surgical scene. This
multiauthored, 31-chapter book deals in
a comprehensive and fact-laden fashion
with problems of the thyroid and para
thyroid glands requiring surgical treat
ment. In the 21 chapters devoted to
thyroid disease, there is a variety of
topics embracing embryology, surgical
anatomy, pathology, fine-needle aspira
tion biopsy, thyroid function testing,
various thyroid entities, malignant dis
ease, surgical procedures and adjuvant
therapy. Eight chapters (about 69
pages) are devoted to parathyroid dis
ease, including the radiologic features,
clinical presentation, diagnosis, surgery,
recurrent problems and cancer.
There are separate chapters dealing

with thyroid and parathyroid disease
during pregnancy and surgical compli
cations and management. The editors
have contributed much to an apprecia
tion of the behaviour of differentiated
thyroid cancer with respect to correla
tion of risk, prognosis and age factors.
Their chapter on differentiated carcino
ma of the thyroid gland represents an
interesting compendium of their clinical
research. They have used their observa
tions to support a conservative surgical
approach but, interestingly enough,
with liberal criteria for surgical selec
tion. In recognition of the controversial
aspects of surgical treatment of thyroid
cancer, they have included an articulate
commentary by Clark and Sipperstein
as advocates of total thyroidectomy.
The chapter on medullary thyroid can
cer by Wells represents an authoritative
treatise, and, in the parathyroid sec
tions, chapters on familial hyperpara
thyroidism by Block and recurrent para
thyroid surgery by Gaz are very well
prepared.
A book of this economical dimension
dealing with a field that is still rife with
controversy is bound to stimulate some
criticism. I think the book would have
benefited by the omission of commen
tary sections in preference to their
inclusion in a viable chapter, greater
use of updated illustrations dealing with
surgical techniques of neck dissection,
neck-node sampling and parathyroidec
tomy, an appreciation of surgical treat
ment of hyperthyroidism, the consider
ation of thyroid-associated embryogenic
problems, citation of Hurthle cell tu
mour as a particular concern, streamlin
ing an otherwise valuable chapter on
thyroid needle biopsy, addressing the
concepts of parathyroid transplantation,
special parathyroid problems such as
crisis and the asymptomatic patient,
thyroid neoplasia associated with preg
nancy and aggressive treatment of ag
gressive thyroid cancer. I think the
fields of thyroid and parathyroid sur
gery have developed sufficiently that
there should have been a more distinct

separation of the two. They may require
separate volumes in future editions.
This book represents a substantial con
tribution to endocrine surgery and pro
vides a text that is easy to read, infor
mative, authoritative and is still kept to
a very reasonable length. The bibliogra
phy is extensive and current and repre
sents an additional source of informa
tion for the inquisitive. This is an ideal
gift for the surgical resident and should
be in the library of all surgeons who are
called upon to deal with such problems.
Irving B. Rosen, MD, FRCSC, FACS
Mount Sinai Hospital
Ste. 445
600 University Ave.
Toronto, ON
M5G 1X5

CRYOSURGICAL TREATMENT FOR
SKIN CANCER. Emanuel G. Kuflik
and Andrew A. Gage. 266 pp. Illust.
Igaku-Shoin, New York. 1990. Price
not stated. ISBN 0 -8 9 6 4 0 -157-X

Cryotherapy with liquid nitrogen is
widely used by dermatologists in certain
large medical centres in the United
States to treat smaller and relatively
noninvasive skin cancers. Based primar
ily on their own experience the authors
review this subject in detail. The book
contains chapters on cryobiology, cryo
surgical equipment, basic technique,
monitoring techniques, treatment of
malignant lesions, tissue response and
wound healing, eight chapters on the
treatment of cancers in certain sites,
melanoma, palliative therapy and results
and perspective.
Review of the basic science, the mon
itoring techniques using cryoprobes and
the details of the actual treatment are
well covered by both narrative and
photographic descriptions. The pitfalls
are clearly outlined. The results clearly
are about as good as other traditional
methods.
CJS, VOL. 34, NO. 2, APRIL 1991
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The authors face head-on the future
of cryosurgery for skin cancers. Com
petition against such proven methods
as electrodesiccation and curettage, sur
gery and ionizing radiation is difficult
because there is no tradition, and cryo
surgery is not widely taught to resi
dents. The latest and, for problem
cases, most definitive method is Mohs’
chemosurgery. As more and more cen
tres use the microscopically controlled
Mohs’ method, it is hard to see how
cryosurgery can continue to exist. For
those interested, this book covers well
what cryosurgery for skin cancer has to
offer.
R obert Jackson, MD, FRCPC
Ste. 508
1081 Carling Ave.
Ottawa, ON
K1Y 4G2

DIAGNOSTIC TECHNIQUES IN
UROLOGY. Edited by Patrick H.
O’Reilly, Nicholas J.R. George and
Robert M. Weiss. 617 pp. Illust. W.B.
Saunders Company, London/Harcourt
Brace Jovanovich, Inc., Philadelphia;
HBJ-Holt-Saunders Distribution Ser
vices, Toronto. 1990. Price not stated.
ISBN 0 -7 2 1 6 -3 1 1 6 -9

Over the past two decades urology has
become a more precise surgical special
ty. It has been associated with an
increasing array of diagnostic tech
niques of increasing complexity and
cost. The surgeon should have a full
understanding and appreciation of the
theory behind each test, the details of
how it should be performed and inter
preted, and the risks and benefits of
some of the more invasive procedures.
This rather large, well-produced book is
written by 55 authors, all recognized
experts in their particular field, from
the United States, Canada, the United
Kingdon and Western Europe.
The first half of the book is devoted
to a comprehensive critique of diagnos
tic techniques. The list of topics cov
ered is complete, ranging through radi
ologic investigations, endoscopic and
cytologic techniques, and urodynamic
evaluations. The theoretical and practi
186
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cal aspects of each investigation are
discussed, and the whole text is well
illustrated with excellently produced il
lustrations. The second half of the book
deals with the clinical applications of
the diagnostic techniques. Again, the
list of topics covered is full and com
plete.
The book is up to date in most
aspects, although a few chapters do not
have any references after 1987. Perhaps
because each section is written by a
different author, certain topics are du
plicated. For example, the investigation
of renal masses is covered in three
areas; however, this provides for slight
ly differing perspectives on the situation
and is far from being a wasted duplica
tion.
A chapter on the value of screening
tests, particularly for prostatic cancer,
should have been included.
Overall, this is a useful textbook and
should be of value to urologists and
radiologists alike. It is recommended for
any department and hospital library.
Norman G. Futter, MB, FRCSC
Head of urology
Ottawa General Hospital
501 Smyth Rd.
Ottawa, ON
K1H 8L6

UROLITHIASIS: A MEDICAL AND
SURGICAL REFERENCE. Edited by
Martin I. Resnick and Charles Y.C.
Pak. 375 pp. Illust. W.B. Saunders
Company, London/Harcourt Brace Jo
vanovich, Inc., Philadelphia; HBJHolt-Saunders Distribution Services,
Toronto. 1990. Price not stated. ISBN
0 -7216-2439 -1

This book is edited by two experts, one
an expert on the physicochemical as
pects and the other an expert on the
surgical aspects of urinary stone dis
ease. It has a limited number of collabo
rators for the chapters dealing with the
surgical aspects. The sections on etiolo
gy and medical treatment reflect primar
ily the expertise and knowledge of Dr.
Pak, whose leadership in the field is
widely recognized.
This volume is a positive acquisition
for physicians and surgeons dealing

with urinary stone disease. The intro
duction successfully summarizes the
importance of a comprehensive, inte
grated approach to the problem. I also
found the chapter dealing with the
physicochemistry of stone formation
particularly enlightening and surpris
ingly easy to read — a most remarkable
feat since this has been, traditionally,
an aspect of renal physiology consid
ered arid and difficult to grasp.
Perhaps the major merit of the book
is the integration of all fundamental
aspects of urolithiasis in a concise and
readable form. The chapters are brief,
thus allowing a review of each subject
quite rapidly, a definite asset for this
subject. Although the volume reflects
only the experience of a limited number
of individuals, their views are presented
in a balanced way. Most of the chapters
reviewing medical considerations are
written by Dr. Pak. We have become so
accustomed to multiauthored publica
tions that the single-handed production
of so many chapters is a rarity and
frequently viewed with scepticism. Not
in this case: Pak’s expertise in the
various areas he covers remains unchal
lenged, and each one is addressed
knowledgeably and concisely. The
blessing of brevity in some chapters
leaves the reader occasionally wishing
for additional information. At our insti
tution, for example, we have been fa
vourably impressed with the effective
ness of laser lithotripsy; our enthusiasm
has been somewhat tempered by the
fragility of the instruments used to gain
access to ureteric stones. This is the
type of practical information that the
readership likes to have available to
facilitate the planning and selection of
equipment from the confusing array
currently offered by a variety of manu
facturers. On the other hand, each
chapter is accompanied by a rich and
balanced number of useful references.
Yes, the book is informative, reliable
and up to date. It is recommended with
very good marks for trainees and spe
cialists alike.
A. Morales, MD, FRCSC
Department of Urology
Queen’s University
Kingston General Hospital
Kingston, ON
K7L 2V7
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books received. It does not preclude
review at a later date.

Helms. 297 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. $49.95. ISBN
0-7216-3541-5

Advances in Ophthalmic Plastic and
Reconstructive Surgery: the Anophthalmic Socket. Volume 8. Edited by
Stephen L. Bosniak. 288 pp. Illust.
Pergamon Press, New York. 1990. $75.
ISBN 0-08-040292-5

The History of Orthopaedics. David
LeVay. 693 pp. Illust. The Parthenon
Publishing Group, Park Ridge, NJ.
1990. $125. ISBN 1-85070-145-8

Atlas of Abdominal Surgery. Edited by
John W. Braasch, Cornelius E. Sedg
wick, Malcolm C. Veindenheimer and F.
Henry Ellis, Jr. 446 pp. Illust. W.B.
Saunders Company/Harcourt Brace Jovanovich, Inc., Philadelphia. 1991.
$123. ISBN 0-7216-5601-3
Atlas of Breast Reconstruction. Edited
by Luis O. Vasconez, Madeleine Lejour
and Mabel Gamboa-Bobadilla. 228 pp.
Illust. Gower Medical Publishing, New
York. 1991. Price not stated. ISBN 0397-44662-4
Atlas of Hernia Surgery. Edited by
George E. Wantz. 230 pp. Illust. Raven
Press, New York. 1990. $115. ISBN 088167-724-8
Atlas of Pulmonary Surgical Patholo
gy. Thomas V. Colby, Charles Lom
bard, Samuel A. Yousem and Masanori
Kitaichi. 380 pp. Illust. W.B. Saunders/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. $172. ISBN 07216-2893-1

The Kidney, Volumes 1 and II. 4th
edition. Edited by Barry M. Brenner and
Floyd C. Rector, Jr. 2443 pp. Illust.
W.B. Saunders Company/Harcourt
Brace Jovanovich, Inc., Philadelphia.
1991. $330. ISBN 0-7216-2618-1
Operative Urology. Edited by Fray F.
Marshall. 631 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. $162. ISBN
0-7216-6121-1
The Pediatric Airway: the Principles
and Practice of the Pediatric Surgical
Specialties. Edited by Stephen L. Cans.
229 pp. Illust. W.B. Saunders Com
pany/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. Price not stated.
ISBN 0-7216-2778-1
Phacoemulsification Surgery. Edited
by Terence M. Devine and William
Banko. 130 pp. Illust. Pergamon Press,
New York. 1990. $125. ISBN 0 -0 8 036840-9

Bone Tumors: Diagnosis, Treatment,
and Prognosis. 2nd edition. Andrew G.
Huvos. 784 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. $162. ISBN
0-7216-2050-7

Practical Guide to Anorectal Testing.
Lee E. Smith. 258 pp. Illust. IgakuShoin Medical Publishers, Inc., New
York. 1990. Price not stated. ISBN 0 89640-4185-5

Disorders of the Foot and Ankle. 3
vols. 2nd edition. Edited by Melvin H.
Jahss. 2957 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. Price not stat
ed. ISBN 0-7216-1327-6 (set), ISBN
0-7216-3457-5 (vol. 1), ISBN 07216-3458-3 (vol. 2), ISBN 0-72163459-1 (vol. 3)

Sexual Rehabilitation of the SpinalCord Injured Patient. Edited by Jose
Florante J. Leyson. 572 pp. Illust. Hu
mana Press, Clifton, NJ. 1991. $89.5
ISBN 0-89603-145-5

Fundamentals of Body CT. W. Richard
Webb, William E. Brant and Clyde A.

Shackelford’s Surgery of the Alimenta
ry Tract. 5 vols. 3rd edition. George D.
Zuidema. 2513 pp. Illust. W.B. Saun
ders Company/Harcourt Brace Jovano
vich, Inc., Philadelphia. 1991. $475.
ISBN 0-7216-2505-3

Spinal Cord Injuries: Anaesthetic and
Associated Care. Edited by J.D. Alderson and Elizabeth A.M. Frost. 258 pp.
Illust. Butterworth & Co. (Publishers)
Ltd., London. 1990. $70. ISBN 0 -4 0 7 01148-X
Surgery of the Ear. 4th edition. Edited
by Michael E. Glasscock III and George
E. Shambaugh, Jr. 640 pp. Illust. W.B.
Saunders Company, London/Harcourt
Brace Jovanovich, Inc., Philadelphia;
HBJ-Holt-Saunders Distribution Ser
vices, Toronto. 1990. Price not stated.
ISBN 0-7216-2063-9
Surgical Management of the Diabetic
Patient. Edited by Michael Bergman
and Gregorio A. Sicard. 427 pp. Illust.
Raven Press, New York. 1990. $90.
ISBN 0-88167-720-5
Surgical Pathology of the Female Re
productive System and Peritoneum.
Edited by Stephen S. Sternberg and
Stacey E. Mills. 305 pp. Illust. Raven
Press, New York. 1990. $85. ISBN 0 88167-726-4
Tumor Stereotaxis. Patrick J. Kelly.
409 pp. Illust. W.B. Saunders Com
pany/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. $162. ISBN 0 7216-5360-X
Tumors of the Spine: Diagnosis and
Clinical Management. Narayan Sundaresan, Henry H. Schmidek, Alan L.
Schiller et al. 553 pp. Illust. W.B.
Saunders Company, London; HBJHolt-Saunders Distribution Services,
Toronto. 1990. Price not stated. ISBN
0-7216-2896-6
Urolithiasis: a Medical and Surgical
Reference. Martin I. Resnick and
Charles Y.C. Pak. 375 pp. Illust. W.B.
Saunders Company, London/Harcourt
Brace Jovanovich, Inc., Philadelphia;
HBJ-Holt-Saunders Distribution Ser
vices, Toronto. 1990. Price not stated.
ISBN 0-7216-2439-1
Vascular Surgery. 3rd edition. Edited
by Wesley S. Moore. 767 pp. Illust.
W.B. Saunders Company/Harcourt
Brace Jovanovich, Inc., Philadelphia.
1991. Price not stated. ISBN 0 -72163512-1
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T h e Canadian Journal o f Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $55
for the first 40 words or less, additional words 70<f each (additional $21 for frame). Special Display under 100 words, 55 X 55 mm, $125.
$15 charge (first insertion only) for CJS reply box numbers. Display rates available on request. VISA, M ASTERCARD AN D AM E RIC AN
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Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified, Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.
Send all box number replies to: Box . . . , Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.

ACADEM IC APPOINTMENT, GENERAL
SURGERY: ON - Queen's University, De
partment of Surgery, geographic full-time po
sition in general surgery commencing July 1,
1992. Applicants should be licensed to prac
tise in Ontario and be fellows of the Royal
College of Physicians and Surgeons of Cana
da. The successful candidate will be expected
to teach at undergraduate and postgraduate
levels and engage in research. He/she will be
expected to have specialized training and
interest in colo-rectal surgery. He/she will be
expected to take a proportion of emergency
calls. Salary, ceiling and academic rank will be
by negotiation according to qualifications and
experience. Closing date for applications is
June 30, 1991. In accordance with Canadian
immigration requirements this advertisement
is directed to Canadian citizens and perma
nent residents. Queen's University has an
employment equity program and encourages
applications from all qualified candidates in
cluding women, aboriginal peoples, people
w ith disabilities and visible minorities. Appli
cations w ith a curriculum vitae and the names
of three referees should be sent to: Dr.
Charles Sorbie, Head, Department of Surgery,
Queen's University, Kingston, ON K7L 3N6.
-S91-54

GENERAL PEDIATRIC SURGEON: PQ The McGill University sub-department of Pa
ediatric General Surgery seeks a full time
pediatric general surgeon. The position will
include an appointment at an appropriate
academic rank in the School of Medicine and
privileges at the Montreal Children's Hospital.
In addition to patient care, responsibilities will
include teaching. Research will be a necessary
major commitment (50%). The candidate
must have completed a residency in general
pediatric surgery. The candidate should have
a working knowledge of both French and
English. The appointment is available immedi
ately. Please send curriculum vitae to: Dr.
Frank M. Guttman, Director, General Paediatr
ic Surgery, Room C-1137, The Montreal Chil
dren's Hospital, 2300 Tupper St., Montreal
PQ H3H 1P3. In accordance with Canadian
immigration requirements, this advertisement
is directed to Canadian citizens and perma
nent residents of Canada.
-S91-50
NON-CARDIAC THORACIC SURGEON:
US - Due to retirement, the Mary Imogene
Bassett Hospital is seeking a general thoracic
surgeon. MIBH is a multispecialty group prac
tice with a surgical residency and research
opportunities. Excellent lifestyle and recre
ation. Academic appointment at Columbia
University. Contact: Michael S. Gold, MD,
Surgeon-in-Chief, One Atwell Rd., Cooperstown, NY 13326. Tel: (607) 547-3968.
-S91-51

Applications are invited for the position of physician assistant in
neurosurgery. The post becomes vacant July 1, 1991 and is for a period of 1
year (renewable). The Provincial Neurosurgery Unit is based at the Health
Sciences Centre and you will be expected to assist at the Janeway Children's
Hospital. Previous experience in surgery and the Medical Council of
Canada Evaluating Examination is required. Salary: $67 471.

In accordance with Canadian immigration requirements, priority will be
given to Canadian citizens and permanent residents. Closing date for
this advertisement is May 31, 1991.

JCC, V O L 34, NO 2 .A V R IL 1991

Unlike a tabloid or newspaper that is read today and discarded
tomorrow, an advertisement in the Classified Advertising section
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of
any medical journal in Canada, and the latest readership
studies confirm the best and most cost efficient way to reach
Canadian surgeons is through the pages of CJS.

For further information contact:
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CARDIAC SURGICAL FELLOWSHIP: ON Available beginning July 1, 1991 at university
medical centre doing a large volume and
diversity of adult cardiac surgical procedures:
program affiliated with the University of To
ronto, Canada. Medical licence in Ontario
necessary. Ideal for FRCS or ABTS board
eligible/certified general surgeon awaiting
thoracic residency, or board eligible/certified
individual in thoracic surgery seeking addition
al experience. Salary commensurate with ex
perience, board status and potential for billing
(Canadians only). Please respond with CV to:
Bernard S. Goldman, MD, Head, Division of
Cardiovascular Surgery, Sunnybrook Health
Science Centre, 2075 Bayview Ave., Suite
H410, Toronto, ON Canada M4N 3M5. Tel:
(416)480-6070.
-S91-48

CLASSIFIED ADVERTISING

PHYSICIAN ASSISTANT
IN NEUROSURGERY

Dr. F.B. Maroun, Acting Chairman
Department of Surgery
The General Hospital
Health Sciences Centre
St. John’s, NF
A1B 3V6

GENERAL SURGEON: PE - A general sur
geon is required for a 30-member clinic in
Charlottetown, Prince Edward Island. The
clinic is staffed with several family physicians
and specialists. One of the tw o general sur
geons is appoaching retirement. The area is
served by a new, modern 350-bed hospital.
The recreational facilities in the area are excel
lent with numerous golf courses as well as
boating facilities. Subspecialties are well cov
ered. Apply to: Mr. Ken Heckbert, Manager,
Polyclinic, 199 Grafton St., Charlottetown, PE
C1A 1L2.
-S91-49

—S91-53

LET CJS CLASSIFIED ADS WORK FOR YOU

-CJS-1

Medical Hospital
FOR SALE
(TOBAGO W. I.)

in sq. ft.

Accommodation
The Location
Two-storey freehold medical
complex situated at the North
eastern comer of Northside Road
and Calderhall Road, Tobago (just
before the 1 1/4 mile post on the
Northside Road).

The Site
The site occupies approximately
36,000 sq. ft. It is well
proportioned and generally level,
although irregular in shape. Mains,
water and electricity provided.
Two 400 gallon water storage
tanks are located on the second
(2nd) floor level.

Construction &Condition
Two-storey reinforced concrete
medical complex in good structural
condition approximately ten (10)
years old. One elevator and three
flights of stairs provide access to
the first (1st) floor.
Electrical fittings are comprised in
part of concealed fluorescent
fixtures. A stand-by generator is
available. Sanitary fittings
standard.
A partially completed works/
utilities building is situated at the
north-eastern comer of site with
overall dimensions 24' - 6" x 21'.

The Ground Floor occupies a total floor
area of 6,706 sq. ft. and comprises:
in sq. ft.
Drug Sales & Chemist
Reception Area
Waiting Room
3 Consulting Offices
Examination Room
Darkroom
Ultra Sound &
X-ray Room
3 Storage Areas
Nurses Station
7 Convalescent Rooms
2 Patios
Staffroom
Laundry Room
Autoclave
Bulk Storeroom
Plant Room
Passageway
First Floor occupies
a total floor space of
7 Convalescent Rooms
Nurses Changing Room
Toilet & Shower Area
Dirty Room
Sterilizer Room
Operating Theatre

738
592
176
Total o f 472.5
155
62.5
239
Approx.383.1
52.5
Total of 1560
Total of
679.25
157.5
102.5
39
273.57
64
960
6,282 sq. ft.
Total of 1,560
90
80
65
107.25
390

Doctor's Changing Room
Recovery Room
Scrub-up Room
Labour Room
Examination Room
Toilet & Shower Room
Toilet
Storage
Sitting Room
Kitchen
Linen Storage
Secretariat Room
Balcony
3 Offices
Store Room
Utilities Room
2 Balconies
3 Passageways
Total Floor Area
for both levels:

90
170
50
352
100
50
22.5
45
157.5
157.5
157.5
428
130
Total o f 601
49
71
Total o f 525
Total o f 834
12,988 sq. ft.

The Price
The present open market value of the
property is TT $2,000,000.00
Please address enquiries to:

S 91-56

The Administrative Officer
NATIONAL INSURANCE PROPERTY
DEVELOPMENT COMPANY LIMITED
56/60 ST. VINCENT STREET,
PORT OF SPAIN
Tel: 1-(809)-625-9165, 9166, 8749, 8750
Fax: 1-(809)-623-0877
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PLASTIC SURGERY
ACADEMIC APPOINTMENT
HEAD, DIVISION OF PLASTIC SURGERY
UNIVERSITY OF SASKATCHEWAN
SASKATOON, SASKATCHEWAN
Applications are invited for a full-time position with the Division
of Plastic Surgery, in the Department of Surgery at the University
of Saskatchewan. The successful candidate will be appointed
Head of the Division of Plastic Surgery with the College of
Medicine at the University of Saskatchewan, and Head of the
Division at the Royal University Hospital in Saskatoon.
Interested applicants should have clinical experience in adult and
pediatric plastic surgery. A recorded commitment to undergradu
ate and postgraduate education is essential. Administrative
experience would be of benefit and the candidate should have
a background of surgical research activity.
Candidates must have certification in plastic surgery from the
Royal College of Physicians and Surgeons of Canada. They must
be eligible for registration with the College of Physicians and
Surgeons of Saskatchewan. In accordance with Canadian
immigration requirements, this advertisement is directed to
Canadian citizens and permanent residents. The University of
Saskatchewan is committed to the principles of employment
equity.
Please submit a current curriculum vitae and names of three
referees by May 31, 1991 to:
Dr. Roger G. Keith
Professor and Head
Department of Surgery
University of Saskatchewan
Royal University Hospital
Saskatoon, Saskatchewan
S7N 0X0

S91-55

University of W estern Ontario - Faculty of M edicine
DEPARTMENT OF SURGERY

Merck Sharp & Dohme Canada
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Pfizer Canada Inc.
Diflucan

9 0 ,1 2 6 ,1 2 7

Ross Laboratories
Jevity

132

Roussel Canada Inc.
Claforan

136 A,B

SmithKline Beecham Pharma Inc.
Mesasal

10 2,16 6

Syntex Inc.
Anaprox DS
1 4 4 ,1 4 5 , 165
Toradol
9 5 ,9 6 ,9 7 ,9 8 ,9 9 ,1 6 2
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CHAIR OF PLASTIC AND RECONSTRUCTIVE SURGERY

1 2 8,17 2, 173
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The University of Western Ontario Department of Surgery
invites applications for the position of Chairperson of the
U niversity Division of Plastic and R econstructive
Surgery.
Applicants must be eligible to practise in Ontario and hold
certification from the Royal College of Physicians and
Surgeons of Canada in plastic and reconstructive surgery.
The Department of Surgery is seeking a surgeon with a
record of excellence in clinical and academic practice,
leadership skills and potential to develop a strong
research program in plastic and reconstructive surgery.
Applicants are requested to forward their curriculum
vitae and the names of three referees prior to June 30,
1991 to:
Dr. John H. Duff
Professor and Chair
D epartm ent of Surgery - U .W .0.
U niversity Hospital
339 W inderm ere Road
London, Ontario
N6A 5A5

Positions are subject to budget approval. In accordance
w ith C a n a d ia n im m ig ra tio n re q u ire m e n ts , th is
advertisement is directed to Canadian citizens and
permanent residents of Canada. The University of
Western Ontario is committed to employment equity,
welcomes diversity in the workplace and encourages
applications from all qualified individuals including
women, members of visible minorities, aboriginal persons
and persons with disabilities.
S91-52

